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ABSTRACT 
 
Differentiation of human endometrial stromal cells (HESCs) into decidual 
cells represents a highly coordinated process essential for embryo implantation. 
Following the post ovulatory rise in progesterone levels HESCs undergo biochemical 
and morphological transformations in a process known as decidualization. These 
radical changes led us to investigate the extent to which chromatin modifying proteins 
are themselves regulated. Manual mining of microarray data revealed that over 100 
epigenetic effectors are regulated upon three days of decidualization and among these 
is the histone methyltransferase EZH2. ChIP on chip analysis showed that 
downregulation of this enzyme in decidual cells in response to differentiation cues 
results in a genome-wide redistribution of trimethylation of lysine 27 on histone 3 
(H3K27). Loss of this repressive histone mark at specific promoters is associated with 
acquisition of the competitive activation mark, H3K27 acetylation. Furthermore, 
functional studies indicated that EZH2 inhibits the decidual response. Histone 
methyltransferases are not the only methyltransferases that are regulated upon 
decidualization. Expression of DNA methyltransferases also responds to 
differentiation cues. However, this is not accompanied by equal changes in global 
DNA methylation levels, as emerged from colorimetric assays and pyrosequencing, 
nor in a change in the methylation status of the promoter of IGFBP-1, a decidual 
marker gene. Numerous diseases are associated with aberrant epigenomes; here we 
compare, through MeDIP-seq, the methylome of women with and without recurrent 
pregnancy loss. From our preliminary analysis, no significant differences in DNA 
methylation were observed. Taken together this work highlights the fundamental role 
epigenetics plays in the progression of the menstrual cycle. 
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1.1 Decidualization 
1.1.1 The menstrual cycle 
 The endometrium is the ovarian-hormone responsive mucosa characterized by 
glands and stroma which lines the lumen of the uterus. It is composed of two layers: 
the basal layer, which is in contact with the myometrium, and the functional layer, 
which undergoes radical cyclical changes in response to ovarian steroid hormones 
during the menstrual cycle (figure 1.1). Estradiol, dominant early in the cycle (during 
the proliferative/follicular phase) induces the ordered growth of the endometrium, 
from a thickness of about 0.5-1mm to about 5-7mm. After ovulation the corpus 
luteum secretes progesterone that controls the secretory/luteal phase. This 
postovulatory rise in progesterone initiates a cascade of cellular and molecular events 
leading to the remodeling of the endometrium in preparation for pregnancy (figure 
1.2) (Gellersen et al, 2007). This progressive profound process starts around the 
terminal spiral arteries of the superficial endometrial layer and eventually spreads to 
the entire endometrium. It is characterized by the inhibition of the proliferative 
activity induced by estradiol and by the attenuation of the contractile activity of the 
junctional zone myocytes. There is an increase in the secretory activity of the 
endometrial glands followed by the differentiation of the human endometrial stromal 
cells (HESCs) into specialized epitheloid decidual cells in a process known as 
decidualization (Brosens & Gellersen, 2006; Wynn, 1974). This differentiation is 
further characterized by remodeling of the spiral arteries, angiogenesis and influx of 
various bone marrow-derived immune cells, including macrophages and uterine 
natural killer cells (Gellersen & Brosens, 2003). 
Decidualization only occurs in species in which placentation involves 
breaching of the luminal epithelium by the trophoblast. In fact, the degree of 
trophoblast invasion strictly correlates with the extent of decidualization (Martin, 
2007). For example, in humans where trophoblast invasion encompasses not only the 
endometrium but also the uterine junctional zone – the inner third of the myometrium 
– decidualization affects all uterine compartments including myocytes, spiral arteries, 
local immune cells and endometrial, epithelial and stromal compartments. 
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Ultimately, high progesterone levels leading to this uterine transformation 
allow attachment of the embryo to the endometrium followed by extra-embryonic 
trophoblast lineage invasion (Dunn et al, 2003). In the absence of pregnancy, 
however, declining progesterone levels trigger a switch in the secretory repertoire of 
decidual stromal cells. These cells express pro-inflammatory cytokines, chemokines 
and matrix metalloproteinases, which in turn activate a sequence of events leading to 
tissue breakdown of the superficial endometrial layer, focal bleeding and menstrual 
shedding (Brosens & Gellersen, 2006). 
Uterine bleeding associated with ovulation or intercourse occurs in a variety of 
species but does not constitute menstrual bleeding. Apart from simian primates, true 
menstruation, defined as shedding of the superficial endometrial layer in response to 
falling progesterone levels accompanied by overt bleeding, is found only in certain 
bat species, such as wild fulvous fruit bats, and perhaps the elephant shrew (Martin, 
2007). There is wide debate on the purpose of menstruation: Profet (Profet, 1993) 
argues that cyclical shedding of the endometrium protects the uterus from pathogens. 
Strassmann (Strassmann, 1996), instead, suggests that it is metabolically more 
efficient than maintaining the endometrium in the active state required for 
implantation. Yet menstruation is widely viewed as serving no purpose other than to 
reinitiate the endometrial cycle in the absence of pregnancy. It is striking that cyclic 
endometrial decidualization followed by menstrual shedding is confined to the few 
species, including humans, where placenta formation entails deep trophoblast 
invasion of maternal tissues and vasculature. Both menstruation and pregnancy are 
inflammatory conditions that cause a degree of physiological ischemia-reperfusion 
tissue injury, albeit much more so in pregnancy. These observations led to the 
hypothesis that the emergence of cyclic menstruation may not have been an 
evolutionary coincidence, but rather serves to protect uterine tissues from the 
profound hyperinflammation and oxidative stress associated with deep placentation, a 
process known as preconditioning (Brosens et al, 2009). The term preconditioning 
refers to the paradoxical yet ubiquitous biological phenomenon that a brief exposure 
to a harmful stimulus at a dose below the threshold for tissue injury provides robust 
protection against, or tolerance to, the injurious effects of a subsequent more severe 
insult. In order to confer protection during pregnancy cyclic uterine preconditioning 
must have prolonged and sustained effects that impact on the cellular responses in the 
basal endometrial layer. While direct proof of cyclic menstrual preconditioning is 
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lacking, recent studies indicate that the ability of endometrial stromal cells to undergo 
a decidual response may be subject to programming events. For example, endometrial 
stromal cells derived from patients with and without endometriosis, a common 
inflammatory reproductive disorder, exhibit different responses to decidualizing 
stimuli, even after prolonged culture (Burney et al, 2007). Furthermore, numerous 
mechanisms underpinning preconditioning are also key features of the menstrual 
cycle, such as, but not limited to, production of reactive oxygen species (ROS), 
resistance to cell death and expression of angiogenic factors. Whatever the underlying 
purpose of menstruation, the unifying feature of the endometrium of all menstruating 
species is cyclic decidualization of the stromal compartment independently of 
pregnancy. In other words, while all mammals with invasive placenta exhibit an 
endometrial decidual response upon embryo implantation, only in menstruating 
species is this process directly under maternal control and occurs spontaneously 
during the late secretory phase of each cycle (Finn, 1998). This manifestation of 
cyclical ovarian function is essential for the regeneration of the endometrium assuring 
uterine receptivity in the next cycle. The changes in function and structure of this 
tissue, which occur at each of the over 400 cycles an average woman in a developed 
country undergoes, are under the control of ovarian steroids.  
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1.1.2 Functional consequences of decidualization  
Decidualization is first apparent in the stromal cells surrounding the terminal 
spiral arteries of the superficial endometrial layer around day 23 of a 28 days cycle 
(10 days after the surge in luteinizing hormone) (de Ziegler et al, 1998). It coincides 
with the termination of the limited period of endometrial receptivity (the implantation 
window) during which embryo attachment can take place. The elongated spindle-like 
stromal cells transform into cobblestone-like enlarged decidual cells with multiple 
club-shaped projections arising from their cell surface (Wynn, 1974). The decidual 
cells form a dense cellular matrix that allows coordinated trophoblast invasion while 
simultaneously protecting the conceptus from maternal and environmental insults 
(Kliman, 2000; Red-Horse et al, 2004). In pregnancy, the endometrium is under the 
continued support of steroid hormones as well as blastocyst-derived signals such as 
human chorionic gonadotropin. This provides the hormonal milieu for full 
decidualization of the entire endometrium. Decidual cells produce numerous 
cytokines to amplify and propagate the decidual process in an autocrine and paracrine 
manner during gestation. Indeed, during early pregnancy only 9.8% of the stromal 
cells express the decidual marker gene prolactin (PRL) and by the end of term this 
percentage increases to 58%. Some cells remain undifferentiated throughout 
pregnancy although they are able to decidualize in vitro (Richards et al, 1995).  
Morphological changes of HESCs –which are mesenchymal cells with a 
fibroblastic appearance– during decidualization include cell enlargement and 
rounding of the nucleus, an increase in the number and complexity of nucleoli, 
expansion of the rough endoplasmic reticulum and the Golgi complex as well as 
cytoplasmic accumulation of glycogen and lipid droplets (Christian et al, 2002a; 
Oliver et al, 1999). Formation of adherent and gap junctions are also observed 
between decidual cells. Furthermore, differentiated HESCs also express α-smooth 
muscle actin and desmin, suggesting the acquisition of a myofibroblastic phenotype 
(Oliver et al, 1999). This transformation of the endometrial fibroblasts into highly 
secretory cells is accompanied by profound biochemical changes. Microarray studies 
have demonstrated that decidualization involves sequential reprogramming of 
functionally related families of genes involved in extracellular matrix organization, 
cell adhesion, cytoskeletal organization, signal transduction, metabolism, stress 
response, cell cycle progression, differentiation and apoptosis (Giudice, 2004).  
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The success of a pregnancy depends on regulated trophoblast invasion, growth 
and protection of the placental semi-allograft from local immune responses. Decidual 
cells are paramount for conferring these specialized functions. For example, these 
cells express tissue factor and plasminogen activator inhibitor 1 which are crucial for 
the maintenance of vascular stability (Schatz et al, 2003). Macrophage inflammatory 
protein 1β, interleukin (IL) 11, IL15 and PRL are key molecules for chemotactic and 
differentiation signals for uterine natural killer cells (Dimitriadis et al, 2005b; Gubbay 
et al, 2002; Kitaya et al, 2003). Suppression of T-cell immune response to fetal 
alloantigens also occurs thanks to decidua-secreted factors such as indoleamine 2,3-
dioxygenase, tumor necrosis factor -related apoptosis-inducing ligand and Fas ligand 
(Kudo et al, 2004; Makrigiannakis et al, 2004; Popovici et al, 2000). Production of 
growth factors, binding proteins and the remodeling of the extra cellular matrix 
orchestrated and initiated by decidual cells is fundamental to regulate trophoblast 
invasion and decidualization in general (Dimitriadis et al, 2005b). In summary, upon 
biochemical reprogramming endometrial stromal cells acquire many new functions 
that critically govern successful trophoblast invasion and placenta formation.  
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1.1.3 Differentiation cues 
1.1.3.1 Cyclic adenosine monophosphate initiates decidualization 
Activation of the cyclic adenosine monophosphate (cAMP) pathway is 
essential to start the decidualization and progesterone is indispensable to maintain the 
acquired phenotype (Gellersen & Brosens, 2003). The complex nature of this process 
requires multiple highly coordinated pathways. They are activated by increased 
exposure of the endometrium to a variety of local and endocrine factors such as 
prostaglandins, estradiol, relaxin, corticotropin releasing hormone (CRH) and 
pituitary gonadotropins following ovulation (Christian et al, 2002a; Dimitriadis et al, 
2005a). These molecules are ligands of G-protein coupled receptors (GPCRs). GPCRs 
are a family of seven-transmembrane domain receptors, fundamental for cellular 
responses, which are coupled to guanine-nucleotide-binding proteins (G-proteins). 
The inactive receptor is bound to an, also inactive, heterotrimeric G-protein composed 
of the α, β and γ subunits. When the ligand, external to the cell, binds to the GPCR it 
disrupts an ionic block, which causes a conformational change in the receptor. This in 
turn activates the G-protein, which dissociates from the GPCR and the α subunit is 
freed and able to modulate other proteins, known as effector proteins, within the cell 
(Dessauer et al, 1996; Wettschureck & Offermanns, 2005). The cAMP signaling 
pathway is among the principal ones regulated by GPCRs with adenylate cyclase 
(AC) being the effector protein. AC, which increases during the menstrual cycle, 
catalyzes the conversion of adenosine triphosphate (ATP) into the ubiquitous second 
messenger cAMP (figure 1.3 A). Increased concentrations of cAMP during the 
secretory phase of the menstrual cycle are not only due to the increased activity of AC 
but also to a parallel decrease in degradation of the second messenger (Mehats et al, 
2002). Breakdown of cAMP into AMP is catalyzed by phosphodiesterases (PDE). In 
HESCs PDE4 and PDE8 are the predominant isoforms and inhibition of PDE4 was 
shown to be sufficient to induce expression of decidual marker genes (Bartsch et al, 
2004). This further highlights the role of cAMP in initiating decidualization. Two 
cAMP molecules bind to each of the two regulatory subunits of protein kinase A 
(PKA), causing a conformational change that leads to the release of the two catalytic 
subunits. They phosphorylate cytoplasmic and nuclear target molecules thus 
propagating the extracellular signal.  
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Once migrated in the nucleus of HESCs the catalytic subunit of PKA phosphorylates 
numerous target proteins. These include cAMP response element binding protein 
(CREB), cAMP response element modulating protein (CREM), CCAAT-enhancer 
binding protein (CEBP), STAT5 and Forkhead box protein O1 (FOXO1, also known 
as FKHR) (figure 1.4) (Brosens & Gellersen, 2006; Christian et al, 2002a; Gellersen 
et al, 2007; Gellersen & Brosens, 2003; Mayr & Montminy, 2001; Skalhegg & 
Tasken, 2000).  
CREB and CREM are two proteins which belong to the basic region/leucine 
zipper (bZIP) transcription regulator family (Walker & Habener, 1996). Once 
activated by PKA-dependent phosphorylation they bind to the cAMP response 
element (CRE) on the promoter of cAMP-regulated genes (Walker & Habener, 1996). 
These proteins, which dimerize through the leucine zipper and bind to the CRE 
through the basic region, consist of a bipartite trans-activation core domain that 
consists of one or two glutamine-rich regions. They also have a central kinase-
inducible domain containing phosphorylation sites. Once phosphorylated CREB is 
activated and able to bind to the DNA. Phosphorylated CREM functions as a 
transcriptional activator by forming homo- or kinase-inducible domain containing 
phosphorylation sites (Mayr & Montminy, 2001). Once phosphorylated CREB is 
activated and able to bind to the DNA. Phosphorylated CREM forms heterodimers 
(with CREB) and it can further enhance its activity by complexing with CREB 
Binding Protein (CBP). CREB is constitutively expressed and strictly regulated by its 
phosphorylation state. Due to differential promoter usage and alternative splicing the 
cells express a multitude of different isoforms of these two genes (Gellersen et al, 
2002; Gellersen et al, 1997). According to the constituents of the trans-activation 
domain, they can act both as transcriptional activators and repressors (Skalhegg & 
Tasken, 2000). Of particular interest is the inducible cAMP early repressor (ICER) 
isoform of CREM, which is expressed from an alternative internal promoter and 
contains the C-terminal bZIP region (composed of two DNA binding domains and the 
dimerization domain) but lacks the N-terminal transactivation functions. It dimerizes 
with CREB and CREM acting as a potent regulator and establishing a strong negative 
feedback loop which downregulates cAMP inducible promoters including its own, P2 
(Foulkes et al, 1996).  
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Interestingly though, HESCs are an exception to this as ongoing cAMP stimuli 
do not result in a transient increase in ICER but rather in sustained high levels of it, 
thus these cells are permissive to ongoing cAMP activation (Gellersen et al, 1997). 
cAMP-mediated expression of decidual specific genes are not strictly regulated by 
binding of CREB and CREM to the CRE. A study suggests that the classic 
PKA/CREB/CREM pathway may be responsible for the initial weak decidual-
response which is then sustained by alternative cAMP-dependent signaling events 
involving activation of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase complex and ROS production (Al-Sabbagh et al, 2011). 
One of the key mediators of cAMP during decidualization is thought to be 
CEBPβ. CEBPβ, also a member of the bZIP transcription factor family, plays a 
critical role in female reproduction (Ramji & Foka, 2002). It is required for ovulation 
as well as development and function of the mammary glands. During the menstrual 
cycle its expression increases with the onset of the secretory phase (Christian et al, 
2002c). It is induced by cAMP and is highly expressed during decidualization where 
it acts as a key regulator of many decidual-specific genes (Pohnke et al, 1999). This 
protein has two isoforms: the full length liver-enriched activator protein (LAP) and 
the truncated liver-enriched inhibitory protein (LIP) that lacks the N-terminal 
transactivator domain. HESCs only express the LAP isoform, whose regulatory 
activity is enhanced by interacting with the progesterone receptor (PR) (Christian et 
al, 2002b; Christian et al, 2002c).  
FOXO1 is part of the winged helix family of transcription factors and is a 
helix-turn-helix DNA binding protein with a butterfly-like appearance. It increases 
during the late secretory phase of the menstrual cycle and is regulated by PKA. 
FOXO1 is found in many multimeric transcription complexes and is a mediator in cell 
fate decisions, response to growth factors as well as hormonal and environmental cues 
(Accili & Arden, 2004; Christian et al, 2002a). Upon treatment of HESCs with cAMP 
FOXO1 is induced and translocates to the nucleus where it interacts with CEBPβ to 
enhance expression of decidual specific genes such as PRL and insulin-like growth 
factor binding protein 1 (IGFBP-1) (Accili & Arden, 2004; Buzzio et al, 2006; 
Christian et al, 2002c; Kim et al, 2005; Kim et al, 2003). In the presence of progestin 
a considerable fraction of FOXO1 translocates into the cytoplasm. FOXO1 has a 
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paramount role as an effector of the decidual response and as a mediator of the 
cAMP-signaling pathway.  
 Another important cAMP-regulated transcription factor involved in 
modulating decidual genes is the signal transducer and activator of transcription 5 
(STAT5). The STAT family is composed of seven members (STAT1, STAT2, 
STAT3, STAT4, STAT5a, STAT5b and STAT6) that are implicated in growth and 
differentiation of a wide range of cells. During the secretory phase of the cycle 
STAT5a and STAT5b are expressed in the glandular epithelium and in a subset of 
stromal cells, which express the PRL receptor (Jabbour et al, 1998; Ramji & Foka, 
2002). cAMP-signaling leads to the phosphorylation of a conserved tyrosine residue 
causing STAT5 to dimerize and translocate to the nucleus where it enhances 
expression of decidual gene such as PRL (Mak et al, 2002).  
Due to the critical role of cAMP during the menstrual cycle it is not surprising 
that the signaling cascade is regulated at virtually all the levels starting from the 
expression of adenylate cyclase and the receptors. As already mentioned not only 
anabolism of the second messenger is controlled but so is its catabolism, which is 
under the action of phosphodieasterases. By modifying the composition of the PKA 
holoenzyme the cell is able to further modulate signal transduction.  
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1.1.3.2 Progesterone maintains the decidual phenotype 
The cAMP cascade activates a multitude of factors that not only contribute to 
the expression of decidual-specific genes but also to the expression and secretion of 
cytokines and growth factors that induce decidualization, both in a paracrine and 
autocrine manner. Although cAMP induces expression of decidual marker genes it is 
unable to sustain prolonged expression of these genes and, as a matter of fact, of the 
decidual phenotype in general. For full decidualization and sustained expression of 
this phenotype the synergistic effects of cAMP and progesterone are required 
(Brosens et al, 1999). Treatment of HESCs with progesterone alone only induces a 
modest decidual response (Gellersen & Brosens, 2003).  
The progestational steroidal ketone (progesterone), produced by the corpus 
luteum in the later half of the menstrual cycle is thus critical to maintain the decidual 
phenotype induced by cAMP (Graham & Clarke, 1997). In the absence of pregnancy, 
luteolysis and falling levels of circulating progesterone provide the endocrine cues 
during the late secretory phase for menstrual shedding. In the presence of a conceptus, 
the corpus luteum will maintain high progesterone levels for the first trimester until 
the placenta synthesizes the hormone (Graham & Clarke, 1997).  
The hydrophobic 21-carbon steroid hormone, consisting of four hydrocarbon 
rings containing ketone and oxygenated functional groups and two methyl branches 
(figure 1.3 B), diffuses through the plasma membrane where it binds to the 
intracellular progesterone receptor (Norman et al, 2004). PR is a ligand activated 
transcriptional factor that functions in the nucleus as a modulator of gene expression. 
There are two different isoforms of PR arising from differential promoter usage: PR-
A and PR-B (figure 1.5) (Kastner et al, 1990). The shorter PR-A isoform, lacking the 
164 N-terminal amino acids, is the predominant one in HESCs (Brosens et al, 1999; 
Mote et al, 1999; Wang et al, 1998).  
Binding of progesterone to PR causes a conformational change which leads to a series 
of events including dissociation from the multimeric chaperone complex (containing 
heat shock proteins), phosphorylation, dimerization and sumoylation (Chauchereau et 
al, 2003; Christian et al, 2002a; Jones et al, 2006).   
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This ultimately results in the binding and activation of specific response elements on 
target genes. Recruitment of the basal transcription machinery to specific promoters 
by activated PR requires interaction of steroid receptor co-activators (SRCs) 
(Giangrande et al, 2000). This results in the recruitment of, among other things, 
histone acetyl transferases (HATs), such as p300/CBP-associated factor (pCAF), and 
methyltransferases like the coactivator associated arginine methyltransferase 1 
(CARM1) (figure 1.6) (Chen et al, 1999; Wardell et al, 2002).  
CBP/p300 HAT activity has been widely characterized: it is able to acetylate 
lysine residues in the amino-tails of all four histones either free in solution or 
assembled into chromatin (Kraus et al, 1999; Ogryzko et al, 1996). CBP/p300 not 
only hyperacetylates promoters to which it is recruited but it also coordinates 
assembly of essential proteins such as the RNA polymerase II (RNA pol II) 
holoenzymes, CREB, CREM, FOXO1 and CEBPβ to the transcription start site 
(Georges et al, 2002; Glass & Rosenfeld, 2000). It thus acts as the contact between 
the signaling cue, the chromatin landscape and the transcriptional machinery. In 
HESCs, it is recruited to the pre-initiation transcriptional complex containing 
progesterone through SRC-1. SRC-1 itself is crucial for the stabilization of the pre-
initiation complex both by, as described above, interacting and recruiting other 
transcription factors and by acetylating histone tails, either directly or through 
recruitment of other more potent HATs (Wieser et al, 2002). The co-activator’s C-
terminus domain has HAT activity, although weaker than that presented by 
CBP/p300. Acetylation of the histones further stabilizes the complex as it facilitates 
transcription both by allowing the chromatin to decondense and by serving as 
anchoring points for other proteins. Hence, progesterone binding to PR leads to a 
series of events that result in the recruitment of a myriad of co-activators, chromatin 
remodeling complexes and the transcriptional machinery to target genes. PR is able to 
control the expression of a variety of genes involved in decidualization and cell fate 
decision even if they lack a progesterone response element (PRE). It hijacks other 
transcription factors, thus being able to indirectly bind to a wide range of response 
elements. FOXO1, CEPBβ, p53 and STAT5 all form multimeric complexes with PR; 
in fact the steroid receptor stabilizes these transcription factors and enhances their 
modulatory activity (Maruyama & Yoshimura, 2008).  
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In summary, progesterone released by the corpus luteum following ovulation 
carries out genomic actions which, in HESCs, regulate their transcriptome and assure 
the maintenance and enhancement of the decidual response. Indeed, once 
decidualization of the stromal compartment has occurred the fate of the endometrium 
becomes progesterone dependent. In the absence of pregnancy the decline in 
progesterone concentration ultimately leads to menstrual shedding of the superficial 
endometrial layer (Brosens & Gellersen, 2006).  
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1.1.3.3 cAMP and Progesterone cross-talk 
The human endometrium is exposed to progesterone for nine/ten days before 
decidualization is observed and only a handful of genes respond to the hormone in the 
short term (Watanabe et al, 2005). These genes include the decidual protein induced 
by progesterone, Depp, which is upregulated within 30 minutes of progesterone 
exposure, but whose function still remains to be fully elucidated (Watanabe et al, 
2005). The promelocytic leukemia zinc finger protein (PLZF) is also an early-
response gene which functions as a transcription repressor involved in controlling the 
cell cycle and conferring resistance to apoptosis (Shaknovich et al, 1998). Although 
HESCs are not readily responsive to progesterone, this hormone is absolutely 
essential for the maintenance and the enhancement of the cAMP-induced decidual 
response. Indeed, cAMP sensitizes HESCs to the progesterone signaling leading to a 
cross talk between the two pathways. In vitro, treating stromal cells with both cAMP 
and progesterone results in enhanced decidualization. cAMP activation of the PKA 
pathway disrupts the interaction between PR and its corepressors (such as the histone 
deacetylases – HDACs – and the nuclear receptor corepressors 1 and 2 -N-CoR and 
SMRT, respectively) (Wagner et al, 1998), thus liberating the receptor and facilitating 
recruitment of the coactivator SRC-1 (Rowan et al, 2000). cAMP also attenuates 
sumoylation of PR-A, which increases PR activity and ultimately PR-A dependent 
transcription (Jones et al, 2006). Furthermore, cAMP induces expression of 
transcription factors, such as FOXO1, specificity protein (SP) 1, STAT5 and CEBPβ 
which all have been shown to form multimeric complexes with PR (Maruyama & 
Yoshimura, 2008).  
In summary, following ovulation the human endometrium is under the control 
of progesterone; however its action on HESCs is only evident about nine days later. 
Other local and endocrine factors, by increasing cAMP concentrations, activate the 
PKA pathway. This leads to a cascade of events and to the expression of key 
transcription factors and co-activators which form multimeric transcription complexes 
with progesterone-bound PR. Recruitment of other transcription factors by PR allows 
the hormone receptor to control numerous genes essential for decidualization, even on 
promoters lacking the PRE, such as prolactin. Once cAMP sensitizes HESCs to 
progesterone, the decidual phenotype becomes dependent on the steroid hormone.   
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1.1.4 Regulation of PRL and IGFBP-1 
 Prolactin is a key decidual gene widely used as a marker of decidualization 
(Telgmann & Gellersen, 1998). PRL in HESCs is implicated in a wide range of 
functions including trophoblast growth, angiogenesis, modulation of the immune 
system and, in a paracrine manner, regulation of epithelial cell differentiation. This 
hormone is expressed in pituitary lactotrophs, in hematopoietic cells, in dermal 
fibroblasts and in decidual cells (Lynch et al, 2009). PRL is transcribed from a single 
copy gene composed of five exons (exons 1 to 5). Pituitary PRL is expressed from the 
transcription start site (TSS) found on exon 1 and contains several binding sites for 
pituitary-specific transcription factors (Truong et al, 1984). Decidual cells use an 
alternative TSS located on an additional non-coding exon (exon 1a) found 6kb 
upstream of the pituitary TSS. This results in a transcript with an elongated 5’UTR 
although the resulting protein is identical to the pituitary PRL (Gellersen et al, 1989).  
 The PRL promoter contains two transposable elements: medium reiterated 
frequency repeat (Mer) 20 (located -395 to -148 bp from the TSS) and Mer39 (figure 
1.7 A) (Emera et al, 2011). Mer 39 has binding sequences for CREB and the 
transcription factor ETS-1. Mer20, which is eutherian specific, carries a wide range of 
regulatory elements for proteins such as the nuclear factor NFκB, the Transforming 
Growth interacting factor, CAAT displacement protein, the ubiquitous cofactor Oct-1 
and a crucial enhancer region located at –332 to -270 bp from the TSS (-332/-270 bp 
TSS) (Christian et al, 2002b; Gellersen et al, 1994). This region contains binding sites 
for HoxA-11 and PKA-activated, PR-interacting proteins such as FOXO1 and 
CEBPβ. cAMP-dependent activation of the PRL promoter is biphasic: an initial and 
very rapid, albeit weak, response is mediated by the imperfect CRE sequence 12 bp 
upstream from the TSS. It is then followed by a delayed (about 12 hours after cAMP 
treatment) but much stronger induction orchestrated from the Mer20 enhancer region 
-332/-270 bp TSS. It must be noted that the rapid CRE-dependent expression of PRL 
is not crucial for the later upregulation as mutation of the CRE sequence still leads to 
elevated PRL following PKA activation (Emera et al, 2011; Lynch et al, 2009; 
Telgmann & Gellersen, 1998; Telgmann et al, 1997). Interestingly, this region, and 
the PRL promoter as a whole, lacks a full PRE but rather has a PR binding half site 
adjacent to the two overlapping CEBPβ binding sites. Indeed, PR has been shown to 
transactivate PRL via CEBPβ.  
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The LIP isoform of CEBPβ only interacts with PR-B and favors the expression of PR-
dependent genes containing PRE on their promoters. On the other hand, LAP 
associates with PR-A and regulates CEBPβ-dependent genes such as PRL (Christian 
et al, 2002b). LAP is not the only example of PKA mediated transcription factors that 
interact with PR on this promoter. Another example is FOXO1, which also has a 
consensus binding site on -332/-270 bp TSS of the PRL promoter. FOXO1 response 
elements overlap the CEBPβ sites located on opposite strands of the promoter. As a 
matter of fact, FOXO1 has been shown to enhance CEBPβ transactivation of PRL 
(Christian et al, 2002c). Furthermore, the two transcription factors cooperate in the 
recruitment of shared co-activators. FOXO1 also interacts with HoxA-11 on the PRL 
promoter (Lynch et al, 2009). HoxA-11, one of the homeobox proteins, is a hormone-
inducible cofactor, and along with HoxA-10 is expressed in the mid-lutheal phase of 
the menstrual cycle. Both Hox proteins are involved in implantation of the embryo. 
Intrinsically, HoxA-11 is a potent repressor of PRL, however, interaction with 
FOXO1 transforms it into an activator of this decidual gene and together they form 
part of the multimeric transcriptional complex containing p300, CEBPβ and perhaps 
RNA Pol II and PR as well (Lynch et al, 2009). FOXO1 also interacts with HoxA-10 
and they have been shown regulate the IGFBP-1 promoter in HESCs but not the PRL. 
So, although both associated with FOXO1 HoxA-10 and -11 target different genes, 
further indicating that expression of decidual genes is under a complex and precise 
control of multiple and extremely specific transcription factors.  
IGFBP-1 is one of the major secretory proteins in decidual cells and is thought 
to be implicated in mitogenesis during differentiation of HESCs. It acts as a regulator 
of cellular function during the late secretory phase of the cycle and early pregnancy 
(Giudice et al, 1992a; Giudice et al, 1992b). The IGFBP-1 promoter has an insulin 
response element, to which FOXO1 binds to, two PREs, a very active distal SP1 site 
and an SP3 one, as well as a proximal CAAT site, which represses the promoter 
(figure 1. 7B) (Durham et al, 1999; Gao et al, 2000b).  As for PRL, FOXO1 interacts 
with PR and this further stabilizes the transcription machinery.  
The SP proteins are important transcription factors involved in early 
development. SP1 expression, which is cAMP dependent, increases in the secretory 
phase, whereas SP3 is downregulated in decidual cells. SP3 is a competitive repressor 
of SP-1 dependent transcription and the ratio of the two proteins is crucial in gene 
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regulation. The tipping of this fine balance towards an increase in SP1 concentration 
on the IGFBP-1 promoter is thought to be responsible for 95% of this gene’s 
induction (Gao et al, 2000a). Like PRL, IGFBP-1 expression requires activation of the 
PKA cascade and binding of progesterone to its receptor to fully orchestrate its 
induction. 
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1.1.5 Decidualization and Recurrent Pregnancy Loss 
 Compared to most mammalian species, human reproduction can only be 
described as inefficient. Monthly fecundity rates in fertile couples are low, on average 
20%. This is largely attributable to the high incidence of embryo loss, estimated to be 
30% prior to implantation (pre-implantation loss) and a further 30% before 6 weeks 
gestation (pre-clinical/biochemical pregnancy loss). In addition, in excess of 10% of 
clinical pregnancies result in miscarriage, mostly prior to 12 weeks gestation, and 1-
2% of couples experience recurrent pregnancy loss (RPL), defined as failure of 3 or 
more consecutive pregnancies (Teklenburg et al, 2010a). 
 RPL, along with infertility, is among the prevalent causes of reproductive 
failure. Absence of decidualization results in infertility (Lee et al, 2007) whereas 
impaired differentiation of HESCs results in altered embryo-maternal interactions 
leading to RPL (Salker et al, 2010). Numerous anatomical, endocrine, immunological, 
thrombophilic and genetic perturbations have been associated with RPL, yet none are 
specific or prevalent. It is however thought to be due to a failure in natural embryo 
quality control (Quenby et al, 2002). Indeed, decidual cells recognize and eliminate 
unwanted implanting embryo acting as biosensors of embryo viability (Teklenburg et 
al, 2010b) and are implicated in terminating the uterine window of embryo 
receptivity. Recent studies suggest that women suffering from RPL present impaired 
decidualization. Studies on both endometrial biopsies and cultured HESCs showed 
that patients with recurrent miscarriages had lower levels of PRL than the control 
group; this suggests an aberrant decidual response (Salker et al, 2010; Teklenburg et 
al, 2010b). Furthermore, they presented higher levels of prokineticin-1 (PROK-1) that 
is a cytokine involved in promoting embryo receptivity and promotes embryo-uterine 
interaction by inducing leukemia inhibitor factor. Interestingly, in HESCs derived 
from patients with RPL and decidualized in culture PROK-1 level remained high even 
after eight days of treatment rather than declining as occurs in patients not affected by 
this disorder (Salker et al, 2010).  This implies that there is not only an enhanced 
uterine receptivity but that it is also prolonged in time. Furthermore, the decrease in 
PRL levels, and of the decidual response, suggest a less stringent embryo selection. 
Women who have had even more than three recurrent miscarriages may have a 
successful pregnancy, which would show that this is a modifiable programming event, 
perhaps of epigenetic nature. Menstrual preconditioning and the repeated 
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inflammatory events and tissue trauma associated with each cycle may be crucial to 
sensitize the endometrium to environmental signals and coordinate a precise spatio-
temporal decidual response (Brosens et al, 2009).  
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1.2 Epigenetics 
Epigenetics is the study of hereditable changes in gene functions which are not 
controlled by changes in the DNA sequence (Dupont et al, 2009). As known, the term 
derives from the Greek επί, (epi), above and γενετικός (genetikos), origin so above 
genetics. These molecular signatures must be hereditable, self-propagating and 
reversible (Bonasio et al, 2010). Usually the term epigenetics has been used for many 
regulatory systems including DNA methylation, histone post translational 
modifications (PTMs) and histone variants, nucleosome localization, non-coding 
RNAs (ncRNA) and, although an unusual form, prions (figure 1.8) (Bonasio et al, 
2010; Halfmann & Lindquist, 2010). There is widespread debate on whether histone 
PTMs are truly epigenetic marks as to date the mechanism by which the modification 
is transmitted onto chromatin of replicating DNA has yet to be discovered 
(Riddihough & Zahn, 2010). Similar issues arise with regards to the different variants, 
ncRNAs and nucleosome positioning. Although it can be argued if these mechanisms 
pass on the memory of a given chromatin state, and are hence hereditable, they 
undoubtedly implement cellular memory. Therefore, in a wider sense, where 
epigenetics encompasses any molecular mechanism that alters the outcome of a given 
genomic region without altering the DNA sequence, histone modifications can be 
considered an epigenetic mechanism. DNA methylation is mostly responsible for the 
long term global repression of the chromatin whereas other marks such as covalent 
histone modifications and ATP-dependent remodeling of the nucleosome tend to have 
more short-term local effects stimulated by environmental cues. Epigenetics is 
fundamental for X-inactivation, commitment of the cells to a particular lineage, 
maintain nuclear organization and function as well as guaranteeing genome stability 
by condensing centromeres and telomeres and by silencing transposable elements 
(Bonasio et al, 2010). For example, the transposable element Mer20 harbors 
regulatory elements on the PRL promoter, alters the epigenetic landscape of the 
genomic region it is found in and bears the typical epigenetic marks associated with 
enhancers (Emera et al, 2011).   
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Figure 1.8 Epigenetic Mechanisms
Epigenetics is the study of hereditable changes in gene functions which are not controlled by changes 
in the DNA sequence but rather by other mechanisms such as DNA methylation, histone modifications, 
histone variants and chromatin binding proteins.  
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1.2.2 DNA methylation 
DNA methylation is the epitome of the epigenetic mark as it is the only one 
which, strictly speaking, satisfies the three criteria of epigenetics: hereditability, self-
propagation and reversibility (Klose & Bird, 2006). It is found in prokaryotes, on 
cytosines and adenines, and is associated with the restriction modification system. In 
eukaryotes, it only occurs on cytosines and plays a crucial role in chromatin 
repression and inhibition of gene expression. It is involved in numerous processes 
such as X-inactivation, genomic imprinting, embryonic development, tumor 
suppression and chromosome stability and, in general, with the formation of 
heterochromatin (Prokhortchouk & Defossez, 2008).  
DNA methylation is believed to carry out its function by hampering the 
recognition of the transcription factor to its response element by masking the cytosine. 
For example methylation of the CRE consensus sequence inhibits CREB binding and 
transcription of the downstream gene (Iguchi-Ariga & Schaffner, 1989). Nuclear 
positioning may also be affected by the modified cytosine and this could lead to the 
assembly of specialized nucleosome structures that repress transcription (Kass et al, 
1997). The third mechanism by which DNA methylation is able to regulate expression 
is by recruiting nuclear factors and methyl-CpG binding proteins to target sites. This 
impedes binding of transcriptional activators and interacts with other co-repressors to 
form a complex and to silence the loci directly.  
 DNA methyltransferases (DNMTs; EC 2.1.1.37) are a family of enzymes that 
transfer a methyl group from S-adenosyl-L-methionine (SAM), which then becomes 
S-adenosyl homocysteine (SAH), to the position 5’ of the cytosine pyrimidine ring of 
a CpG dinucleotide (Bestor, 2000; Law & Jacobsen, 2010; Wu & Santi, 1985). 
DNMTs bind to the DNA and flip the cytosine so that it protrudes out of the double 
helix and into the active site pocket of the enzyme, which through a nucleophilic 
attack covalently binds the base on the carbon in position 6 via a conserved cysteine 
residue. The methyl group is then transferred from SAM to the carbon 5 of the 
pyrimidine ring of the nucleotide. The newly added monocarbon group remains 
projected into the major groove of the double helix and when the CpG is 
symmetrically methylated both groups face in the same direction in proximity of one 
another (Jeltsch, 2006a). The mammalian genome has a CG content of 40-45% of 
which only 2-8% are found in CpGs and of these 60-90% are methylated. The 5mCs 
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represent 0.75-1% of total nucleotides with 4-6% of them lying outside CpGs. CpG 
islands (CGIs) are genomic regions of no more than 500 bp which have a CG content 
greater than 55%, an average CG periodicity of 8-19 bp, and have an observed to 
expected CpG ratio of 0.62. About 40-60% of all promoters have CGIs but about half 
of the total CGIs are actually found in inter- or intra-genic regions (Espada & Esteller, 
2010). One study showed that intragenic DNA methylation leads to a decrease in 
RNA pol II occupancy and chromatin accessibility (Lorincz et al, 2004).  
 The most abundant DNMT in human somatic cells is DNMT1, which shows a 
strong preference for hemimethylated DNA and colocalizes at the replication fork 
during the S-phase of the cell cycle (Espada & Esteller, 2010; Klose & Bird, 2006). 
DNMT1 is also known as the maintenance DNMT as it methylates the nascent 
daughter strand during replication and when only one strand of the DNA is modified 
(as during DNA damage). This enzyme is retained responsible for the memory and 
hereditability of DNA methylation. DNMT1 assures 5mCs are maintained within the 
cells and in daughter cells (Chuang et al, 1997; Leonhardt et al, 1992; Yokochi & 
Robertson, 2002). DNMT3a and DNMT3b, on the other hand, preferentially add the 
mark on unmethylated CpGs, hence are termed de novo methylases (Okano et al, 
1999). They are mostly found in embryonic and undifferentiated cells where two 
waves of de novo methylation occur following demethylation and are crucial for 
development. DNMT3L lacks the canonical DNA methyltransferase domain and thus 
has no catalytic potential (Goll & Bestor, 2005). It interacts with the other DNMT3s 
functioning as a co-factor and modulates their activity. For example DNMT3L 
associates with an unmodified histone residue associated with gene repression (lysine 
4 of the histone H3) and targets DNMT3a to imprinted genes following the wave of 
demethylation in primordial germ cells (Goll & Bestor, 2005; Jeltsch, 2006b). The 
fifth DNMT, DNMT2, is similar in sequence to the other members of the family, 
although it lacks the N-terminal regulatory domain and has a very weak DNA 
methyltransferase activity. Indeed, knockout experiments showed no effects on global 
methylation. Despite the sequence homology with the DNMTs it actually methylates 
the aspartic acid in position 38 of transfer RNA rather than DNA (Goll et al, 2006). 
 The fifth base, 5’-methylcytosine (5mC), is directly recognized by three 
protein families. Two of them bind both methylated and unmethylated DNA, the ones 
containing the methyl-CpG binding domain (MBD) and the Zinc-finger proteins 
(Filion et al, 2006; Klose & Bird, 2006; Prokhortchouk et al, 2001). The protein 
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family harbors the SET and RING finger associated (SRA) domain, which only 
interacts with CpGs containing the monocarbon alkyl. DNMT1 is believed to be 
recruited to hemimethylated CpGs at replication forks and repair sites by the 
ubiquitin-like plant homeodomain finger domain 1 (UHRF1), one of the SRA 
proteins. Mutations in the SRA domain result in global hypomethylation (Bostick et 
al, 2007; Woo et al, 2008). UHRF1 physically binds the DNA and stabilizes DNMT1-
chromatin interaction. Studies showed that UHRF1 also interacts with DNMT3a and 
DNMT3b (Meilinger et al, 2009). Some studies speculate that UHRF1 may also be 
able to bind histone tails, further integrating DNA methylation with other epigenetic 
marks to strengthen, maintain and distribute the repressed chromatin state (Hashimoto 
et al, 2009). 
 Another protein which is essential for DNA methylation is the helicase 
lymphoid specific (HELLS or lymphoid-specific helicase 1, LSH) (Myant & 
Stancheva, 2008). It is a member of the SNF2 family of chromatin-modifying 
proteins. SNF2 members make up the SNF/SWI ATP-dependent complexes, which 
are essential to disrupt DNA-histone interactions and allow nucleosome sliding 
(Brzeski & Jerzmanowski, 2003; Huang et al, 2004). This results in an increased 
accessibility of the chromatin by protein complexes and transcription factors. Loss of 
HELLS results in a global loss of methylation, although the precise mechanism by 
which it mediates DNMT activity remains unknown (Huang et al, 2004). This enzyme 
mostly associates with repetitive elements in pericentromeric heterochromatin. It has 
been shown to physically interact with DNMT3a and DNMT3b as well as with 
HDACs. Furthermore, HELLS is also a crucial mediator of histone methylation (Niu 
et al, 2011; Yan et al, 2003). These roles of HELLS in mediating DNA methylation, 
nucleosome positioning and covalent modification of histone tails are a very elegant 
example of how the different epigenetic mechanisms work in a cooperative manner in 
orchestrating formation and maintenance of heterochromatin.  
 DNA methylation in mammals has been widely characterized, but the reverse 
mechanism still remains a mystery. The dynamism of DNA methylation and the 
global waves of demethylation during early development suggest the existence of a 
mechanism which actively remove the methyl group (Wu & Zhang, 2010). However, 
to date specific machinery has yet to be discovered. Various hypotheses on how 
demethylation is achieved have been proposed. Direct removal of the methyl group by 
a dedicated enzyme would be the simplest way, albeit extremely thermodynamically 
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unfavorable (Cedar & Verdine, 1999; Kress et al, 2001; Smith, 2000). To date no 
compelling evidence has been found of an enzyme responsible of breaking the very 
stable carbon-carbon covalent bond between the methyl group and the cytosine. 
Another proposed mechanism, which is present in plants, is by recruitment of DNA 
glycosilases which remove the 5mC resulting in an abasic site. The base excision 
repair (BER) machinery is then recruited to replace the cytosine (Ikeda & Kinoshita, 
2009; Sancar et al, 2004). Again, there is a lack of evidence that this also occurs in 
mammals. Another proposed mechanism is through deamination of the fifth base, 
which then becomes a thymine. This then requires the T/G mismatch to be replaced 
by BER. Recent studies also suggest that DNA demethylation may involve a DNA-
repair-like process whereby methylated cytosines are excised by nucleotide excision 
repair (NER) (Barreto et al, 2007). How this process is initiated still remains 
unknown. A less studied mechanism, which seems to occur only in the paternal 
pronuclei genome-wide demethylation, is that of radical SAM-based mechanism (Wu 
& Zhang, 2010). Recent studies have identified a new potential mechanism for active 
demethylation through oxidative demethylation that involves the ten-eleven 
translocation protein (TET) 1. TET1 converts 5mC into 5-hydroxymethylcytosine 
(5hmC), which in turn acts as an intermediate for various possible mechanisms (Ito et 
al, 2010; Tahiliani et al, 2009; Valinluck & Sowers, 2007). Ultimately these result in 
the replacement of 5hmC with an unmodified cytosine. The 5hmC may also play a 
role in passive demethylation as CpG binding proteins and DNMTs have low affinity 
for this “base” (Valinluck & Sowers, 2007). 5hmC may actually be the sixth base as it 
is stable and may act like the other chromatin marks affecting secondary and tertiary 
structure of the DNA and/or chromatin, although its functions still remain unclear.  
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1.2.3 Histone modifications 
The building block of chromatin is the nucleosome, which is 147 bp of DNA, 
wrapped in a 1.67 left handed super helical turns around a histone octamer. The 
octamer is composed of a central heterotetramer of histones 3 (H3) and 4 (H4) 
flanked by two heterodimers of histones H2A and H2B (figure 1.9). The nucleosomes 
are arranged in a beads-on-string fashion with 10-60 bp of linker DNA between each 
one. This 10 nm chromatin fiber is then folded into thicker fibers of 30 nm stabilized 
by linker histones (which are different in sequence and unrelated to the core histones) 
that bind to each nucleosome. The chromatin is further condensed into interphase 
fibers of 100-400 nm thick. During metaphase the chromatin structure becomes even 
more complicated and condensed (Hansen, 2002; Kornberg, 1974; Kornberg & 
Thomas, 1974; Peterson & Laniel, 2004).  
The core histones have a globular domain, around which the DNA is wrapped, 
that mediates interaction between each histone. The histone tails are the 20-35 amino 
acid N-terminal domains rich in basic residues. H2A is the only histone to also have a 
35 amino acid C-terminus tail. The two types of tails are involved in condensation of 
the nucleosomes into higher order chromatin structures rather than conferring stability 
to the structure of the nucleosomal array (Peterson & Laniel, 2004). These N-terminal 
domains can harbor covalent PTMs, known as histone marks. Recent studies suggest 
that some modifications may also occur on the C-terminus tail and, to a lesser extent, 
on the central domain as well (Mersfelder & Parthun, 2006; Robzyk et al, 2000). 
Fourteen different residues can be modified on the N-terminal histone tails (of H3 and 
H4) alone and over sixty different PTMs have been identified. This number is thought 
to be an underestimate. These modifications include acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ADP-ribosylation, deimination and 
proline isomerization (Kouzarides, 2007a). Methylation occurs exclusively on lysines, 
which can be mono-, di- or tri-methylated, and on arginines which can accept up to 
two groups. Lysines can also be ubiquitinylated or sumoylated, whereas 
phosphorylation occurs exclusively on serines or threonines. A single PTM, or a 
combination of them, usually correlate with either gene silencing or activation. For 
example acetylation and phosphorylation are usually associated with gene 
transcription whereas the other marks tend to silence genes.   
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Figure 1.9 Model of a Nucleosome and a Histone Methyltransferase Placing an Epigenetic Mark
The nucelosome is 147 bp of DNA wrapped around a histone octamer. The octamer is composed of a 
central heterotetramer of histones 3 (H3) and 4 (H4) flanked by two heterodimers of histones H2A and 
H2B. The histone have N-terminal tails of 20-35 amminoacid which can be covalently modified. The
most common of these modifications are methyaltion and acetyation. The histone methyltransferase 
EZH2, for example, trimethylates lysine 27 of  H3.
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Methylation and ubiquitinylation can act both as a repressor and as a gene activator 
(Kouzarides, 2007a; Peterson & Laniel, 2004). However, this “histone code” is not 
very strict and mostly depends on the chromatin context (Jenuwein & Allis, 2001; 
Strahl & Allis, 2000). There is a cross talk between histone PTMs, especially as these 
marks often occur in combination, as well as among other epigenetic mechanisms. 
Establishment of some motifs is dependent on other PTMs as well as on the CpG 
content of promoters. For example, high CG content promoters always carry 
trimethylation of H3K4 (H3K4me3) but promoters with low CG content gain the 
mark only when expressed. Another example is that of acetylation of H3K27 
(H3K27Ac), which is mostly found on active promoters with a high CG content 
(Karlic et al, 2010). This mark is thought to cooperate in activation of the promoter by 
both preventing trimethylation of that residue, a strong repressive mark, and by 
recruiting protein complexes that enhance transcription. Indeed in general histone 
acetylation usually precedes chromatin remodeling and transcription whereas 
trimethylation of lysine 27 on H3 (H3K27me3), associated with repression, plays a 
role in transcriptional memory (Bird, 2002). On the other hand, arginine methylation 
recruits RNA Pol II and a loss of methylation on this residue leads to dissociation of 
the polymerase. Acetylation tends to be a more transient mark as opposed to histone 
methylation and to the even more stable DNA methylation. Rather than an actual 
histone code which implies strict rules to “read” the marks they are more like histone 
patterns which may be interpreted depending on the cellular context and the 
surrounding chromatin environment (Liu et al, 2005). Histone marks contribute to the 
establishment of the chromatin state by recruiting other proteins that exhibit either 
transcription enhancer or repressor functions. Some histone marks rather than acting 
as stabilizers for other proteins might have steric effects occluding them from binding 
(Kouzarides, 2007a; Peterson & Laniel, 2004). PMTs on histones are thought to affect 
chromatin packaging also by changing the charge of the histone tails and hence 
disrupt contacts between nucleosomes and between nucleosomes and DNA. Some 
studies, however, suggest that histone marks are unable to directly influence 
nucleosomal dynamics by perturbing ionic interactions with DNA and between other 
nucleosomes, as the change in charge is not sufficient. For example H3 tails have 
thirteen positively charged amino acids. If 1-4 of these residues gets acetylated it 
would only lead to a 10-30% decrease in positive charge (Peterson & Laniel, 2004). 
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The acetyl group is placed on the histone tail by the HAT proteins. Three 
families of HAT proteins are known in mammals: GNAT, MYST and CBP/p300 
proteins. These tend to be specific enzymes acting on certain residues only. As 
mentioned above, liganded nuclear hormone receptors interact with HAT complexes 
such as CBP/p300 to activate transcription of target genes (Kraus et al, 1999; 
Ogryzko et al, 1996). On the contrary, unliganded nuclear hormone receptors interact 
with HDAC complexes, such as NCoR and SMRT, which direct deacetylation of 
histone tails and thus repression of chromatin (Li et al, 2000). These enzymes are not 
very specific and belong to one of three families of HDACs (HDAC I- HDAC III).  
Instead, histone methyl transferases (HMTs) responsible for lysine modification are 
extremely specific. This high level of specificity could also be due to the wide 
spectrum of functions lysine methylation carries out (Cheung & Lau, 2005). For 
example methylation of K4 and K36 of H3 are involved in gene activation and 
transcriptional elongation, but methylation on K27 of H3 and K20 on H4 are 
associated with repression. H3K9 methylation can act both as a gene silencer or an 
activator according to its position within the gene, in the first case it is found on the 
promoter whereas in the latter in the coding region (Kouzarides, 2007a; Peterson & 
Laniel, 2004). These are just few examples to illustrate the complexity of the histone 
code. Methylation on lysine residues is removed by one of two types of lysine 
demethylases harboring either an LSD1 or a JMJC domain (Seenundun et al, 2010; 
Swigut & Wysocka, 2007). 
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1.2.4 Polycomb Repressive Complex 2 
One of the most widespread histone PTMs is methylation of H3K27. In 
embryonic stem cells 50% of H3K27 are dimethylated, 15% are monomethylated and 
a further 15% carry three methyl groups. Only 20% of lysine 27 on histone 3 are 
unmethylated and methylation is distributed on at least 10% of the genes (Margueron 
& Reinberg; Peters et al, 2003). Di and trimethylation of this residue, which is 
associated with repression, is placed by the polycomb repressive complex (PRC) 2 
and removed by the demethylases UTX and JMJD3 (Seenundun et al, 2010; Swigut & 
Wysocka, 2007). How H3K27 gets monomethylated remains an open question as 
PRC2 is only able to methylate H3K27me and H3K27me2. The function of 
H3K27me2 is unclear as it has limited silencing capacity, but likely it acts as an 
intermediate product of PRC2 and prevents acetylation of that amino acid (which is a 
strong transcriptional enhancer and antagonizes methylation) (Tie et al, 2009). 
Trimethylation of H3K27 acts as a docking platform for other repressive mechanisms 
as well as providing steric hindrance, which prevents certain proteins to bind histones. 
In mammals, distribution of this mark occurs around the TSS and, at a lesser density, 
at the TSS as well (Zhao et al, 2007). Some intragenic H3K27s may be decorated with 
trimethylation but this frequently features on telomeres and long terminal repeat 
retrotransposons (Cui et al, 2009; Leeb et al, 2010). The wider distribution of 
H3K27me3 is either in very large domains (greater than 100 kb) such as those 
containing the HOX genes, or in smaller domains of only few kilo base pairs (Boyer 
et al, 2006; Bracken et al, 2006; Lee et al, 2006).  
Polycomb group (PcG) proteins are transcriptional repressors that act as 
epigenetic regulators as they maintain gene silencing long after the initial stimulus. 
The action of these proteins is counteracted by the transcriptional activators trithorax 
group proteins (TRX), which in mammals are known as the MLL complex. It contains 
the histone methylase SET1, which binds RNA pol II during elongation, and ASH2L, 
essential for trimethylation of H3K4me2 (Schwartz & Pirrotta, 2007).  
Polycomb groups are crucial in development of many organisms (Margueron 
& Reinberg, 2011; Schuettengruber & Cavalli, 2009). PcG-proteins make up 
polycomb repressive complex 1 (PRC1) and PRC2. PRC1 forms various different 
complexes with only two components which always feature RING1A or RING1B and 
BMI1, MEL18 or NSPC1 (Margueron & Reinberg, 2011). PRC1 is able to compact 
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chromatin regardless of this enzymatic activity, although the precise mechanism 
remains unclear (Buchwald et al, 2006; Cao et al, 2005; de Napoles et al, 2004; Wang 
et al, 2004). It has also been shown to bind to H3K27me3. Although it would be 
tempting to speculate that PRC2 initiates repression and PRC1 maintains it, co-
localization studies have shown that not all PRC2 targets bind PRC1 and vice versa 
(Ku et al, 2008; Margueron & Reinberg, 2011).  
In mammals, the PRC2 is composed of: the histone-lysine-N-
methyltransferase enhancer of zeste homologue 1 (EZH1) or 2 (EZH2), the WD40 
domain protein ectopic endoderm development (EED), the zinc finger protein 
suppressor of  zeste 12 (SUZ12) and the retinoblastoma binding protein 4 and 7 
(RBBP4 and RBBP7, also known as RbAp48 and RbAp46, respectively) (Margueron 
& Reinberg, 2011). The enzymatic subunits, EZH1 and EZH2, di and trimethylate 
H3K27me, thus regulating chromatin structure. Whereas EZH1 is expressed both in 
dividing and non dividing cells, EZH2 is only present in proliferating cells. EZH2 has 
a stronger methyltransferase activity than its homologue (Margueron et al, 2008). 
Although the two enzymes have slightly different chromatin binding patterns, EZH2 
is implicated in establishing the di- and tri-methylation patterns whilst EZH1 restores 
H3K27me2/3, which are lost during histone exchange or because of demethylating 
enzymes. A mechanism has been proposed by which EZH2 locates at the replication 
forks with CAF1, PCNA (which is also known to localize with DNMT1 at the 
replication foci) throughout the S-phase and thus perpetuates the mark to the 
subsequent generations (Karlic et al, 2010). PRC2 also contains other proteins, albeit 
they are not essential for its activity. These proteins include the zinc finger protein 
adipocyte enhancer binding protein 2 (AEBP2); this protein enhances enzymatic 
activity of the complex and binds to the DNA, and to proteins of the polycomb like 
(PCL) family (Cao & Zhang, 2004; Kim et al, 2009). The three PCLs (PCL1, PCL2, 
PCL3) are differentially expressed in a tissue-specific manner and are also required to 
regulate the enzymatic activity of PRC2 as well as the recruitment of the complex to 
the target genes (Walker et al, 2010). PCLs strongly interact with EZH2 as well as 
with SUZ12 (although with less affinity) and with RBBP4 and RBBP7 (Nekrasov et 
al, 2007). The jumonji AT rich interactive domain 2 (JARID2) may also be found in 
PRC2 (Li et al, 2010). It belongs to the jumonji family of histone demethylases but 
lacks the enzymatic activity as it is missing essential residues implicated in cofactor 
binding. It however binds to EZH2 and DNA (preferring CG rich sequences) 
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inhibiting PRC2 activity, although in certain environments it may act as an enhancer 
of the complex (Li et al, 2010; Margueron & Reinberg, 2011).  
In Drosophila melanogaster PRC2 is recruited to the chromatin to specific 
polycomb response elements, in mammals however no such sequences have been 
identified and the precise recruitment mechanism remains unknown. Some studies 
suggest that the complex prefers regions of the DNA, which are rich in CG. As 
described above, some proteins which compose the complex such as JARID2 prefer 
GC regions (Li et al, 2010). Recently evidence has emerged on the role of ncRNAs as 
a possible mechanism to target PRC2 to the chromatin. For example, the 17 kb 
ncRNA, XIST, which is implicated in X-chromosome inactivation, has been shown to 
recruit PRC2. The ncRNA coats the chromosome and the latter becomes 
trimethylated on H3K27 in cis in a XIST-dependent manner (Maenner et al, 2010; 
Plath et al, 2003; Zhao et al, 2008). Another example of PRC2 directed to its target by 
ncRNA is promoted by HOTAIR RNA and results in repression of the HOXC and 
HOXD genes, although this time binding occurs in trans. Rather than the ncRNA 
sequence it is more likely that the tertiary structure of the ribonucleic acid is involved 
in this process (Khalil et al, 2009; Rinn et al, 2007; Tsai et al, 2010). It is probable 
that numerous mechanisms act together to direct PRC2, other than the one described 
above. Components of the complex themselves might be implicated in mediating 
PRC2 binding to the chromatin. For example, JARID2 and AEBP2 bind to the DNA; 
RBBP4 and RBBP7 interact with histones H3 and H4; PCLs associate with other 
histone marks and EED interacts with H3K27me3. PRC2 enzymatic activity is 
actually enhanced by the presence of the mark it catalyzes in a feedback manner 
(Margueron & Reinberg, 2011). The chromatin environment and the other marks 
present (or absent) might also direct PRC2 with further specificity. For example 
somatic cells reinforce repression by increasing the length of the H3K27me3 domains 
and by a complementary mechanism involving other repressive mechanisms such as 
DNA methylation and the presence of H3K9me3. Indeed PRC2 is known to interact 
with HDACs and DNMTs (Morey & Helin, 2010). However in certain contexts two 
antagonizing marks might coexist. This is especially true in embryonic stem cell 
differentiation where the majority of PRC target genes have both the repressive 
H3K27me3 mark, as well as the H3K4me3, which is linked with transcriptional 
activity (Rodriguez et al, 2008). These domains, known as bivalent domains, are 
occasionally found in somatic cells. They are in a ‘poised’ state where they are curbed 
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in a non-active state and the removal of the repressive mark leads to expression of the 
genes. These repressive mechanisms are not all-or-nothing and low levels of 
expression may be detected. Often shorter transcripts are expressed which actually act 
as repressors. 
There is compelling evidence showing that PRC2 directly controls DNA 
methylation. H3K27me3 acts as an anchorage point for DNMTs (Vire et al, 2006). 
All three DNMTs have been shown to interact with various Polycomb group (PcG) 
proteins. For example EZH2 interacts with the amino- and carboxyl- terminal 
domains of DNMT1 and with the PHD domains of the two DNMT3s. The DNA 
methyltransferases also interact with EED and SUZ12 interacts with their enzymatic 
activity (Hernandez-Munoz et al, 2005). This further shows the cooperation between 
different epigenetic mechanisms.  
PcG proteins are paramount players in cell differentiation. Indeed, most genes 
which are not required in a given cell type are silenced by PcG proteins and the 
H3K27me3 mark (Prezioso & Orlando, 2011). However, these proteins are also 
important in the dynamic response to environmental cues (Prezioso & Orlando, 2011). 
Pluripotency in embryonic stem cells is also maintained by, among other regulators, 
the PcG proteins and depletion of PRC2 components in mice results in early 
embryonic lethality (O'Carroll et al, 2001; Pasini et al, 2004). PRC1 and PRC2 
complexes are essential for differentiation and lineage commitment but not for stem 
cell self-renewal (Chamberlain et al, 2008; Pasini et al, 2007). Taken together these 
results emphasize the importance of these proteins in lineage commitment and in 
maintaining a differentiated phenotype. Early differentiation marker genes are 
silenced by PcG proteins thus allowing embryonic stem cells to remain pluripotent. 
Once cell fate commitment has begun, these genes are activated by loss of 
H3K27me3. Lineage-specific late differentiation marker genes are still repressed by 
PcG proteins. In the final stage of differentiation, downregulation of PcG proteins 
activates late marker genes thus resulting in a specific cell type (Schuettengruber & 
Cavalli, 2009). In the same way as this gain of cellular memory is essential for the 
correct development of an organism, the loss of it often leads to cancer, where cells 
forget their lineage and acquire aggressive proliferative potential. Many types of 
cancers, including prostate and breast, are characterized by an upregulation of PRC2 
components which in turn leads to aberrant H3K27me3 and subsequent silencing of 
tumor suppressor genes (Kleer et al, 2003; Valk-Lingbeek et al, 2004). Aberrant 
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expression of epigenetic effectors is also found in endometriosis. This disease is 
characterized, among other things, by the uncontrolled expression of mir26a – a 
microRNA that tightly regulates EZH2. This is thought to promote malignant 
transformation in endometriosis, as the strict control on cell cycle is lost (Teague et al, 
2010). Indeed, EZH2 itself is abundant in endometrial tumors, and it positively 
correlates with high proliferation rate and aggressiveness of the tumor itself 
(Bachmann et al, 2006). 
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1.2.5 Epigenetics in the human endometrium 
Each cell type has a specific chromatin landscape. The different packaging and 3D 
structure of the chromatin leads to differential accessibility to regulatory elements. 
John et al. suggest that the tissue specific actions of steroid hormones, such as 
glucocorticoids, are due to pre-stimuli chromatin accessibility of exposed receptor 
recognition sites. Sequential epigenetic modifications during development and 
differentiation may pre-dispose the cells to hormonal sensitivity. Reprogramming of 
the chromatin landscape at selected loci may alter the patterns of accessibility for 
subsequent factors. This results in a directional process requiring fundamental and 
well coordinated regulation of multiple regulators for its alteration (John et al, 2011). 
Glucocorticoids are not the only known steroid hormones involved in epigenetic 
regulation. Steroid hormones such as estrogens and androgens are known to repress 
EZH2 (Bohrer et al, 2010; Bredfeldt et al, 2010). EZH2 can bind to the repressor of 
estrogen receptor activity (REA) modulating the repression of estrogen-dependent 
genes (Hwang et al, 2008). In uterine myometrial cells, for example, 17β-estradiol 
activates a signaling pathway that leads to inactivation of EZH2 and subsequent 
decrease of H3K27me3 in hormone-responsive cells (Bredfeldt et al, 2010). 
Whether progesterone is able to alter the chromatin landscape of HESCs has not 
been shown. In fact, a comprehensive understanding of the functional role of 
epigenetics in HESCs and in decidualization remains elusive. There have been few, 
non-comprehensive studies on the expression of epigenetic modulators in these cells.  
Pioneering studies on acetylation and phosphorylation of histones in decidual cells 
were carried out in the 1970s (Libby, 1972; Serra et al, 1979). One study revealed that 
upon decidualization, in mice, histones H1, H2A and H3 become phosphorylated and 
H2B and H4 get acetylated (Serra et al, 1979). Injection of estrogen in rats leads to an 
increase in histone acetylation in the uterus (Libby, 1972). Although over thirty years 
ago it was hypothesized that “histone modifications may be involved in the 
differentiation of stromal cells into decidual cells” (Serra et al, 1979), very little 
research has been done since then. One study treated HESCs with the HDAC 
inhibitor, trichostatin A (TSA), that led to an increase in the expression of IGFBP-1 
and PRL, further confirming Serra’s hypothesis.  
The HAT CBP/p300 is constitutively expressed throughout the menstrual cycle, as 
are the three HDACs. Protein analysis of the HDACs revealed that HDAC 2 increases 
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in the secretory phase and the other two remain constant. A comprehensive profiling 
of histone acetylation during the menstrual cycle has been carried out. A series of 
acetylation marks (H2AKAc, H3K9Ac, H3K14/18Ac, H4K5Ac, H4K8Ac) are 
strongly expressed during the early proliferative phase and then decline until 
ovulation (Munro et al, 2010). Globally acetylation of H3 and H4 increases during 
decidualization, and acetylation of H4K8, H3K9 and H3K14 has been shown to be 
upregulated. Surely other histone marks are regulated during the menstrual cycle and 
decidualization. All these studies have looked at changes in global levels of histone 
PTMs. But in order to gain a more profound understanding of their role in the 
decidual process a more loci-specific approach is needed.   
Expression of DNMTs was also shown to be regulated during the menstrual 
cycle. One study showed that mRNA levels of DNMTs were significantly lower in 
the mid-secretory phase of the cycle and expression of DNMTs was lower in the 
secretory phase than in the proliferative phase. Regulation of DNMTs at protein levels 
remains controversial as one paper claims that DNMT1 is downregulated during the 
secretory phase (Yamagata et al, 2009) whereas another study reports that it does not 
change (van Kaam et al, 2011). There seems to be a general agreement that in the 
second half of the cycle there is a decline in transcript levels of the DNMTs. 
Treatment of HESCs with DNA methyltransferase inhibitor 5’-aza-2’-deoxycytidine 
(5-aza-dC) for ten days leads to an upregulation of decidual marker genes PRL and 
IGFBP-1, suggesting an involvement of DNA methylation in decidualization. During 
the menstrual cycle DNA methylation is strictly regulated, furthermore aberrant 
methylation of CpGs in the endometrium leads to a spectrum of pathological 
conditions, including endometriosis and ovarian cancers. Alterations in DNA 
methylation of specific promoters (i.e. PR-B, ER-β, HoxA10 and E-cadherin) are 
typical of both ectopic and eutopic endometriosis lesions (Nasu et al, 2011). 
Interestingly, abnormal DNA methylation occurs also on ribosomal DNA (rDNA) of 
patients with endometrial cancers. Indeed, it has been suggested that rDNA 
methylation could be used as a prognostic indicator for this disease and for a 
prediction of the patient’s survival rate (Powell et al, 2002). A more accurate insight 
and a fundamental understanding of the expression profile of epigenetic effectors in 
health and in disease could lead to the identification of biomarkers, possible causes 
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and, perhaps in not a very distant future, possible cures of numerous reproductive 
disorders.   
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1.3 Aims 
Epigenetic modifications have emerged as a major mechanism for modulating 
gene expression and cellular differentiation. Epigenetic regulation appears to be 
involved in numerous processes which are fundamental for decidualization of HESCs. 
The purpose of this project is to explore the extent in which histone modifications and 
DNA methylation play a dynamic role in differentiation of HESCs. The specific aims 
of this project include: 
∼ to understand the magnitude of the extent by which chromatin binding 
proteins are regulated upon decidualization  
∼ to unravel the dynamics and effects of selected histone marks on decidual 
genes and how they are regulated 
∼ to characterize the changes in methylation status of DNA in response to 
decidualization  
∼ to explore whether aberrant DNA methylation underlies recurrent 
pregnancy loss. 
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This study was approved by the Hammersmith and Queen Charlotte's & Chelsea 
Research Ethics Committee (1997/5065). 
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2.1 Materials 
2.1.1 Antibodies and serums 
2.1.1.1 Primary Antibodies 
Antibody Company Cat. no 
DNMT1 Abcam ab13537 
DNMT3a Abcam ab2850 
DNMT3b Abcam ab2851 
EZH1 Abcam ab13665 
EZH2 Leica NCL-L-EZH2 
H3 Abcam ab1791 
H3K27Ac Abcam ab4729 
H3K27me3 Millipore 07-449 
HELLS Abcam ab3851 
IgG Sigma M7023 
UHRF1 Abcam ab57083 
β-actin Sigma a1978 
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2.1.1.2 Secondary Antibodies 
 
Antibody Conjugated to Company Cat. no 
anti-mouse IgG AlexaFluor 594 Invitrogen A11005 
anti-mouse IgG HRP Dako P0448 
anti-rabbit IgG FITC Dako F0205 
anti-rabbit IgG HRP Dako P0448 
 
 
2.1.1.3 Normal Serum 
Goat (Dako, X0907) 
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2.1.2 Oligonucleotides 
2.1.2.1 Gene Expression Primers 
Primer Name Sequence 
ASXL1 F AGT CTG CGC ACC GGC CAT TC 
ASXL1 R ATT GGT CGT CCT GCC ACG CC 
BRD3 F GGG CTG TGG GGA GAG GAG GT 
BRD3 R TCC CAG TGC CCA CCA CAG GA 
BRD4 F GGC CAG GGC AGG ACA CGA AC 
BRD4 R ACG GCC CTT CCT AGG GAG CG 
CBX1 F GGC CTT CGG GAT GGA GCC CT 
CBX1 R AGC TGC CGC ATC ATG CCT GG 
DNMT1 F TAC CTG GAC CCT GAC CTC 
DNMT1 R CGT TGG CAT CAA AGA TGG ACA 
DNMT3a F TAT TGA TGA GCG CAC AAG AGA GC 
DNMT3a R GGG TGT TCC AGG GTA ACA TTG AG 
DNMT3b F GGC AAG TTC TCC GAG GTC TCT G 
DNMT3b R TGG TAC ATG GCT TTT CGA TAG GA 
dPRL* F AAG CTG TAG AGA TTG AGG AGC AAA C 
dPRL* R TCA GGA TGA ACC TGG CTG ACT A 
EZH2 F TTC ATG CAA CAC CCA ACA CT 
EZH2 R CTC CCT CCA AAT GCT GGT AA 
HELLS F CCG GAA GTG TAA TGG TCA GCC AGT 
HELLS R AGC ATC CTA AGC CAT TCC ATG CC 
IGFBP-1* F CGA AGG CTC TCC ATG TCA CCA 
IGFBP-1* R TGT CTC CTG TGC CTT GGC TAA AC 
L19 F GCG GAA GGG TAC AGC CAA T 
L19 R GCA GCC GGC GCA AA 
SUV39H2 F CTG CAG AGA TGG CAA GAT GA 
SUV39H2 R TGG GCC CTC TAA ATC AAC AG 
SUV420H1 F AGG CCA ACT GTC GCC TGG TTG 
SUV420H1 R CGA CTG TCG TGG CGG TGG AC 
UHFR1 F GGA GGT GGC CCG AGC AGG 
UHFR1 R GCC GGT CCT TGA GTG ACG CC 
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2.1.2.2 ChIP Primers 
Primer Name Sequence 
dPRL-332/270  A F	   TGC TTT AAC ATT TTT GCC TAG TAA	  
dPRL-332/270 A R	   AAA TGG AGT GTC TAA AAA CGT TGA	  
IGFBP-1 Prom  F	   CGT CGC TTC GGC CAG TGT GT	  
IGFBP-1 Prom R	   TCC AGA GGT GGG GGT GCG AG	  
 
 
2.1.2.3 Plasmids 
pCMV-SPORT6::EZH2 (Open Biosystems) 
 
 
2.1.2.4 Small interfering RNAs (siRNAs) 
siCONTROL nontargeting (NT) siRNA pool (Dharmacon)  
EZH2 siGENOME SMARTpool siRNA (Dharmacon)  
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2.1.3 Buffers 
Elution Buffer 
1% SDS 
100 mM NaHCO3 
 
High Salt Buffer 
20 mM Tris-HCl pH 8.1 
500 mM NaCl 
2 mM EDTA 
0.1% SDS 
1% Triton-X100 
 
IP Buffer 
16.7 mM Tris-HCl pH 8.1 
16.7 mM NaCl 
1.2 mM EDTA 
0.01% SDS 
1.1% Triton-X100 
 
Laemmli Buffer 
50 mM Tris-HCl pH 6.8 
50 mM Imidazole 
1% SDS 
10% Glycerol 
2% 2-Mercaptoethanol 
0.002% Bromophenol blue 
 
Lithium Chloride Buffer 
10 mM Tris-HCl pH 8.1 
250mM LiCl 
1 mM EDTA 
1% Nonidet p40 
1% Deoxycholate 
 
 
Low Salt Buffer 
20 mM Tris-HCl pH 8.1 
150 mM NaCl 
2 mM EDTA 
0.1% SDS 
1% Triton-X100 
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SDS Lysis Buffer 
0.5 M Tris-HCl pH 8.1 
10 mM EDTA 
1% SDS 
1% Triton-X100 
0.5% Deoxycholate 
 
Shorty Buffer 
0.2 M Tris HCl pH 9.0 
0.4 M LiCl 
25 mM EDTA 
1% SDS 
 
Swelling Buffer 
25 mM HEPES pH 7.9 
1.5 mM MgCl2 
10 mM KCl 
0.1% Nonidet 
 
TE Buffer 
10 mM Tris-HCl pH 8.0 
1 mM EDTA 
 
Transfer Buffer 
50 mM Tris-HCl pH 6.8 
40 mM Glycine 
20% Methanol 
0.05% SDS 
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2.2 Methods  
2.2.1 Cell culture 
2.2.1.1 Human Endometrial Tissue Collection 
Endometrial samples were obtained from pre-menopausal women undergoing 
diagnostic laparoscopy or hysteroscopy. The patients did not present any uterine 
pathology, had a regular menstrual cycle and were not under hormonal treatment at 
the time of surgery. Written informed consent was obtained from all participating 
subjects prior tissue collection.  
 
2.2.1.2 Primary cell culture  
HESCs were isolated from endometrial biopsies as follows. The tissue was 
finely cut and digested for one hour, with frequent shaking, at 37°C in DMEM/F-12 
(Invitrogen) with 0.5 mg/ml type 1A Collagenase (Sigma) and 0.1 mg/ml DNaseI 
(Roche). These enzymes destroyed the extracellular matrix and brokedown the 
viscous DNA released by the dead cells, respectively. Once the tissue was digested 
the cells were collected by centrifugation (180 g for 5 minutes at room temperature). 
The cells were transferred in T75 flasks containing 10% DCC-DMEM [DMEM/F-12 
supplemented with fetal bovine serum (Invitrogen) treated with 10% dextran (Sigma) 
coated charcoal (Sigma) (DCC-FBS), 2 mM L-glutamine (Invitrogen), 1X 
antibiotic/antimycotic solution (Invitrogen), 1 nM estradiol (Sigma) and 2 µg/ml 
insulin (Sigma)]. The cell population is mixed: composed by epithelial, stromal and 
blood cells. To ensure purification of HESCs, the media was changed after one hour 
as the other types of cells take longer to adhere and at this point are still found in 
suspension whereas HESCs have already attached to the flask. The cells were cultured 
until they formed a confluent monolayer. The culture media was changed every other 
day.  
 
2.2.1.3 In vitro decidualization 
Twenty four hours prior to any experiment the cultures were synchronized in 
their cell cycle. By culturing HESCs in 2% DCC-DMEM (DMEM/F-12 containing 
2% DCC-FBS, 2mM L-glutamine and 1X antibiotic/antimycotic solution) the cells 
arrest their cell cycle progression in G1. For in vitro decidualization the cultures were 
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treated with 0.5 mM 8-Bromo-cAMP (8-Br-cAMP) (Sigma), more lipophilic and 
therefore a more membrane-permeable analogue of cAMP, and 100 µM 
medroxyprogesteroneacetate (MPA) (Sigma), a stable analogue of progestin.  
 
2.2.1.4 Blocking proteosomal degradation 
 Proteolytic activity of the proteosome complex was inhibited with MG132 
(LEE 1998). HESCs were decidualized for eight days as described above. Three and 
six hours before harvesting the cells were treated with 20 µM MG132. This drug 
blocks degradation of ubiquitin-conjugated proteins. 
 
2.2.1.5 Transient transfection of primary cultures 
Primary HESCs were transfected with siRNAs or plasmids, in 6-well culture 
plates, by calcium phosphate co-precipitation using the ProFection Mammalian 
Transfection kit (Promega, Madison, Wi, USA) according to manufacturer’s 
instructions. The negatively charged DNA/RNA interacts with the positive calcium 
ions forming precipitates in the phosphate buffered solution. This facilitates its 
binding to the cell membrane and its entry via endocytosis. Furthermore, calcium 
phosphate protects the nucleic acids from nuclease digestion found intracellularly and 
in the serum (Loyter et al, 1982).  
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2.2.2 DNA methods 
2.2.2.1 DNA isolation 
Genomic DNA was isolated from HESCs using a crude method involving 
direct lysis of the cells and phenol-chloroform extraction. In detail, the cells grown in 
6-well culture plates or 10cm culture Petri dishes were washed in Tris-borate EDTA 
(TBE) before adding 500 µl of Shorty buffer (0.2M Tris HCl pH 9, 0.4M LiCl, 25mM 
EDTA, 1% SDS). The cells were scraped off and transferred into a dounce 
homogenizer for lysis, where the cells were homogenized on ice. The suspension was 
then transferred into a 1.5ml microfuge tube containing 500 µl of 
Phenol:Chloroform:Isoamyl alcohol 25:24:1 for liquid-liquid extraction of the DNA. 
The mixture was vortexed thoroughly and the two liquid phases separated by 
centrifuging at 16,000 g for 5 minutes at 4°C. The DNA, found in the upper aqueous 
layer, was transferred into new 1.5ml microfuge tube and recovered by precipitating it 
with 350 µl of propan-2-ol. The nucleic acid was collected in a pellet by 
centrifugation (16,000 g, 10 minutes, 4°C) and washed twice with 80% pre-chilled 
ethanol. The genomic DNA was resuspended in 50 µl of water. 
 
2.2.2.2 In silico analysis of CpG islands 
 CpG islands were identified in silico using the EBI Emboss CpG Plot software 
(www.ebi.ac.uk/Tools/emboss/cpgplot/index.html). Promoter sequences were 
uploaded on the software that predicted putative CpG islands. The same DNA regions 
were also searched for CpGs on the Genome Browser CpG island track database 
(www.genome.ucsc.edu). 
 
2.2.2.3 Bisulfite Conversion and amplification of DNA  
Extracted DNA was sodium bisulphate treated using EZ DNA Methylation-
Gold (Zymo Research) following the manufacturer’s instructions. This process is 
based on the different reactivities of methylated and unmethylated cytosines to 
bisulfite in acidic conditions. During this reaction unmethylated cytosine get 
deaminated in position 4 becoming uracil, following a three step reaction 
(sulphonation, hydrolic deamination and alkali desulphonation) (Clark et al, 1994). 
Methylated cytosines can also react with bisulfite but this reaction is extremely slow 
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and the equilibrium of the reaction is unfavorable towards thymine, the deaminatied 
product.  
 
2.2.2.4 PyroMark CpG Assays 
The bisulfite treated DNA was amplified using PyroMark CpG Assays prior to 
pyrosequencing, following the manufacturer’s instructions. The PyroMark Q96 CpG 
LINE-1 Assay (Qiagen) was used to quantify global methylation levels in 
transposable elements and the Hs_IGFBP-1_01_PM PyroMark CpG Assay (Qiagen) 
was used to determine the methylation status of the IGFBP-1 promoter. These kits 
ensure amplification and biotinylation of bisulfite converted DNA for subsequent 
pyrosequencing via a standard polymerase chain reaction (PCR) with biotinylated 
primers.   
 
2.2.2.5 Pyrosequencing 
Pyrosequencing was carried out on a PyroMark Q96 ID (Qiagen). 10 µl of 
biotinylated DNA obtained with the PyroMark CpG Assays were complexed with 38 
µl Streptavidin Sepharose High Performance beads (GE Healthcare) in a solution 
containing 10 µl of water and 38 µl PyroMark Binding Buffer (Qiagen). This buffer 
facilitates binding of the amplicons to the beads. The mixture was vortexed for ten 
minutes at room temperature before washing the beads using the PyroMark Q96 
Vacuum Workstation (Qiagen). The beads where washed in ethanol for five seconds 
before placing them for five seconds in 0.2 M NaOH, which denatures the 
complementary strand from the biotin-tagged strand. The latter will be used as the 
pyrosequencing template. The beads are then rinsed in water for a further five seconds 
before being placed for the same amount of time in PyroMark Wash Buffer (Qiagen) 
which ensures that only single stranded DNA remains attached to the beads. They are 
then placed on a sequencing plate containing 12 µl of the appropriate sequencing 
primers from the PyroMark CpG Assays resuspended in PyroMark Annealing Buffer 
(Qiagen). The plate is then heated for ten minutes at 80°C before loading it on the 
pyrosequencer. The pyrosequencing assays that were used were supplied with the 
PyroMark CpG Assays.   
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2.2.2.6 Global Methylation Levels 
 Global methylation levels were also determined using a colorimetric assay: the  
Methylamp™ Global DNA Methylation Quantification Kit (Epigentek)  according to 
the manufacturer’s instructions. In this Enzyme Linked Immunosorbent Assay 
(ELISA)-like protocol DNA is immobilized to a well with high affinity to DNA. 
Methylated DNA is detected with an antibody against 5mC and measured through a 
chromogenic reaction which is quantified by measuring the optical density with a 
spectrophotometer.  
 
2.2.2.7 MeDIP-sequencing 
Immunoprecipitation of methylated DNA and subsequent high throughput 
sequencing (MeDIP-seq) was outsourced to Arraystar Inc. This technique consists of 
enrichment of methylated DNA by employing an antibody against the DNA 
modification. The isolated fragments are then analyzed via next generation high 
throughput sequencing. A minimum of 3 µg of genomic DNA at a concentration of 
1µg/ml - whose integrity and quality were assured using the Agilent 2100 
BioAnalyzer - were processed by Arraystar Inc. A schematic representation of the 
steps involved is shown in figure 2.1.  
In brief, DNA samples were fragmented to a size range of ~100 - 500 bp with 
a Diagenode Bioruptor. About 1 µg of fragmented DNA was prepared for 
Illumina/Solexa sequencing as the following steps:  
1) End repair of DNA samples with T4 DNA polymerase, Klenow DNA 
polymerase, and T4 PNK;  
2) A single ‘A’ base was added to the 3' ends with Klenow (exo minus) 
polymerase;  
3) Ligation of Illumina's genomic adapters to DNA fragments;  
4) MeDIP to enrich methylated DNA by anti-5-methylcytosine antibody;  
5) PCR amplification to enrich precipitated fragments;  
6) Gel purification to extract ~200 - 300 bp DNA fragments.  
The completed libraries were quantified by BioAnalyzer 2100 and denatured 
with 0.1 M NaOH to generate single-stranded DNA molecules, captured on Illumina 
flow cell and amplified in situ. The libraries were then sequenced on the Genome 
Analyzer IIx following the TruSeq SBS Kit v5 protocol. 
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Figure 2.1 MeDIP-Seq Workflow
Schematic representation of the steps involved in preparing the DNA samples for MeDIP-seq 
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After the sequencing platform generated the sequencing images, the stages of image 
analysis and base calling were performed using Off-Line Basecaller software (OLB 
V1.8). After passing Solexa CHASTITY quality filter, the clean reads were aligned to 
Human genome (UCSC Hg19) using BOWTIE software (V0.12.7). 
About 94 million uniquely mapped reads, which represented over 3.3 billion 
bases of sequence, were obtained for all the samples. Each read was extended to 200 
bp in length. A methylation score for any region in the genome was defined as 
number of extended reads per kb (Maunakea et al, 2010). The DNA methylation 
status of a specific region (e.g. CGIs) was defined as unmethylated if its MeDIP-score 
was less than 4.25 reads·kb-1, as partially methylated if its MeDIP-score was between 
4.25-18.28 reads·kb-1 and completely methylated if its MeDIP-score was greater than 
18.28 reads·kb-1. 
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2.2.3 RNA methods 
2.2.3.1 RNA Extraction  
RNA was extracted using RNA STAT-60 (AMS Biotech) and following 
manufacturer’s instructions. This method involved a phenol-chloroform extraction 
using RNA STAT-60 which is a patented reagent containing phenol and the 
chaotropic agent guanidinium thiocyanate. In brief, 500 µl of RNA STAT-60 was 
added to each well of a 6-well plate and incubated at room temperature for five 
minutes. The cells were scraped and transferred to a 1.5 ml microfuge tube. 100 µl of 
chloroform were added to the monophase solution, which caused it to separate into 
two phases. The mixture was vortexed, incubated for three minutes at room 
temperature and centrifuged at 16,000 g for thirty minutes at 4°C. The organic phase 
containing denatured proteins and DNA was discarded. Total RNA was separated into 
the aqueous phase, which was transferred to a 1.5 ml microfuge tube containing 250 
µl of ice cold isopropanol and left at room temperature for 15 minutes. During this 
time, the isopropanol caused the RNA to precipitate out of the solution and was then 
collected by centrifugation (under the same conditions as above). The pellet was 
washed twice with 75% ethanol and air dried at room temperature for 15 minutes 
before resuspending it in 10 µl of DEPEC-treated water.  
 
2.2.3.2 cDNA synthesis 
Isolated total RNA was treated with DNase I to assure that any DNA 
contamination was removed. The following reaction was made up and left at room 
temperature for 15 minutes. 
0.5-1 µg RNA 
1 µl 10X DNase Buffer (Invitrogen) 
1µl DNase I (Invitrogen) 
 Water to a final volume of 20 µl 
The reaction is then blocked by the addition of 1 µl of the chelating agent EDTA (at 
an initial concentration of 25mM) and placed at 65°C for ten minutes. 1 µl of 10 mM 
dNTP mix and 1 µl of oligodT were added to the solution and incubated for a further 
five minutes at 65°C before cooling it down for one minute on ice. The following 
master mix was prepared and added to each RNA sample.  
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2 µl 10X RT Buffer (Invitrogen) 
4 µl 25 mM MgCl2 
2 µl 0.1 M DTT 
1 µl RNase OUT (Invitrogen) 
 The reaction mixture was heated for two minutes at 42°C and 0.5 µl of SuperScript™ 
II reverse transcriptase (Invitrogen) was added before incubating for a further 50 
minutes at 42°C. The temperature was then raised to 70°C and left for 15 minutes. 
The newly synthesized cDNA was stored at -20°C. 
  
2.2.3.3 Real-time quantitive PCR 
Real-time quantitative PCR (qPCR) was carried out on BioRad Opticon 
Monitor 3 Real-Time PCR System. PCR reactions were set up using SYBR Green 
JumpStart Taq (Sigma), 0.20 µM of each primer, 0.5 µl of template in a 15 µl 
reaction. The following program was run on the thermocycler: 50°C for 2 minutes, 
95°C for 10 minutes followed by 40 cycles of 95°C° for 15 seconds, 60°C for 1 
minute and 72°C. for 30 seconds. For gene expression analysis (reverse transcriptase 
qPCR) input variance was normalized against the expression of the L19 gene, which 
encodes for a non-regulated universally expressed ribosomal protein.  
 
2.2.3.4 Microarray analysis 
Microarrray analysis used in this work was carried out and published by 
Takano et al. (Takano et al, 2007). In brief, three separate primary HESC cultures 
derived from three different patients were used for microarray analysis. Each culture 
consisted of four experimental conditions; hence, a total of 12 microarray chips were 
used. The experimental conditions were: 1) mock transfected (no siRNA oligos); 2) 
transfected with a pool of NT oligonucleotides; 3) transfected with NT oligos and 
treated with 8-Br-cAMP and MPA; and 4) transfected with a siRNA pool targeting 
FOXO1 with subsequent treatment of cAMP and MPA. All RNA samples were 
processed at the Microarray Core Facility in the Center for Genetic Medicine at 
Northwestern University (Chicago, IL). The quality of total RNA was evaluated using 
Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA). 1.5 µg of each RNA 
sample, with 260/280 and 28S/18S ratio of greater than 1.8, was used to make double-
stranded cDNA and labeled cRNA following the One-Cycle Target Labeling Assay 
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from Affymetrix. The size distribution and fragmentation quality of the biotin-labeled 
cRNA were checked by the Bioanalyzer 2100. The fragmented labeled cRNA was 
hybridized to the Human U133-Plus 2.0 Array (Affymetrix, Inc.) for 18 h. The chips 
were then scanned, the data extracted using the Affymetrix GeneChip Operating 
Software (Affymetrix, Inc.), and analyzed further by use of GeneSpring software 
(Agilent Technologies, Inc.). The normalized data were analyzed by pair-wise 
comparisons to create a list of differentially expressed genes. Gene expression levels 
were quantified using the RMA algorithm with the quantile normalization built in. 
Data analysis was conducted using the Bioconductor/R package (Dudoit et al, 2003; 
Wettenhall & Smyth, 2004). To find statistically consistent genes of differential 
expression, we used a linear model with empirical Bayesian correction, and changes 
in transcript levels of at least 1.5-fold were validated by Student’s t test (P < 0.05).  
For the purpose of this work only conditions 2 and 3 (transfected with a pool 
of NT oligos and either treated with 8-Br-cAMP and MPA or not) will be analyzed.  
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2.2.4 Chromatin methods 
2.2.4.1 Chromatin extraction 
HESCs were cultured in 10 cm culture dishes, fixed with 1% formaldehyde 
and incubated for 10 minutes at 37°C. After having stopped the fixation with 125 mM 
glycine the nuclei were isolated by incubating at 4°C for 10 minutes in 1 ml Swelling 
buffer (25 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.1% Nonidet). The 
cells were then scraped and homogenized with a dounce homogenizer. The samples 
were centrifuged for 3 minutes at 16000g at 4°C and the nuclei, collected in a pellet, 
were resuspended in 500 µl SDS lysis buffer (1% SDS, 1% Triton-X100, 0.5% 
deoxycholate, 10 mM EDTA, 500 mM Tris-HCl pH 8.1) and sonicated for 30 minutes 
(with 30 second cycles) at 4°C on high power on the Diagenode Bioruptor sonicator. 
The resulting suspension was centrifuged for 15 minutes at 16000 g at 4°C and the 
supernatant containing the sonicated chromatin was subsequently used in ChIP 
experiments.  
 
2.2.4.2 Chromatin immunoprecipitation (ChIP) 
Approximately 150 µl of extracted and sonicated chromatin were used in each 
ChIP reaction. The suspension containing the chromatin was diluted ten times in IP 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl pH 8.1, 
167 mM NaCl) and then precleared at 4°C for 3 hours with 30 µl of Protein A 
Dynabeads (Invitrogen).  30 µl of Protein A Dynabeads were complexed in IP buffer 
with 5 µg of antibody. This binding reaction took place at 4°C for 3 hrs. 10% of the 
precleared chromatin was transferred into a clean microfuge tube and frozen at -80°C, 
which will then be used as the input. The remaining chromatin was then complexed 
overnight at 4°C with the antibody bound to Protein A Dynabeads. The beads-
antibody-chromatin complex was then washed with the following buffers: Low Salt 
Buffer (0.1% SDS, 1% Triton-X100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM 
NaCl), High Salt Buffer (0.1% SDS, 1% Triton-X100, 2 mM EDTA, 20 mM Tris-
HCl pH 8.1, 500 mM NaCl), Lithium Chloride Buffer (250 mM LiCl, 1% Nonidet, 
1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1), TE buffer (10 mM Tris-
HCl pH8, 1 mM EDTA) before eluting the chromatin with 250 µl Elution buffer (1% 
SDS, 100 mM NaHCO3) and incubated at room temperature for 15 minutes. 200 mM 
NaCl were added to reverse crosslink the proteins and the DNA; from this step 
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onwards the input was also handled. After an overnight incubation at 65°C 10 mM 
EDTA, 40 mM Tris-HCl pH 8 and 40 µg/ml Protease K (Sigma) were added and the 
sample incubated for a further hour at 55°C, prior to proceeding with the DNA 
purification using QIAquick PCR Purification Kit (Qiagen). All the buffers were 
supplemented with protease inhibitors, 1 mM phenylmethanesulfonylfluoride (PMSF) 
and10 mM sodium butyrate (an HDAC inhibitor). The purified DNA was amplified 
by RT-qPCR (as described above) and the data normalized to the input.  
 
2.2.4.3 ChIP-on-chip 
ChIP DNA was amplified using the Whole Genome Amplification 2 (WGA2) 
Kit (Sigma), following manufacturer’s instructions. The ChIP-chip assays were 
performed in triplicate, each representing a primary culture from an individual patient. 
A total of 12 primary cultures were assayed. Labeling of ChIP DNA and input, 
hybridization to NimbleGen Human ChIP-chip 3x720K RefSeq promoter arrays 
(Roche), and scanning were performed by NimbleGen in their service laboratory. 
Peak detection and statistical analysis were carried out using Partek® Genomic Suite 
™ (Partek, St. Louis, MO, USA).  
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2.2.5 Protein methods 
2.2.5.1 Protein extraction 
Whole cell protein extracts were obtained by direct lysis. 50 µl of Laemmli 
buffer (50 mM Tris-HCl pH 6.8, 50 mM imidazole, 1% w/v SDS, 10% v/v glycerol, 
2% v/v 2-mercaptoehtanol, 0.002% w/v bromophenol blue) were added to each well 
of a 6-well plate and scraped off with a cell scraper. The lysate was then heated at 
100°C for 10 minutes to ensure complete denaturation of the proteins. 
 
2.2.5.2 SDS-PAGE 
Proteins were resolved by SDS-PAGE using the NuPAGE® Novex 4-12% 
Bis-Tris gradient gels (Invitrogen) and running them in NuPAGE® MOPS SDS-
Running Buffer (Invitrogen). 
 
2.2.5.3 Western Blot 
The proteins were then transferred, using a semi-dry transfer system, to a 
PVDF membrane for immunoblotting. A blotting sandwich was composed as follows, 
with a total of four sheets of blotting paper acting as “the bread”. Between the blotting 
paper there was the polyacrylamide gel (closer to the anode plate) and the methanol 
activated PVDF membrane. All the components of the blotting sandwich had been 
pre-equilibrated in transfer buffer (50mM Tris-HCl, 40mM glycine, 20% methanol, 
0.05% SDS) prior to assembly. Transfer was performed for 2 hours and 30 minutes 
with a current of 135 mA. The membrane was then blocked with 5% w/v milk in 
TBS-T for one hour at room temperature and then incubated over night at room 
temperature with the primary antibody. After a series of washes in TBS-T it was 
incubated in an HRP-conjugated secondary antibody for one hour at room 
temperature. The chemiluminescence was detected using the ECL+ kit (GE 
Healthcare). 
 
2.2.5.4 Densitometry Analysis with Image J 
 Intensities of the bands obtained by western blot were measured with the 
software Image J (http://rsbweb.nih.gov/ij/) and normalized to the intensities of the 
corresponding β-actin bands.  
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2.2.5.5 Confocal Microscopy 
HESCs were cultured on 4-well chamber slides and fixed with 4% 
paraformaldehyde (Thermoscientfic) for 30 minutes. Subsequently they were 
permeabilized by incubating for 30 minutes with 0.5% Triton-X and blocked with 
7.5% normal goat serum and 3% BSA in PBS. The slides were hybridized with the 
primary antibody for one hour and, following several washes with PBS, they were 
incubated for one hour with the secondary antibody conjugated with Alexa Fluor 594. 
The chambers were washed several times and mounted on Vectashield with DAPI. 
Alexa Fluor 594 and DAPI were visualized under a Leica SP5 confocal microscope 
with a 63× oil-immersion objective.  
 
2.2.5.6 Immunohistochemistry 
Paraffin-embedded, formalin-fixed endometrial tissue sections were placed on 
1% w/v polylysine slides. Immunostaining was performed using Vectastain Elite 
ABC kit (Vector Laboratories), according to manufacturer’s instructions.  
 
    
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 REGULATION OF EPIGENETIC EFFECTORS UPON DECIDUALIZATION 
OF HESCS 
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3.1 Introduction 
The human endometrium is characterized by cyclic inflammation and 
oxidative stress, important environmental cues for epigenetic modifications. Yet it is 
not known if epigenetic programming plays a role in endometrial differentiation under 
physiological or pathological conditions. To date, very little is known about the role 
of epigenetic programming that underpins the cyclical waves of endometrial 
proliferation, differentiation, menstrual shedding and regeneration. Yet there are 
several lines of preliminary evidence implicating epigenetic regulation in the 
endometrial decidual process. A pioneering study conducted in mouse uterus revealed 
that, upon decidualization, histone acetylation and phosphorylation increase (Serra et 
al, 1979). Indeed, a recent study confirmed that some histone acetylation marks are 
being regulated during the human menstrual cycle (Munro et al, 2010), and treatment 
of HESCs with the HDAC inhibitor, TSA, enhances expression of decidual marker 
genes (Sakai et al, 2003). Preliminary researches on other epigenetic mechanisms, 
such as DNA methylation, have also been reported (Logan et al, 2010; Yamagata et al, 
2009). Furthermore, women affected by endometriosis present aberrant expression of 
DNA methyltransferases, this suggests that tight control of epigenetics and of its 
regulators must occur in the endometrium (Wu et al, 2007). 
Despite these studies, however, there is still no clear picture of the extent in 
which epigenetics is involved in decidualization. To address this question we used 
microarray analysis to compare undifferentiated and decidualized cells to identify 
expressed genes encoding for chromatin modifying proteins. The microarray 
elucidating differential expression of genes in HESCs and decidual cells had been 
previously carried out and published (Takano et al, 2007). In brief, three HESC 
cultures derived from different patients were decidualized for three days in vitro with 
8-Br-cAMP and MPA. Total RNA from these and from undifferentiated parallel 
cultures was extracted, reverse transcribed, labeled and hybridized to a Human U133-
Plus 2.0 Array (18 h) (Affymetrix). Differential expression was extrapolated using a 
linear model with empirical Bayesian correction and the significance of the fold 
change in expression was calculated with a Student’s t-test (Takano et al, 2007). A list 
of chromatin modifying proteins and their subdivision into categories was obtained 
from the literature (Kouzarides, 2007a; Kouzarides, 2007b; Kouzarides & Bannister). 
This list of proteins was then used to manualy mine the microarray to verify which 
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histone-associated transcripts, subdivided into histone-tail modifying enzymes, their 
cofactors, histone binding proteins and histone variants, were expressed in HESCs. 
Some of the highly regulated genes in each of the categories were further analyzed in 
vitro in a decidualization time-course. A similar approach was taken to identify the 
expression of genes implicated in DNA methylation (in the second part of this 
chapter, sections 3.2.6 to 3.2.9). These transcripts were subdivided in CpG binding 
proteins, DNMTs, and DNMT-interacting proteins.  
Chapter 3   Regulation of epigenetic effectors 
 
 
71 
3.2 Results 
3.2.1 Histone modifying proteins 
 Histone modifying proteins are enzymes that catalyze the addition or removal 
of PTMs on histone tails. These proteins include lysine methyltransferases, acetylases 
and deacetylases. Microarray analysis revealed that of all the HESCs’ transcripts 49 
of them encode for histone modifying enzymes (appendix I). In other words 0.5% of 
all transcripts expressed in HESCs encode for histone modifying proteins and of these 
five transcripts (EZH2, SUV420H1, SUV39H2 and two probe sets picked up 
HDAC4) are highly significantly regulated upon decidualization (table 3.1). These 
proteins are key in regulating chromatin dynamics in cells.  
 EZH2 is the enzymatic subunit of PRC2 and it catalyzes di- and trimethylation 
of H3K27 (Cao et al, 2002). Of the five highly regulated genes encoding for histone 
modifying enzymes, changes in EZH2 expression showed greatest changes. Transcript 
levels decrease three-fold upon treatment of HESCs with 8-Br-cAMP and MPA for 
three days (table 3.1). A detailed study on EZH2 expression and function in HESCs is 
presented in the following chapter.  
 As may be seen from the microarray data, HDAC4 mRNA is expressed two 
and a half times more in decidualized cells than in undifferentiated ones, suggesting 
that HDAC4-dependant deacetylation increases upon 8-Br-cAMP and MPA treatment 
(table 3.1). The histone deactylase, HDAC4, acts as a transcriptional repressor when 
tethered to the promoters. HDAC4 is also known to interact with RbAP48, a PRC2 
protein, as well as with nuclear receptor corepressors (NCoR1 and NCoR2) 
(Grozinger et al, 1999; Huang et al, 2000; Margueron & Reinberg, 2011). Various 
studies have already profiled HDAC expression and the effects of their inhibition in 
HESCs (Krusche et al, 2007; Sakai et al, 2003), therefore it will not be examined 
here. 
 The two suppressor of variegation proteins (SUV) significantly regulated upon 
decidualization are both histone-lysines-N-methyltransferases. SUV420H1 
(suppressor of variegation 4-20 homologue 1) trimethylates lysine 20 of histone H4, a 
mark associated with transcriptional repression, and plays a crucial role in 
establishing constitutive heterochromatin especially in the pericentromeric regions 
(Ait-Si-Ali et al, 2004; O'Carroll et al, 2000; Tryndyak et al, 2006; Yang et al, 2008). 
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SUV39H2 (suppressor of variegation 3-9 homologue 2) transfers two methyl groups 
to H3K9me converting it into H3K9me3. It also establishes constitutive 
heterochromatic regions on pericentric repeats as well as on telomeres. H3K9me3 is 
required to direct DNA methylation in these regions (Ait-Si-Ali et al, 2004; O'Carroll 
et al, 2000). These two lysine histone methylases, like EZH2, appear to be 
downregulated upon decidualization with their expression decreasing to slightly more 
than half of that in undifferentiated cells (table 3.1).  
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Table 3.1 Histone Modifying Enzymes Regulated Upon Decidualization	  
Probe Set	  
Gene 
Symbol	   Gene Name	  
Fold 
Change	   p-value	  
203358_s_at	   EZH2	  
enhancer of zeste homolog 2 
(Drosophila)	   0.3	   7.6E-05	  
228813_at	   HDAC4	   histone deacetylase 4	   2.6	   3.8E-04	  
204225_at	   HDAC4	   histone deacetylase 4	   2.5	   5.2E-04	  
222566_at	   SUV420H1	   suppressor of variegation 4-20 homolog 1 (Drosophila)	   0.6	   6.5E-03	  
1554572_a_at	   SUV39H2	   suppressor of variegation 3-9 homolog 2 (Drosophila)	   0.6	   8.1E-03	  
List of genes encoding for histone modifiers regulated upon treatment of HESCs with 8-Br-
cAMP and MPA for three days. Multiple probe sets for the same gene are listed. Fold changes 
greater than one indicate genes upregulated upon differentiation, whereas those less than one 
are downregulated. Only the genes with p < 0.01 are listed.   
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3.2.2 Cofactors of histone modifying proteins  
 Chromatin modifying proteins act within large complexes with activators, 
repressors, recruiters and other numerous cofactors. Two of such complexes are the 
polycomb repressive complexes and their antagonists, the trithorax proteins. Mining 
of the microarray revealed that 143 transcripts encoding for 60 different nucleosome-
associated proteins are expressed in undifferentiated and decidualized cells (appendix 
I). Of these proteins: five interact with HATs or HDACs, two with enzymes involved 
in regulating histone methylation and a further seven are implicated in histone 
phosphorylation. Proteins that associate with the polycomb complex are the most 
abundant in this category, featuring 102 transcripts. Messenger RNAs of 27 trithorax-
associating proteins are also expressed in HESCs (appendix I). Taken together these 
transcripts make up 0.6% of the transcriptome.  
  Of these genes only three were highly significantly regulated: ZBTB16, 
ASXL1, RBBP4, with the first two being PRC-related proteins and the last one a 
TRX-associating macromolecule (table 3.2). ZBTB16 and ASXL1 are two polycomb 
cofactors with the former being involved in complex assembly and the latter a PRC 
interacting protein. ZBTB16 (previously known as PLZF) has been shown to tether 
the PRC1 (via binding to BMI1) to target promoters such as HOX (Barna et al, 2002). 
ASXL1 interacts with PRC2 and functions as a ligand-dependent co-activator of 
retinoic acid receptor in cooperation with NCoA1 (Cho et al, 2006).  
The microarray results revealed that upon decidualization expression of 
ZBTB16 increases eight times whereas the ASXL1 is two-fold downregulated (table 
3.2). Taken together these results show how not only histone-modifying proteins are 
regulated but also how proteins that associate with them are tightly controlled. 
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Table 3.2 Regulated Cofactors of the Polycomb and Trithorax Complexes  
Polycomb Cofactors Regulated Upon Decidualization 
Probe Set	   Gene Symbol	   Gene Name	  
Fold 
Change	   p-value	  
205883_at	   ZBTB16	   zinc finger and BTB domain containing 16	   8.1	   5.2E-04	  
242439_s_at	   ASXL1	   additional sex combs like 1 (Drosophila)	   0.6	   2.1E-03	  
	  
Trithorax Proteins Regulated Upon Decidualization 
Probe Set	   Gene Symbol	   Gene Name	  
Fold 
Change	   p-value	  
244872_at	   RBBP4	   retinoblastoma binding protein 4	   0.6	   4.0E-03	  
List of genes, that are regulated upon treatment of HESCs with 8-Br-cAMP and MPA for 
three days, encoding for cofactors of histone modifying proteins. The cofactors are divided 
according to the proteins with which they complex. Fold changes greater than one indicate 
upregulated gene upon differentiation, whereas those less than one are downregulated. Only 
the genes with a p < 0.01 are listed. 
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3.2.3 Histone binding proteins  
 Histone modifying complexes may be considered the “writers” of the histone 
code, which must be “read” by other proteins. The readers of this ensemble of marks 
are histone-binding proteins, which contain specific chromatin-interacting domains. 
Such motifs include tudor, MBT and chromo- domains, known to be methyl-specific 
interacting proteins which bind to methylated H3 and H4 histone tails (Kim et al, 
2006). Another category of peptide readers are proteins which harbor the PHD finger. 
PHD proteins can be divided in subfamilies depending on their specificity towards 
PTM found on histone tails. These include proteins with high affinity towards 
H3K4me3, H3K9me3, H3Ac, H4Ac and unmodified H3 tails. The role of this domain 
in chromatin mediated gene regulation is well documented and proteins containing 
this motif include CBP/p300 and MLL (Aasland et al, 1995; Pena et al, 2006).  
 Mining of the microarray results showed that of all the probe sets in the array, 
66 –which corresponds to 0.1% of the total- encode for 25 different chromatin 
binding proteins (appendix I). Sixteen of them carry a chromodomain, 21 the PHD, 20 
the tudor motif and nine have the MBT domain.  
 Of these transcripts CBX1, UHRF1, three ING1 probes, BRD3 and BRD4 
were highly significantly regulated (table 3.3). Chromobox homolog 1, CBX1, 
belongs to a conserved family of proteins which have an N-terminal chromodomain 
through which they bind histones by associating with methylated lysine residues on 
the tails (Vincenz & Kerppola, 2008). This protein is enriched at heterochromatic 
regions especially at the centromeres, is known to be involved in epigenetic regulation 
and interacts with numerous chromatin associated proteins including SUV39H1 
(Horakova et al, 2010). The microarray revealed a 40% decrease in expression of 
CBX1 upon treatment with 8-Br-cAMP and MPA (table 3.3).  
 UHRF1 is another highly regulated gene, as it appears from the microarray 
(table 3.3). This protein contains a RING-finger and a PHD domain that confer E3 
ubiquitin ligase activity and DNA binding properties, respectively. UHRF1 is known 
to recruit HDACs to target regions as well as to stabilize DNMT binding to the double 
helix (Bostick et al, 2007; Citterio et al, 2004; Hashimoto et al, 2009). UHRF1 
mRNA levels appear 85% lower in decidualized cells than in undifferentiated cells 
(table 3.3).  
Chapter 3   Regulation of epigenetic effectors 
 
 
77 
ING1 belongs to the family of tumorsuppressors, ING, involved in DNA 
damage repair and genotoxic stress responses. It binds to nucleosomes by interacting 
with H3K4me3, through its PHD module, and tethers the mSin3a/HDAC1 complex 
thus allowing deacetylation (Binda et al, 2008). Microarray results show a consistent 
upregulation of ING1 across three different probe sets, upon decidualization of 
HESCs the observed increase was over five-fold (table 3.3).  
 Members of another family of chromatin binding domains regulated upon 
decidualization are the double bromodomain proteins, BRD3 and BRD4, which 
preferentially associate with acetylated histones. BRD3 binds in regions rich in 
H4K5Ac, H4K12Ac, and lacking in H3K9me2 throughout the entire gene making the 
chromatin permissive for the passage of RNA pol II (LeRoy et al, 2008). BRD4 also 
transiently couples with acetylated histones 3 and 4 (Chiang, 2009). Binding, 
however, becomes more stable as the histones are hyperacetylated. Microarray studies 
revealed that BRD3 and BRD4 transcripts are downregulated by 43% and 42%, 
respectively, upon treatment of HESCs with 8-Br-cAMP and MPA (table 3.3).  
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Table 3.3 Histone Binding Proteins Regulated Upon Decidualization	  
CHROMODOMAIN PROTEINS	  
Probe Set	   Gene Symbol	   Gene Name	   Fold Change	   p-value	  
201518_at	   CBX1	  
chromobox homolog 
1 (HP1 beta homolog 
Drosophila )	   0.6	   5.3E-03	  
	   	   	   	   	  
PHD PROTEINS	  
Probe Set	   Gene Symbol	   Gene Name	   Fold Change	   p-value	  
209808_x_at	   ING1	  
inhibitor of growth 
family, member 1	   5.1	   8.7E-07	  
225655_at	   UHRF1	  
ubiquitin-like, 
containing PHD and 
RING finger 
domains, 1	   0.1	   6.8E-06	  
210350_x_at	   ING1	  
inhibitor of growth 
family, member 1	   9.6	   3.8E-05	  
208415_x_at	   ING1	  
inhibitor of growth 
family, member 1	   3.7	   2.6E-04	  
	   	   	   	   	  
TUDOR PROTEINS	  
Probe Set	   Gene Symbol	   Gene Name	   Fold Change	   p-value	  
238612_at	   BRD4	  
bromodomain 
containing 4	   0.6	   1.7E-03	  
203825_at	   BRD3	  
bromodomain 
containing 3	   0.6	   5.3E-03	  
List of genes, regulated upon three days treatment of HESCs with 8-Br-cAMP and MPA, 
encoding for histone binding proteins, subdivided by their binding motifs. Multiple probe sets 
for the same gene are listed. Fold changes greater than one indicate genes upregulated upon 
differentiation, whereas those less than one are downregulated. Only the genes with a p <0.01 
are listed. 
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3.2.4 Regulation of histone variants upon decidualization 
 Histone variants are another important mechanism by which epigenetic 
regulation occurs as they affect the way chromatin is compacted (although the precise 
mechanism remains unclear). Analysis of the microarray revealed that 21 histone 
transcripts are expressed in HESCs encoding for nine different variants. Four of 
which are significantly regulated (H2AJ, H2AS, H2AV and H2AX) (appendix I, table 
3.4). H2AV and H2AX are downregulated by 40% after a three day treatment with 8-
Br-cAMP and MPA whereas expression of variants H2AJ and H2AS increases by 
approximately 50% and 70%, respectively (table 3.4). 0.8% of the total mRNA of 
HESCs encodes for histone variants suggesting their implication in controlling the 
decidual response. 
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Table 3.4 Histone Variants Regulated Upon Decidualization	  
Probe Set	   Gene Symbol	   Gene Name	   Fold Change	   p-value	  
212205_at	   H2AFV	  
H2A histone family, member 
V	   0.7	   0.02	  
205436_s_at	   H2AFX	  
H2A histone family, member 
X	   0.6	   0.02	  
224301_x_at	   H2AFJ	   H2A histone family, member J	   1.5	   0.03	  
208579_x_at	   H2BFS	  
H2B histone family, member 
S	   1.7	   0.03	  
List of genes encoding for histone variants which are regulated upon treatment of HESCs 
with 8-Br-cAMP and MPA for three days. Fold changes greater than one indicate that the 
gene is upregulated upon differentiation, whereas those less than one are downregulated. Only 
the genes with a p <0.05 are listed. 
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3.2.5 In vitro expression of histone-associating proteins 
 The in silico analysis described above resulted in the identification of 331 
transcripts in HESCs which encode for histone associated proteins. We then examined 
the in vitro expression of seven genes, which were significantly regulated upon 
decidualization. Parallel HESC cultures were set up and treated with 8-Br-cAMP and 
MPA for two, four or eight days. Total RNA was harvested and analysis of transcript 
levels was carried out by RT-qPCR. 
 The two suppressors of variegation (SUV39H2 and SUV420H1) showed an 
initial two-fold decrease in transcript levels after two days of treatment to then return 
to levels comparable to those of undifferentiated cells by eight days (figure 3.1 A and 
B).  
 The histone methyltransferase, EZH2, showed dramatic downregulation of its 
transcript after just two days of treatment. Levels remained five-fold lower than in the 
control cells throughout the entire time course (figure 3.1 C).        
ASXL1, a polycomb cofactor, was also profiled by RT-qPCR. Two days of 
decidualization were enough to decrease the expression levels more than two-fold. 
These low levels were maintained through the time course (figure 3.1 D). 
Downregulation of CBX1 was also confirmed in vitro. However, the decrease 
in mRNA levels of this chromatin binding protein appeared to have a much slower 
kinetics. Decreased expression levels comparable to those observed in the microarray 
were only apparent after eight days of treatment (figure 3.1 E). 
 The gene encoding for the chromatin binding proteins UHRF1 presented a ten-
fold reduction in mRNA levels after two days of decidualization, after four days the 
levels slightly increased but still remained significantly lower (more than half) than in 
undifferentiated cells, and stayed such for the remaining four days of treatment (figure 
3.1 F). Transcripts of two other chromatin-binding proteins were verified by RT-
qPCR. BRD3 and BRD4 transcripts did not appear to be regulated after two days of 
decidualization. However, after four days of treatment mRNA levels were reduced by 
40% and maintained as such throughout the time course (figure 3.1 G and H). 
 Taken together these results confirm the in silico data. There is a significant 
regulation of numerous types of chromatin modifying enzymes that perhaps act 
together to ensure correct decidualization in response to cAMP and progesterone.  
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3.2.6 CpG binding proteins  
 DNA methylation occurs on the cytosine of CpG dinucleotides and is essential 
for chromatin dynamics and regulation of transcription. This epigenetic mark is 
passed onto subsequent cellular generations. Methylated DNA is usually associated 
with heterochromatin and these regions also appear to be hypoacetylated. Proteins 
containing the MBD symmetrically bind to mCpGs and mediate the effects of DNA 
methylation. CpG binding proteins are Kaiso, MeCP2 and members of the MBD 
family (MBD 1 through 6). However, MBD5 and MBD6 are associated with 
formation and function of heterochromatin and do not directly bind methylated CpGs 
(Laget et al, 2010). These proteins recruit chromatin-modifying enzymes, such as 
HDACs, and form complexes by which transcriptional repression is ensured by 
multiple cooperating mechanisms.  
Fifteen transcripts (corresponding to 0.06% of the total mRNA produced by 
HESCs) encode for seven different CpG binding proteins (appendix I). All the CpG 
binding proteins, except Kaiso, are expressed upon decidualization. MBD5 is the only 
one that is significantly regulated. Its expression levels increase by approximately 
37% upon treatment of HESCs with decidualization stimuli for three days (table 3.5).  
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Table 3.5 CpG Binding Proteins Regulated Upon Decidualization	  
Probe Set	   Gene Symbol	   Gene Name	  
Fold 
Change	   p-value	  
220195_at	   MBD5	   methyl-CpG binding domain protein 5	   1.4	   0.02	  
List of genes encoding for CpG binding proteins that are regulated upon treatment of HESCs 
with 8-Br-cAMP and MPA for three days. Fold changes greater than one indicate that the 
gene is upregulated upon differentiation, whereas those less than one are downregulated. Only 
the genes with a p < 0.05 are listed. 
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3.2.7 DNA methyltransferases  
The enzymes responsible for methylating position 5 of cytosines are the 
DNMTs. There are five DNMTs: DNMT1, which preferentially acts on 
hemimethylated DNA, DNMT3a and DNMT3b (the de novo methylases), DNMT3L, 
which does not methylate DNA but rather recruits the DNMT3s to target sites, and 
DNMT2 which methylates transfer RNA and not DNA. From the microarray it 
emerges that all the DNMTs, except DNMT3L, are expressed upon decidualization 
(appendix I). DNMT1 and DNMT3b are the only ones that are significantly regulated 
upon decidualization. Their expression decreases of approximately 35% whereas, 
DNMT3a, although also downregulated by approximately 30% is not statistically 
significant (appendix I). A more detailed study of the expression pattern of the family 
members that directly methylate DNA is presented in chapter 5. 
 
3.2.8 DNMT interacting protein expression upon decidualization 
In order to gain additional insight into the regulation of DNA methylation 
events upon decidualization expression levels of DNMT interacting proteins were 
examined. Specifically the DNMT1 recruiter UHRF1 (Hashimoto et al, 2009) and the 
DNMT3b regulator HELLS (Myant & Stancheva, 2008) were analyzed. As 
mentioned above, UHRF1 is lost upon decidualization (table 3.3 and 3.6). Analysis of 
the microarray revealed that the HELLS transcript is regulated in HESCs. Presence of 
this transcript is 60-70% lower (p<0.05) in decidualized cells than in undifferentiated 
ones (table 3.7).  
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Table 3.6 DNMT Regulators Regulated Upon Decidualization 
Probe Set Gene Symbol Gene Name Fold Change p-value 
225655_at UHRF1 
ubiquitin-like, containing 
PHD and RING finger 
domains, 1 
0.1 6.8E-06 
223556_at HELLS helicase, lymphoid-specific 0.4 8.7E-05 
242890_at HELLS helicase, lymphoid-specific 0.4 8.8E-03 
List of regulated genes encoding for proteins that stabilize DNMT binding to the DNA. 
mRNA was extracted from HESCs treated with 8-Br-cAMP and MPA for three days. 
Multiple probe sets for the same gene are listed. Fold changes greater than one indicate that 
the gene is upregulated upon decidualization, whereas those less than one are downregulated. 
Only the genes with a p < 0.05 are listed. 
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3.2.9 In vitro expression of DNMT-interacting proteins 
To confirm the in silico data and gain additional insight into the extent to 
which proteins associated with DNA methylation are regulated upon decidualization, 
expression levels of UHRF1 and HELLS were analyzed by RT-qPCR. As mentioned 
above, DNMTs will be closely examined in chapter 5 and loss of UHRF1 is described 
above (table 3.6 and figure 3.1F). Parallel primary HESCs were cultured and treated 
with 8-Br-cAMP and MPA in a time-course experiment lasting eight days. RT-qPCR 
analysis showed a general downregulation of HELLS mRNA (figure 3.1 I).  
Not only were the transcript levels already nine-fold lower after 2 days of 
decidualization but also they were maintained as such throughout the entire time 
course. 
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3.3 Discussion 
 Many of the events which occur during decidualization of HESCs have been 
shown to act as important environmental cues for epigenetic regulation in numerous 
cell types (Backdahl et al, 2009). Here we show the extent by which chromatin 
associating proteins are regulated upon decidualization. Manual mining of microarray 
data revealed that of the 24717 probes spotted on the chip 352 of them encode for 139 
different chromatin-associated proteins (table 3.7). Histone modifying proteins and 
their cofactors are the most highly represented class of epigenetic effectors analyzed 
here, expressing 244 transcripts across the different probe sets. Given the striking 
variety of histone marks and proteins that regulate them it is not surprising that 66 
probes hybridize with transcripts encoding for histone binding proteins. These 
macromolecules are important readers of the N-terminal tails and recruit other 
proteins essential to propagate and enforce the silencing or activating marks (Dey et 
al, 2003). Obviously, histone marks are not the only epigenetic mechanisms present in 
HESCs. Histone variants, essential for the compacting of chromatin, are also 
expressed. Precisely, 21 probes hybridize with mRNA encoding for them. Another 
epigenetic mechanism, which was analyzed in this study, is DNA methylation. The 
three DNA methyltransferases, DNMT1, DNMT3a and DNMT3b, essential for the 
maintenance and de novo methylation, were all expressed in HESCs and two of them 
(DNMT1 and DNMT3b) were regulated upon decidualization. The methylated DNA 
must be recognized and bound by specialized proteins; this study revealed the 
presence of 7 different transcripts encoding for CpG binding proteins.  
It must be noted, however, that the division of the proteins into the different 
categories is somewhat arbitrary as most proteins have various functions that overlap 
this forced division. For example, EZH2 is not only a methyltransferase but also a 
DNMT-interacting protein (Hernandez-Munoz et al, 2005; Vire et al, 2006). UHRF1, 
which binds histone tails, also interacts with the DNMTs (Bostick et al, 2007; 
Hashimoto et al, 2009). However, for simplification purposes each protein was placed 
in a group based on its main function. Furthermore, many proteins that are not 
considered epigenetic effectors may underpin a secondary role as such. The majority 
of these chromatin-modifying proteins act in complexes with other proteins such as 
transcription and nuclear factors. Here we only concentrated on proteins that are 
directly involved in modifying the chromatin and binding to the marks.  
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Table 3.7 Overview of the Regulated Epigenetic Effectors Upon Decidualization of 
HESCs 
  
Number 
of probe 
sets 
Percentage 
of total 
probes 
Number 
of genes 
Regulated 
with 
p<0.01 
Regulated 
with 
p<0.05 
       
HESCs transcriptome 24717 100% 3008 1758 587 
 
      
H
is
to
ne
-a
ss
oc
ia
te
d 
pr
ot
ei
ns
 
Histone modifying 
proteins 101 0.41% 49 5 12 
Co-factors of 
histone modifying 
proteins 
143 0.58% 43 3 14 
Histone binding 
proteins 66 0.27% 25 7 8 
Histone Variants 21 0.08% 9 0 4 
       
D
N
A
 m
et
hy
la
tio
n 
as
so
ci
at
ed
 
pr
ot
ei
ns
 
CpG binding 
proteins 15 0.06% 7 0 1 
DNMTs 4 0.02% 4 0 2 
DNMT-interacting 
proteins 2 0.01% 2 2 2 
       
 Total 352 1.42% 139 17 43 
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The HESCs were treated with 8-Br-cAMP and MPA for only three days 
before harvesting the RNA for microarray analysis therefore the cells were not 
completely decidualized. This implies that the majority of the genes were not fully 
activated or repressed giving smaller fold change values. Carrying out the microarray 
at a later time point will undoubtedly yield greater fold changes and perhaps even 
more genes would result regulated. Ideally, analyzing the transcriptome at multiple 
time points would aid in gaining a more profound understanding of the regulation of 
genes encoding for epigenetic effectors. It would also give the opportunity to follow 
expression patterns and identify biphasic genes. However, three days is a convenient 
time point to analyze as it encompasses both early and late responding genes and 
although differential expression levels are probably not at their maximum levels they 
can still be picked up.  
The majority of regulated genes that emerged from the microarray, and not 
solely the epigenetic effectors, showed expression levels in undifferentiated and 
decidualized cultures within the same order of magnitude and thus small fold change 
values, although statistically significant. Other studies on HESCs also show low fold 
change values,. As a matter of fact these studies were carried out on patients with 
endometriosis and polycystic ovary syndrome where, being in an abnormal context, 
even more dramatic fold changes would be expected (Aghajanova et al, 2010; Savaris 
et al, 2011). A standard fold-change cutoff of 1.5 is used when analyzing microarray 
data with a p-value of less than 0.05. Here, however, we included in our analysis also 
genes with a slightly lower fold change value (1.4 and in one case 1.3). In our 
validation we also amplified CBX1, which has a fold change of 40%. It can be seen 
that there is no significant regulation in the initial four days of decidualization, 
although after eight days the transcript levels are indeed reduced. Therefore, even 
though having a lower fold change cutoff likely leads to false positive results, if 
combined with low p-values it can be a good indication of limited gene activity. 
Furthermore, the purpose of this work was to gain an overview of the regulation of 
epigenetic effectors and thus slightly less stringent parameters were suitable.  
The work we presented here is in accordance with the literature. One study 
looked at expression and regulation of transcription factors that modulate chromatin 
structure in rhesus monkey oocytes and pre-implantation stage embryos focusing on 
the temporal coordination between expression of epigenetic effectors and cellular 
differentiation The study revealed that a variety of epigenetic effectors are indeed 
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regulated, by a magnitude and breadth comparable to the ones presented in this work, 
and play crucial roles in orchestrating processes such as lineage determination. 
Furthermore, they show that some of these chromatin modifiers present in oocytes 
and embryos reveal a distinct expression pattern than the one observed in somatic 
cells (Zheng et al, 2004). The fundamental role these proteins play in coordinating a 
variety of processes does not make it surprising that aberrant regulation of these 
factors leads to, among other things, ageing and cancers (Caffarelli & Filetici, 2011; 
Pollina & Brunet, 2011). 
The postovulatory surge in progesterone levels leads to a tight regulation of 
epigenetic effectors that accounts for 1.42% of the total transcriptome. Cyclical waves 
of proliferation, differentiation, menstrual shedding and regeneration involve, at least 
in part, epigenetic control and cellular memory. The human endometrium proliferates 
extremely fast thus requiring the machinery to propagate the epigenetic marks 
following replication. Decidualized cells however do not proliferate and, in case of 
pregnancy, are maintained for nine months. The machinery required to propagate the 
marks is not paramount in decidual cells and hence downregulated. For example, 
BRD4 is mostly found in noncentromeric regions of chromosomes during interphase 
and mitosis and hence could be essential for the transmission of epigenetic memory 
during replication (Dey et al, 2003). BRD4 is expressed in the highly proliferating 
HESCs but not in the decidualized cells. 
Also in line with the notion that decidual cells arrest proliferation, HDAC4, 
which is associated with gene repression, is strongly upregulated upon 
decidualization. The pRB/E2F-DP complex, a strong inhibitor of cell cycle 
progression, has been shown to recruit HDACs to the chromatin (Harbour & Dean, 
2000). This results in suppression of both DNA synthesis and progression of the cell 
cycle into the S phase.  
 On the other hand, decidual cells must respond to maternal and fetal signals 
as well as to an extremely genotoxic environment with high levels of ROS and 
inflammation. This is, indeed, paralleled by an upregulation of transcripts such as 
ING1, which is involved in DNA damage repair and stress responses.  
The profoundly different functions of HESCs and decidual cells are further 
highlighted by the diverse requirements of epigenetic effectors and could be reflected 
on changes in their epigenomes. In the next chapter we will focus on the effects of 
regulation of one of these effectors, EZH2.  
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4.1 Introduction 
Multiple mechanisms have been shown to underpin the convergence of the 
cAMP and progesterone signal pathways in decidualization of HESCs. For example 
cAMP inhibits ligand-dependent sumoylation of PR (Cloke et al, 2008; Jones et al, 
2006), a posttranslational modification that limits the transactivation capacity of this 
nuclear receptor (Abdel-Hafiz et al, 2002). Increased cAMP levels also induce the 
expression of several transcription coregulators of PR, including FOXO1, STAT5, 
and C/EBPβ, and disrupt the binding of the receptor to specific corepressors, such as 
NCoR and SMRT (Christian et al, 2001; Christian et al, 2002b; Mak et al, 2002; 
Pohnke et al, 1999; Wagner et al, 1998). While all these observations indicate that PR 
activity in HESCs is tightly controlled they do not explain well the temporal 
regulation of the decidual process during the cycle. One possibility, as yet untested, is 
that decidual transformation of the endometrial stroma in the cycle is dependent on 
coordinated chromatin modifications. Such modifications in turn create permissive 
and repressive transcriptional environments enabling large gene networks to respond 
to differentiation signals. 
Numerous DNA and histone modifying enzymes govern the accessibility of 
the transcriptional machinery to chromatin, thus determining if a gene is silenced, 
activated, or poised to respond to a stimulus (Kouzarides, 2007a; Sharov et al, 2011; 
Wiench et al, 2011). One of the most widely studied histone modifiers is EZH2, 
which, along with the EED and the SUZ12, makes up the PRC2. Within this 
repressive complex EZH2 serves as the active enzyme that catalyzes the 
trimethylation of histone 3 on lysine 27 (H3K27me3) leading to gene silencing (Cao 
et al, 2002; Czermin et al, 2002). Importantly, aberrant expression of EZH2 occurs in 
a variety of hormone-dependent malignancies, including endometrial, breast and 
prostate cancers (Berezovska et al, 2006; Gonzalez et al, 2009; Karanikolas et al, 
2010; Wei et al, 2008). Furthermore, ovarian hormones reportedly regulate EZH2 
expression and activity in a variety of cell types (Bredfeldt et al, 2010). These 
observations prompted us to examine the expression of EZH2 in human endometrium 
and to determine if cycle-dependent changes in EZH2 methylation activity play a role 
in differentiation of HESCs into specialized decidual cells. 
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4.2 Results 
4.2.1 Cycle-dependent expression of EZH2 in human endometrium  
EZH2 expression during the menstrual cycle was examined in 5 proliferative 
and 5 secretory endometrial biopsies. Western blot analysis of whole tissue lysates 
showed a marked decrease in the expression of this methyltransferase during the 
secretory phase of the cycle (figure 4.1 A). Indeed, densitometric measurements of the 
bands revealed double the amount of protein in the proliferative phase than later in the 
cycle (figure 4.1 B).  To further explore the dynamics of this downregulation, we 
focused on the expression of EZH2 during the secretory phase. RT-qPCR analysis on 
timed endometrial biopsies revealed a 3-fold decrease in EZH2 transcript levels with 
the onset of the mid-secretory phase. This reduction in EZH2 mRNA level was then 
maintained for the remainder of the cycle (figure 4.2 A). Tissue sections obtained 
between day 14 and day 27 were subjected to immunohistochemistry. As shown in 
figure 4.2 B, EZH2 immunoreactivity was prominent in the epithelial glandular 
compartment during the early secretory phase. It was also abundantly expressed in 
stromal cells, although the staining was less homogenous. As the cycle progressed, a 
marked loss of EZH2 expression was apparent in epithelial cells, resulting in virtual 
lack of signal in this cellular compartment by the end of the cycle. A similar trend was 
apparent in the stroma, although individual cells strongly expressing EZH2 were still 
present during the late-secretory phase. Taken together these data suggest that the 
progression of the menstrual cycle results in a gradual but marked loss of EZH2 
expression in differentiating human endometrium. 
Chapter 4 EZH2 in the differentiating endometrium 
 
 
95 
 
 
Chapter 4 EZH2 in the differentiating endometrium 
 
 
96 
  
Chapter 4 EZH2 in the differentiating endometrium 
 
 
97 
4.2.2 Loss of EZH2 expression in decidualizing HESCs 
As EZH2 expression is downregulated in the stromal compartment of 
differentiating endometrium we examined if this would be the case upon 
decidualization of primary HESCs in vitro. Primary cultures were stimulated with 8-
Br-cAMP and the progestin MPA for various time-points (figure 4.3).  Total mRNA 
and protein were extracted from parallel cultures to examine the expression of EZH2. 
Unexpectedly transcript levels were already 80% lower in cells decidualized for two 
days than in undifferentiated cells and this level of repression was maintained 
throughout the entire time-course (figure 4.3 A, top panel). The decline in EZH2 
mRNA expression was paralleled at protein level, although the reduction was more 
gradual. Upon eight days of differentiation, expression of this methyltransferase was 
below the level of detection by Western blot analysis (figure 4.3 A, bottom panel). 
The loss of EZH2 upon decidualization of HESCs was further confirmed by confocal 
microscopy (figure 4.3 B). Again, by two days of treatment the fluorescent signal was 
strongly reduced. 
To provide insights into the mechanism of EZH2 repression, primary cultures 
were treated with 8-Br-cAMP, MPA, alone or in combination, for 48 hours. EZH2 
transcripts decreased modestly upon treatment with 8-Br-cAMP, whereas MPA 
reduced the expression level by approximately 50%. However, a combination of 8-Br-
cAMP and MPA yielded an additive effect, resulting in approximately 80% reduction 
in EZH2 mRNA levels (figure 4.4, top panel). Again, the regulation of EZH2 
transcripts was recapitulated at protein level (figure 4.4, bottom panel). Thus, both the 
cAMP and progesterone signal transduction pathways play a role in EZH2 
downregulation in differentiating HESCs, with progesterone being the dominant 
signal.   
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Figure 4.4. cAMP- and Progesterone-dependent Downregulation of  EZH2 
Confluent HESC cultures either untreated or decidualized with 8-Br-cAMP (cAMP), MPA,
or a combination for 2 days. EZH2 expression at mRNA and protein level was determined 
in parallel cultures by RT-qPCR (upper panel) and Western blot analysis (lower panel). The 
data show the fold change (± SEM of triplicate measurements) in EZH2 transcript levels 
upon treatment relatively to expression in untreated cells. 
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4.2.3 Interplay between acetylation and trimethylation of H3K27  
EZH2 catalyzes trimethylation of H3K27, a histone tail modification 
associated with repressive chromatin and gene silencing (Vire et al, 2006). To 
examine if loss of EZH2 impacts on global cellular H3K27me3 levels confocal 
microscopy as well as Western blot analysis were carried out on undifferentiated 
HESCs and cultures treated with 8-Br-cAMP and MPA for various time-points. 
Unexpectedly, differentiation of HESCs for as long as 8 days was not associated with 
a discernible change in overall methylation of H3K27 either by confocal microscopy 
or by western blot analysis (figure 4.5). This suggested that other enzymes with 
histone H3 methylase activity are likely to be present in decidualizing cells. As shown 
in figure 4.5 B EZH1, a functional homolog of EZH2 (Ezhkova et al, 2009), is indeed 
expressed in HESCs and the abundance of this methyltransferase is maintained upon 
treatment with 8-Br-cAMP and MPA. 
Next, we examined if loss of EZH2 impacts on the methylation status of 
H3K27 at the transcriptional start site (TSS) of highly induced decidua-specific genes. 
dPRL and IGFBP-1 are the most widely studied decidual marker genes and their 
transcriptional regulation has been extensively studied (Al-Sabbagh et al, 2011; 
Christian et al, 2002c; Gao et al, 2000a; Lynch et al, 2009). Notably, dPRL in the 
endometrium is transcribed from an alternative promoter upstream of a noncoding 
exon, located approximately 6 kb upstream of the pituitary-specific TSS (Gellersen et 
al, 1994). ChIP analysis was carried out using an H3K27me3-specific antibody 
followed by amplification of a 98 bp fragment encompassing the -332 to -270 bp 
regulatory region of the decidual-specific dPRL TSS, which contains several response 
elements required for cAMP- and progesterone-dependent regulation (Al-Sabbagh et 
al, 2011; Christian et al, 2002b; Cloke et al, 2008; Telgmann & Gellersen, 1998; 
Telgmann et al, 1997). Time-course analysis revealed that HESC differentiation is 
associated with a gradual but overall dramatic loss of this mark at this locus (figure 
4.5). By two days of decidualization H3K27me3 levels on the PRL promoter had 
decreased by approximately 40% but by eight days presence of this mark was over 
80% less than in undifferentiated cells (figure 4.6, top panel). Loss of H3K27me3 was 
even more rapid and pronounced at the proximal IGFBP-1 promoter (-263 to -33 bp 
relatively to the TSS) where presence of this mark had decreased by more than 60% 
after two days of treatment. Eight days of treatment resulted in over 95% loss of the 
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mark (figure 4.6, bottom panel). Thus, the pronounced decline of H3K27me3 at 
specific loci in the absence of a global change in levels suggests that decidualization 
is associated with a dynamic, albeit specific, redistribution of the mark.  
Acetylation of H3K27 (H3K27ac) antagonizes PRC2-dependent gene 
silencing. Furthermore, acetylation and trimethylation of H3K27 are mutually 
exclusive as both modifications compete for binding to the same lysine residue 
(Pasini et al, 2010; Tie et al, 2009). To determine if complementarity between these 
marks exists in HESCs, we first analyzed global levels of H3K27ac in 
undifferentiated and decidualizing cells. Confocal microscopy revealed an increase in 
H3K27ac upon decidualization in HESCs, apparent after two days but even more 
pronounced after four and eight days of differentiation (figure 4.7 A). This was further 
confirmed by Western blot analysis, demonstrating a gradual increase in the 
abundance of this mark in decidualizing cultures (figure 4.7 B). This increase was not 
accompanied by a change in global H3 levels (figure 4.7 B). To verify if loss of 
H3K27me3 is accompanied by a gain in acetylation at specific loci, ChIP with an 
H3K27ac-specific antibody followed by qPCR amplification of the proximal decidual 
dPRL and IGFBP-1 promoters was carried out. As shown in figure 4.8, differentiation 
of HESCs is indeed associated with rapid and marked increase in H3K27ac signal 
upstream of the TSS of both genes. On the dPRL promoter presence of the H3K27ac 
mark increases over 60-fold after only two days of decidualization and by eight it was 
over 140-fold higher than in undifferentiated HESCs (figure 4.8 top panel). This 
induction was even more dramatic on the IGFBP-1 promoter, where the abundance of 
this modification increased over four orders of magnitude after eight days of 
treatment (figure 4.8 bottom panel).  
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4.2.4 EZH2 downregulation is permissive for decidualization 
We then explored the functional consequences of EZH2 downregulation on the 
expression of decidual marker genes. First, we used siRNA to silence EZH2 
expression in primary cultures, which were then left untreated or decidualized with 8-
Br-cAMP and MPA for two days. The knockdown was highly effective and reduced 
EZH2 expression, but not EZH1, below the level of detection on Western blot 
analysis (figure 4.9). Furthermore, silencing EZH2 resulted in a moderate decrease in 
global H3K27me3 levels but not of total H3 (figure 4.9). Interestingly, EZH2 
silencing was sufficient to decrease H3K27 trimethylation on the decidual dPRL and 
IGFBP-1 promoters by 80% and 60%, respectively (figure 4.10 A). Notably, EZH2 
knockdown enhanced acetylation of the same residue in H3 at the IGFBP-1 by 100% 
but only marginally (only 20%) on dPRL promoter (figure 4.10 B). Furthermore, 
knockdown of this methyltransferase in undifferentiated cells enhanced the 
subsequent induction of both dPRL and IGFBP-1 transcripts in response to 8-Br-
cAMP and MPA treatment by 60% and 30%, respectively (figure 4.11). There was 
also a consistent but very discrete increase in basal expression levels of these marker 
genes upon EZH2 knockdown. To confirm that EZH2 inhibits decidualization, 
primary HESC cultures were transfected with an expression vector encoding EZH2 
and then differentiated with 8-Br-cAMP and MPA for two days. Overexpression was 
confirmed by Western blot analysis (figure 4.12 A). RT-qPCR analysis of parallel 
cultures demonstrated that IGFBP-1 mRNA induction was approximately 40% lower 
in decidualized cultures expressing exogenous EZH2 (figure 4.12 B). This effect was 
even more pronounced for dPRL transcripts where induction was decrease by over 
80%. Together, the data demonstrate that loss of EZH2 alone is insufficient to induce 
a decidual phenotype, yet determines the cellular responsiveness to differentiation 
stimuli. 
 
  
Chapter 4 EZH2 in the differentiating endometrium 
 
 
107 
Chapter 4 EZH2 in the differentiating endometrium 
 
 
108 
  
Chapter 4 EZH2 in the differentiating endometrium 
 
 
109 
  
  
Chapter 4 EZH2 in the differentiating endometrium 
 
 
110 
Chapter 4 EZH2 in the differentiating endometrium 
 
 
111 
4.2.5 Genome-wide redistribution of H3K27me3 upon decidualization and in 
response to EZH2 knockdown 
Our results indicated that loss of EZH2 expression in decidualizing cells 
results in loss of H3K27me3 signal at specific loci yet overall levels of this repressive 
histone modification seem to be maintained. To determine if decidualization is 
associated with genome-wide redistribution of H3K27 methylation, we carried out 
ChIP-chip arrays on undifferentiated HESCs and cells treated with 8-Br-cAMP and 
MPA for 8 days, a time-point at which EZH2 expression is virtually undetectable 
(figure 4.3). Chromatin from three independent, paired, undifferentiated and 
decidualizing cultures was immunoprecipitated with the H3K27me3 antibody, 
labeled, and hybridized to a Roche NimbleGen Human ChIP-chip 3x720K RefSeq 
promoter array. We identified a significant change (P < 0.05) in H3K27me3 signal at 
3008 genomic regions, which included the IGFBP-1 promoter (figure 4.13 and 
appendix II). Of these there was a reduction in methylation in 75% and enrichment in 
25% upon differentiation of HESCs into decidual cells. Gene ontology (GO) analysis 
revealed that gain of this repressive modification was strongly enriched at promoters 
of genes involved in transcriptional regulation (enrichment score: 7.5; P < 0.001) 
whereas loss of the mark was prominent at genes implicated in response to stimulus 
(enrichment score: 12.5; P < 0.001) (figure 4.14). The decidua-specific dPRL 
promoter was not represented on the array.  
To determine if this genome-wide redistribution of H3K27me3 upon 
decidualization of HESCs is caused by the loss of EZH2, we repeated the ChIP-chip 
arrays but this time on chromatin immunoprecipitated from three independent 
undifferentiated primary cultures first transfected with non-targeting or EZH2 siRNA. 
Silencing EZH2 expression was sufficient to significantly alter the abundance of 
H3K27me3 at 2029 distinct genomic regions and a comparable number of loci 
displayed a reduction or enrichment in histone modification, 53% and 47% 
respectively (appendix II). Furthermore, cross-referencing of the two data sets 
revealed altered H3K27me3 at 567 genomic regions in both decidualizing HESCs and 
upon EZH2 knockdown in undifferentiated cultures (figure 4.13 A and appendix III). 
However, the direction of change was discordant in 229 regions (40%). In other 
words, EZH2 knockdown in undifferentiated cells only reproduced the change in 
H3K27 methylation at 338 of 3008 (11%) genomic regions altered upon 
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decidualization (appendix III). These 338 highly EZH2-responsive regions were also 
subjected to GO analysis where loss and gain of the H3K27me3 repressive mark was 
found to occur prominently in the proximity of genes involved in response to stimuli 
(enrichment score: 28; P < 0.001) and cellular growth (enrichment score: 6.8 ; P < 
0.05) respectively (figure 4.15). 
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4.3 Discussion 
This study provides evidence that loss of EZH2 activity in HESCs contributes 
to the chromatin changes necessary for expression of a decidual phenotype in 
response to differentiation cues. While EZH2 transcript levels fell rapidly in response 
to cAMP and progestin treatment, protein levels declined more gradually. The 
kinetics of this response correlated well with the decline in H3K27me3 at the dPRL 
and IGFBP-1 promoters and, inversely, with the level of transcriptional activation of 
these marker genes (Brosens et al, 1999; Cloke et al, 2008). Furthermore, a parallel 
gain in the competing activation mark H3K27ac was observed at both promoters upon 
decidualization of HESCs, although the amplitude of this response was more 
pronounced at the TSS of IGFBP-1. Interestingly, a recent study reported that 
different modifications are predictive of the expression levels of genes that are either 
rich or poor in the CpG content of their promoters. In particular H3K27ac is strongly 
associated with activation of high but not low CpG content promoters (Karlic et al, 
2010). In keeping with this model, acetylation of H3K27 upon HESC differentiation 
was not only more pronounced at the IGFBP-1 promoter, which has 68 CpGs, but 
EZH2 knockdown was sufficient to enrich the mark. In contrast, the decidua-specific 
dPRL promoter is poor in CpG content and enrichment in H3K27ac was strictly 
dependent on cAMP and MPA stimulation. A previous study demonstrated that 
CBP/p300, coactivators that catalyze acetylation of H3K27, are indispensible for 
dPRL expression in differentiating HESCs (Christian et al, 2001), suggesting that 
recruitment of these histone modifiers to decidual promoters requires binding of 
specific transcriptional complexes induced by cAMP and MPA signaling. In other 
words, while loss of EZH2-dependent methyltransferase activity contributes to 
creating a transcriptionally permissive chromatin environment, these changes alone 
are insufficient to trigger the expression of decidual marker genes in undifferentiated 
HESCs, or even upon stimulation with only MPA (data not shown). 
Downregulation of EZH2 expression in decidualizing HESCs was not 
paralleled by a decline in global cellular H3K27me3 levels as determined by Western 
blot analysis or confocal imaging. However, our ChIP-chip array study suggested a 
net reduction in chromatin-bound methylated H3K27 after 8 days of differentiation as 
three-times more genomic regions were reduced than those enriched in this 
modification. Nevertheless, residual H3 methylase activity remained apparent in 
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differentiating HESCs, even with EZH2 expression below the level of detection. This 
residual activity is likely accounted for by the continuous expression of EZH1. Like 
EZH2, EZH1 integrates in PCR2, although there is evidence that these complexes 
differ in their repressive roles. EZH1 has relative weak intrinsic histone 
methyltransferase activity and is thought to elicit its role by compacting chromatin 
through interaction with nucleosomes (Margueron et al, 2003). Interestingly, EZH2 
expression is widely associated with cellular proliferation, whereas EZH1 is 
reportedly more abundant in non-proliferative cells (Margueron et al, 2003).  This 
general pattern of expression fits well with our observation that EZH2 but not EZH1 
is lost upon differentiation of HESCs. 
Furthermore, as widely described in the previous chapter (chapter 3), 
decidualization of HESCs is associated with altered expression of members of several 
classes of chromatin modifying enzymes. Because of the interdependency of various 
chromatin modifications (Karlic et al, 2010; Lee et al, 2003) it was hypothesized that 
EZH2 knockdown in undifferentiated HESCs would at best only partially recapitulate 
the changes in H3K27me3 observed upon decidualization. This was indeed the case. 
Only 11% of the genomic regions altered in H3K27me in response to prolonged 
cAMP and MPA stimulation were modified in a similar manner upon EZH2 
knockdown in untreated cells. These loci could be viewed as highly EZH2 dependent 
for remodeling. Interestingly, GO analysis revealed that those regions that gain the 
transcriptionally repressive H3K27me mark upon decidualization of HESCs are 
enriched for genes associated with growth. Even more strikingly, the same analysis of 
regions that lost the mark, thus acquiring a transcriptionally permissive chromatin 
environment, revealed a preponderance of genes functionally associated with 
responsiveness to stimuli. Thus the result of the ChIP-chip arrays further supports the 
notion that downregulation of EZH2 is a key event that renders endometrial cells 
responsive to differentiation and other environmental cues.  
Taken together our data show that cAMP and progesterone signaling reshape 
the chromatin landscape of HESCs, which in turn enables regulation of large gene 
networks that underpin the expression of a decidual phenotype. Extrapolated from the 
in vivo situation, our findings suggest that cycle-dependent changes in chromatin 
structure are a major determinant in the cellular responsiveness to differentiation 
signals and the subsequent acquisition of a decidual phenotype. In light of the crucial 
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role of EZH2 in this process, it seems likely that perturbations in this or other 
chromatin remodeling enzymes underpin reproductive failure.  
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5.1 Introduction 
Actions of ovarian steroid hormones are essential for a coordinated and correct 
progression of the menstrual cycle, in the later half of which HESCs differentiate into 
decidual cells (Christian et al, 2002a). This process involves marked morphological 
and biochemical changes whose precise regulation is still not fully understood. 
Decidual cells exert paramount functions for a successful pregnancy: controlling 
trophoblast invasion, conferring resistance to stress and promoting angiogenesis 
essential for the survival of the embryo.  
In the previous chapters of this work we describe the breadth of epigenetic 
effectors present in HESCs and how their expression changes in response to the 
ovarian hormone progesterone upon decidualization. DNA methylation, which occurs 
on the cytosine of CpG dinucleotides, is one of the epigenetic mechanisms critical in 
determining the chromatin landscape. It closely interacts with histone modifications 
and chromatin remodeling complexes (Bird, 2002; Hernandez-Munoz et al, 2005; 
Klose & Bird, 2006; Vire et al, 2006). 
 DNA methylation is essential in mediating gene expression, X-inactivation and 
imprinting. Its importance in the endometrium is emphasized by its association with 
pathological conditions such as endometriosis and endometrial carcinomas.  
 The cyclical waves of endometrial regeneration, proliferation, differentiation 
and menstrual shedding may involve DNA methylation. Furthermore, as previously 
mentioned in chapter 3 (section 3.2.7), analysis of a microarray revealed that 
DNMT1, DNMT3a and DNMT3b are expressed in HESCs. DNMT1 and DNMT3b 
are downregulated upon decidualization (table 3.6). Here, we further explore the 
expression profiles of these enzymes and their effects on DNA methylation. 
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5.2 Results 
5.2.1 Regulation of DNMTs upon decidualization 
First we examined the changes in expression of DNMT1, DNMT3a and 
DNMT3b upon decidualization. Parallel cultures of HESCs, established from tissue 
samples, were set up and decidualized for two, four and eight days. The cells were 
then harvested for total RNA and protein; expression patterns were analyzed by RT-
qPCR and Western blot, respectively. DNMT1 transcript levels decreased four-fold 
upon two days of decidualization but then gradually returned to levels comparable to 
those of undifferentiated cells (figure 5.1 4 A, left panel). A similar pattern was 
observed for DNMT3a mRNA expression, although by eight days of treatment with 8-
Br-cAMP and MPA the transcript levels were approximately 2-fold higher than in 
undifferentiated cells (figure 5.1 A, middle panel). DNMT3b expression was strongly 
repressed, by approximately 80% by day two, and the levels remained low throughout 
the time course (figure 5.1, right panel).  
Western blot analysis was used to monitor the protein expression of the 
DNMTs in decidualizing primary HESCs. Notably, for differentiation the culture 
medium of confluent primary cultures is changed from 10% to 2% DCC-FBS which 
causes the cells to synchronize in the G1 phase. As shown in figure 5.1 B, lowering 
serum levels alone appeared sufficient to modestly enhance expression of all three 
methyltransferases. Upon differentiation in response to 8-Br-cAMP and MPA, 
however, there was a gradual downregulation of DNMT3b and DNMT1 expression, 
starting from day four. By eight days of decidualization, the expression levels of both 
enzymes were below the level of detection. In contrast, DNMT3a levels were 
upregulated, especially at the later time-point. The microarray data on HESCs 
analyzed in chapter 3 show a 30% decrease in DNMT1 and DNMT3a mRNA levels 
upon three days of treatment with 8-Br-cAMP and MPA. It must be noted that the p-
value for DNMT3a is greater than 0.05, hence not significant. This is a similar 
decrease as the one observed by RT-qPCR but after four days of treatment. This slight 
discrepancy could be due to the higher sensitivity of RT-qPCR than microarray or that 
there is a rapid increase in DNMT1 and DNMT3a levels after day two. Microarray 
data did not reveal, however, a strong decrease in DNMT3b transcript, which instead 
can be observed by RT-qPCR.  
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The data show that the expression of these DNMT family members is highly 
regulated in differentiating HESCs at both mRNA and protein level. However, there 
was a clear discrepancy between the rapid and transient decline in DNMT1 transcripts 
and the gradual loss of protein over the time-course experiment (figure 5.1 A and B). 
This suggested that additional levels of control might exist to regulate the expression 
of DNMTs in decidualizing HESCs, especially for DNMT1. The lack of DNMT1 
protein expression after eight days of treatment with 8-Br-cAMP and MPA, despite 
mRNA levels comparable to those in undifferentiated cells, indicated enhanced 
protein turnover. To determine the underlying mechanism, undifferentiated HESCs 
and cells decidualized for eight days were treated with MG132, a potent inhibitor of 
the proteasome degradation pathway. As shown in figure 5.1 C, treatment with 
MG132 was sufficient to restore DNMT1 levels in decidualizing cells, confirming 
that lack of expression upon prolonged differentiation primarily reflects increased 
protein degradation.  
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5.2.2 Expression of DNMTs in vivo 
To determine if these enzymes are also regulated in vivo during the menstrual 
cycle, endometrial samples from five women in the proliferative phase of the cycle 
and from five in the secretory phase were collected, lysed and subjected to Western 
blot analysis. Expression of DNMT1, DNMT3a and DNMT3b was thus monitored. 
As shown in figure 5.2, DNMT1 is strongly expressed in the proliferative 
endometrium but not detectable in the secretory phase. DNMT3b also follows a 
similar expression profile. Furthermore, the DNMT3b bands corresponding to 
secretory endometrium appear to migrate faster than in the proliferative endometrium. 
On the other hand, expression of DNMT3a is considerably variable within patients 
but does not seem to be regulated with the progression of the cycle (figure 5.2)  
Given the variability between different tissue samples the intensity of the 
bands representing the various enzymes was measured using the NIH developed 
software Image J (http://rsbweb.nih.gov/ij/) and normalized to β-actin (figure 5.2 B). 
As was the case for primary decidualizing cultures (figure 3.1), endometrial 
differentiation following the postovulatory progesterone surge in vivo was associated 
with a marked decrease in DNMT1, DNMT3b but not DNMT3a expression.  
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5.2.3 Global DNA methylation  
The strong regulation of DNMTs led us to investigate the extent by which 
changes in global DNA methylation levels occur upon decidualization. DNA was 
extracted from cells decidualized for eight days and global methylation was analyzed 
both with a colorimetric assay (MethylampTM Global DNA Methylation 
Quantification Kit, Epigentek) and by measuring the percentage of methylation of 
Long Interspersed Nuclear Element 1 (LINE-1) sequences, a good estimator of global 
methylation (Yang et al, 2004). Methylation of LINE-1 sequences was measured by 
bisulfite conversion of the DNA followed by amplification and biotinylation of these 
sequences, using the PyroMark CpG Line-1 assay (Qiagen), prior to pyrosequencing. 
Both methods of measurement revealed no significant changes in global DNA 
methylation between cells decidualized for eight days and undifferentiated cells 
(figure 5.3). However, the fact that no changes in methylation levels were observed 
could reflect a redistribution of CpG methylation or localized alterations on selected 
promoters. Furthermore, a previous study showed that treatment of HESCs with 5-
aza-dC, a DNMT inhibitor, resulted in enhanced expression of two decidual marker 
genes dPRL and IGFBP-1 (Logan et al, 2010), suggesting that DNA methylation is 
involved in differentiation of HESCs into decidual cells.  
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5.2.4 Changes in methylation on the IGFBP-1 promoter 
Previous studies suggest that DNA methylation on selected promoters may be 
altered upon decidualization. In a human B-lymphoblastoid cell line, methylation of a 
single CpG dinucleotide found on the second protein-coding exon of PRL correlates 
with increased transcription levels (Gellersen & Kempf, 1990). Furthermore, 
treatment of MPA-stimulated HESCs with 5-aza-dC showed a slight reduction in PRL 
mRNA levels with respect to cells subjected to MPA alone but treatment of the cells 
with 5-aza-2dC led to an upregulation of PRL and IGFBP-1 (Logan et al, 2010). We 
thus, decided to directly examine whether the methylation status of dPRL and IGFBP-
1 promoter regions was altered upon decidualization. Presence of CpG islands on 
these promoters was predicted using in silico analysis both with the EMBOSS CpG 
Plot software (www.ebi.ac.uk/Tools/emboss/cpgplot/index.html) as well as by looking 
at the CpG tracks present on UCSC Genome Browser (http://genome.ucsc.edu/). Both 
methods showed no putative CGIs on the dPRL promoter (figure 5.4), suggesting that 
epigenetic regulation on this promoter, if any, involves different mechanisms. On the 
other hand, the IGFBP-1 promoter is rich in CpGs. EMBOSS CpG Plot revealed the 
presence of two very close CGIs which UCSC Genome Browser sees as a single one 
containing 68 CpG dinucleotides (figure 5.4). This slight discrepancy is due to the 
algorithm used by the two softwares but both reveal a high incidence of CpGs in the 
promoter region of this gene. To verify if regulation of IGFBP-1 involves alteration of 
the methylation of the promoter we analyzed the methylation status of the promoter 
via pyrosequencing. DNA extracted from HESCs decidualized with 8-Br-cAMP and 
MPA for eight days was treated with bisulfite, which deaminates cytosines (but not 
5mCs) converting them into uracils. The commercially available PyroMark CpG 
Assays for IGFBP-1 was used to analyze the bisulfite-treated DNA. Of the six CpG 
dinucleotide analyzed, none of them appeared to be methylated above the detection 
level (10% methylation) in undifferentiated HESCs. After eight days of 
decidualization the analyzed region of the IGFBP-1 promoter remained unmethylated 
(figure 5.5).  
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5.3 Discussion 
DNMTs are regulated upon decidualization. Western blot analysis revealed 
high expression levels of DNMT1 and DNMT3b during the proliferative phase of the 
cycle which dropped with the onset of the secretory phenotype (figure 5.2). This 
expression pattern was recapitulated in vitro in an eight days time course (figure 5.1). 
The above observations are in line with a previous study that showed downregulation 
of DNMTs by progesterone and estrogen (Yamagata et al, 2009).  
DNMT1 is responsible for maintaining DNA methylation in the context of 
hemimethylated CpGs. It is mostly associated with DNA replication (where the 
epigenetic status of the template strand is inherited to the newly formed strand) and 
DNA repair (Chen et al, 2003; Mortusewicz et al, 2005). Decidual cells are not very 
proliferative and have an increase resistance to oxidative stress thus making DNMT1 
dispensable. Moreover, during DNA repair this enzyme is recruited to the repair sites 
by PCNA, which is also strongly downregulated upon decidualization. It has been 
shown that DNMT3a is also involved in maintenance of DNA methylation (Chen et 
al., 2003), so the correct maintenance of the methylome is ensured by the 
upregulation of DNMT3a.  
Downregulation of DNMTs was not accompanied by a general decrease of 
global methylation levels that remained unchanged after decidualization (figure 5.3). 
This could signify either a redistribution of DNA methylation, after all DNMT3a (a 
de novo methylase) is expressed in decidual cells, or that the changes are too subtle 
and cannot be detected by either the colorimetric or the LINE-1 assay. This 
observation has also been observed in the endometrium of other species. For example, 
in bovine no changes in global methylation levels were detected during the estrous 
cycle nor after implantation (Furst et al, 2011).  
In silico analysis revealed that the decidual prolactin promoter lacks CpG 
islands whereas the IGFBP-1 has a CpG rich region (figure 5.4). This led us to look at 
the methylation status of the IGFBP-1 promoter in undifferentiated and decidualized 
stromal cells. Interestingly, this promoter appeared to be unmethylated in HESCs and 
no changes in methylation were observed upon decidualization. It must be noted that 
the repressive 5mC base is not present on the six analyzed CpGs of undifferentiated 
cells. Methylation is usually associated with transcriptional repression hence a lack of 
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methylation on the IGFBP-1 promoter upon decidualization reflects its strong 
expression (Al-Sabbagh et al, 2011; Cloke et al, 2008).  
Regulation of DNMTs and DNMT-interacting proteins (chapter 3.2.6 – 3.2.9), 
as well as the effects of 5-aza-dC on the two decidual marker genes (Logan et al, 
2010) appear to be in contrast with the observations that there are no changes in 
methylation levels both globally and on the IGFBP-1 promoter. However, regulation 
of IGFBP-1 and dPRL is extremely complex and involves numerous pathways, 
proteins and complexes. Hence, downregulation of DNMTs may affect transcription 
of these two decidual marker genes by altering expression of factors involved in their 
regulation rather than these promoters directly. For example, PR is known to be 
methylated in undecidualized HESCs (Wu et al, 2006; Xue et al, 2007). 
Moreover, a study on PRL expression in a human B-lymphoblastoid cell line 
revealed a single CpG dinucleotide in the second protein-coding exon whose 
methylation status positively correlates with transcription (Gellersen & Kempf, 1990). 
This non-canonical relationship between DNA methylation and gene activation, as 
well as the location of the single CpG dinucleotide (intragenic rather than on the 
promoter in a CpG rich region) highlights the involvement of this epigenetic 
mechanism on decidual marker genes, albeit, in an alternative manner. More studies, 
not limited to CGIs on the promoter regions, must be undertaken to elucidate DNA 
methylation mechanisms underlying HESCs. This is especially true as recent findings 
have shown that tissue specific differential DNA methylation, which correlates with 
gene expression, is mostly observed in regions up to 2 kb from the actual CpG islands 
in what are known as CpG island shores (Ji et al, 2010). So perhaps, alterations in the 
methylome upon decidualization also occur on the CpG island shores or within the 
genes rather than on the islands themselves.  
Furthermore, DNA methylation is associated with long-term memory rather 
than with fast responses to environmental stimuli, as are the histone marks. Indeed, to 
date no dedicated machinery responsible for removal of the methyl group on the 
cytosine residues has been identified. Decidualization is associated with the response 
to hormonal cues that causes profound transformations, which are then maintained till 
the end of the cycle or until the end of pregnancy, in case of embryo implantation. 
Decidualization could be prevalently under the action of histone modifications and 
less under DNA methylation. However, to confirm this genome-wide analysis should 
be undertaken to identify the precise locations of DNA methylation in HESCs.  
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Even if insights in physiological changes in the methylome of HESCs as the 
menstrual cycle progresses have not yet uncovered the correct DNA methylation 
pattern, this epigenetic mechanism is paramount. Indeed, endometriosis is 
characterized by aberrant DNA methylation on specific promoters such as PR-B 
(NASU 2011) and uterine cancers are also associated with abnormalities in the 
methylome. 
    
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 ANALYSIS OF THE METHYLOME OF HESCS OF PATIENTS WITH  
RECURRENT PREGNANCY LOSS 
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6.1 Introduction 
The process of decidualization is impaired in women suffering from RPL with 
associated increased expression of PROK-1 and decreased levels of PRL transcripts, 
both decidual marker genes (Salker et al, 2010). Given the biological role of these two 
genes, women with RPL present a more modest decidual response, albeit prolonged in 
duration, suggesting enhanced uterine receptivity but reduced stringency in embryo 
selection (Brosens et al, 1999; Cloke et al, 2008; Evans et al, 2009; Hochner-
Celnikier et al, 1984; Lynch et al, 2009; Teklenburg et al, 2010a; Teklenburg et al, 
2010b). 
 Primary HESCs from patients affected with endometrial diseases such as 
endometriosis and RPL retain their altered phenotype when in prolonged culture 
(Aghajanova et al, 2010; Klemmt et al, 2006; Minici et al, 2008). The aberrant 
response to hormonal stimuli distinctive for patients with RPL is recapitulated in 
culture. HESCs from patients with or without RPL were collected randomly in the 
cycle and passaged in culture once and decidualized for eight days. HESCs from 
endometrial biopsies, even if collected during the secretory phase, once in culture 
revert to the undifferentiated, proliferative phenotype. HESCs from RPL patients and 
the control group showed comparable levels of PROK-1 and PRL mRNA in the 
undifferentiated cultures. However, after four days of treatment an aberrant decidual 
response was evident: PRL levels were significantly lower in the RPL samples and 
PROK-1 levels continued to increase while they declined in the control group (Salker 
et al, 2010). These perturbed responses obtained in vitro perfectly recapitulate what 
was observed in vivo, suggesting that HESCs from patients with RPL present an 
impaired cellular programming which is retained even in culture due to cellular 
memory. 
 If impaired decidualization in women affected by RPL was only due to 
alterations in gene expression caused by transcription factors then when HESCs are 
exposed to new environments their responsiveness should also change. This inability 
of HESCs from RPL patients to properly decidualize even when in prolonged culture 
suggests a more fundamental (and stable) restriction of the genome’s transcriptional 
potential. 
 It has long been proposed that DNA methylation has adapted for cellular 
memory (especially in development): it is a very stable mark, it is hereditable, it 
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predominantly occurs during a discrete window during development and there is an 
active decisional process on whether a region is methylated or not (Bird, 2002). It has 
been suggested that during early embryo development DNA methylation follows 
independent silencing events. In other words, other epigenetic mechanisms induce 
silencing of a genomic region and this triggers DNA methylation, which then 
maintains the repressive state throughout the somatic lifetime (Bird, 2002). DNA 
methylation thus plays a crucial role in developmental memory. The level of silencing 
is not necessarily all or nothing but rather presents different strengths of repression 
depending of the methylation density (Boyes & Bird, 1992; Hsieh, 1994). Thus, a 
densely methylated region may result in irreversible repression but if methylation is 
relatively low (and thus weak) silencing may be overcome by the strong activators.  
 The aim of this chapter is to examine if recurrent pregnancy loss is indeed 
underpinned by aberrant cellular memory. Specifically, with the use of next-
generation high throughput analysis we aimed to identify the genomic regions that 
present impaired DNA methylation.  
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6.2 Results 
 We compared the methylome of undifferentiated HESCs from pre-menopausal 
women with and without RPL. We obtained endometrial biopsies, randomly in the 
cycle, from four women with RPL and four without a history of recurrent 
miscarriages purified the HESCs and set up eight independent cultures (see table 6.1 
for details of the cultures). After passaging the undifferentiated cells we extracted the 
DNA Arraystar Inc. conducted methylated DNA immunoprecipitation (MeDIP) 
coupled with next-generation high throughput sequencing (MeDIP-seq). The libraries 
obtained were sequenced on an Illumina Genome Analyzer IIx. After passing Solexa 
CHASTITY quality filter, the reads were aligned to Human genome (UCSC Hg19) 
using BOWTIE software (v.0.12.7). About 94 million uniquely mapped reads that 
represented over 3.3 billion bases of sequence were obtained for all eight samples. 
Each read was extended to 200 bp in length. The differentially methylated regions 
(DMRs) between the RPL and the control cohort were identified using two-side t-test 
(with a cutoff p-value ≤ 0.05, fold change ≥ 2.0 for up-regulation; and p-value ≤ 0.05, 
fold change ≤ 0.5 for downregulation).  
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Table 6.1 Patient details of the cohort used for MeDIP-seq of HESCs 
Group Sample Age Live births Miscarriages Day of cycle 
Days in 
culture 
C
on
tro
l 1 35 0 0 17 10 
2 37 0 0 24 6 
3 39 0 0 10 8 
4 25 0 0 10 4 
R
PL
 
5 43 0 3 26 5 
6 40 1 6 8 4 
7 27 0 4 22 9 
8 32 0 5 23 7 
Miscarriages refer to the number of consecutive losses during the first trimester of 
pregnancy. No patients had miscarriages during the second or third trimester. Patient 
6 had a live birth before the six miscarriages. Days in culture refers to the number of 
days the HESCs were cultured for before being harvested.  
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6.2.1 Comparison of DNA methylation in HESCs of patients with and without RPL 
First, we examined whether or not women suffering from miscarriages 
presented aberrant distribution of 5mC.  
MeDIP-scores (Read-counts/kb) represent the absolute methylation level of 
that region calculated as the number of extended reads per kb in the region. By doing 
a simple two-tailed paired t-test on the MeDIP-scores of the eight samples a total of 
653 differentially methylated regions (DMRs) were identified of which 352 had 
higher methylation in HESCs derived from RPL patients than in the control cells. The 
majority of the DMRs (544) were found on CGIs, of which more than half (298) were 
not on promoters but rather dispersed in intergenic regions of the DNA (figure 6.1).  
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6.2.3 Gene ontology analysis   
  Gene ontology (GO) analysis using the database for annotation, visualization 
and integrated discovery (DAVID) revealed that DNA methylation was 
predominantly enriched in RPL patients in regions within or proximal to genes 
involved in base-excision repair/DNA ligation and chromosome organization (table 
6.2). GO analysis on regions in which DNA methylation is lost in patients with 
recurrent miscarriages did not result in any enrichment with a false discovery rate 
(FDR) less than 20% (table 6.3). Pathway analysis using DAVID revealed that the 
DMRs occur in regions adjacent to genes involved in the biosynthesis of unsaturated 
fatty acids (KEGG pathway hsa01040) (figure 6.2) and the androgen and estrogen 
metabolism, however only the former is statistically significant (table 6.4). Taken 
together these results do not show compelling evidence of distinct pathways or sets of 
genes that are affected in RPL patients. 
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Table 6.2 GO analysis of genes found in hypermethylated regions in RPL 
Term Fold Enrichment P-value FDR 
GO:0006288~base-excision repair, 
DNA ligation 375.78 0.01 7.33 
GO:0051276~chromosome organization 4.65 0.01 10.79 
GO:0051103~DNA ligation during 
DNA repair 187.89 0.01 14.12 
GO:0006266~DNA ligation 93.94 0.02 26.25 
GO:0048015~phosphoinositide-
mediated signaling 12.81 0.02 27.51 
GO:0014068~positive regulation of 
phosphoinositide 3-kinase cascade 62.63 0.03 36.67 
GO:0014066~regulation of 
phosphoinositide 3-kinase cascade 57.81 0.03 39.04 
GO:0006268~DNA unwinding during 
replication 53.68 0.04 41.32 
GO:0006259~DNA metabolic process 3.71 0.04 45.55 
GO:0006637~acyl-CoA metabolic 
process 46.97 0.04 45.62 
GO:0046579~positive regulation of Ras 
protein signal transduction 46.97 0.04 45.62 
GO:0007166~cell surface receptor 
linked signal transduction 2.02 0.04 47.15 
GO:0035239~tube morphogenesis 8.88 0.04 47.19 
GO:0051057~positive regulation of 
small GTPase mediated signal 
transduction 
44.21 0.04 47.66 
GO:0032392~DNA geometric change 41.75 0.05 49.61 
GO:0032508~DNA duplex unwinding 41.75 0.05 49.61 
GO:0045087~innate immune response 8.17 0.05 52.47 
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Table 6.3 GO analysis of genes found in hypomethylated regions in RPL 
Term Fold Enrichment P-value FDR 
GO:0021587~cerebellum morphogenesis 16.18 0.01 20.51 
GO:0007224~smoothened signaling pathway 16.18 0.01 20.51 
GO:0045935~positive regulation of 
nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
2.14 0.02 25.04 
GO:0010604~positive regulation of 
macromolecule metabolic process 1.91 0.02 25.93 
GO:0009953~dorsal/ventral pattern 
formation 6.83 0.02 27.94 
GO:0021575~hindbrain morphogenesis 13.37 0.02 28.27 
GO:0045941~positive regulation of 
transcription 2.18 0.02 28.72 
GO:0051173~positive regulation of nitrogen 
compound metabolic process 2.07 0.02 30.21 
GO:0006351~transcription, DNA-dependent 2.81 0.02 31.55 
GO:0010557~positive regulation of 
macromolecule biosynthetic process 2.04 0.02 32.98 
GO:0032774~RNA biosynthetic process 2.77 0.03 33.29 
GO:0010628~positive regulation of gene 
expression 2.12 0.03 33.71 
GO:0045944~positive regulation of 
transcription from RNA polymerase II 
promoter 
2.49 0.03 36.25 
GO:0031328~positive regulation of cellular 
biosynthetic process 1.94 0.03 42.16 
GO:0021549~cerebellum development 10.25 0.03 42.33 
GO:0009891~positive regulation of 
biosynthetic process 1.92 0.04 45.26 
GO:0045893~positive regulation of 
transcription, DNA-dependent 2.15 0.04 49.71 
GO:0003002~regionalization 3.12 0.04 50.08 
GO:0051254~positive regulation of RNA 
metabolic process 2.13 0.04 51.27 
GO:0022037~metencephalon development 8.78 0.04 52.00 
GO:0007389~pattern specification process 2.69 0.05 52.34 
GO:0006350~transcription 1.41 0.05 52.54 
GO:0019722~calcium-mediated signaling 8.31 0.05 55.67 
GO:0006355~regulation of transcription, 
DNA-dependent 1.45 0.05 59.09 
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Table 6.4 Pathway analysis of genes proximal to DMRS 
Term Genes Fold Enrichment P-value FDR 
hsa01040:Biosynthesis of unsaturated 
fatty acids 
BAAT, ACOT2, 
ACOT1 11.37 0.03 25.66 
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6.2.4 DMRs of interest 
 The genomic regions with the greatest difference in DNA methylation, 
reflected by MeDIP-score, between the two patient groups were analyzed. The 
regions with the highest difference in MeDIP-score between RPL and control patients 
occurred on CpG Islands. Interestingly, in both data sets the top two do not occur on a 
promoter region but rather intergenically (appendix IV).  
The region with the most significant difference in methylation was an 
intergenic region located on chromosome 14 (chr14:76604999-76605268) which 
completely lost methylation (MeDIP-score 0) in patients with recurrent pregnancy 
loss and presented an average MeDIP-score of 14.46 in the control cohort (figure 6.3). 
The second most differentially methylated region was on chromosome 9 
(chr9:68377476-68377826) and showed a twelve-fold decrease in DNA methylation 
in the RPL samples (figure 6.4). The third most hypomethylated region in the RPL 
samples (with over an eleven-fold difference) is the found on the promoter of 
RHOBTB1 (figure 6.5). RHOBTB1 encodes for Rho-related BTB domain-containing 
protein 1, which is involved in small GTPase-mediate signal transduction and in 
organization of the actin filament (Beder et al, 2006).  
Of the three most significantly hypermethylated DMRs in RPL patients two 
are intergenic regions, located on chromosome six and seven (chr6:150335525-
150336278 and chr7:35225363-35226580). These are completely unmethylated in the 
control cohort but have average MeDIP scores of 1 and 1.83, respectively, in the RPL 
patients (figures 6.6 and 6.7). The third most significant DMR is found on the ZMIZ2 
promoter. This region is also completely unmethylated in the control samples but has 
an average MeDIP-score of 8.56 (figure 6.8). This gene encodes for a protein, zinc 
finger MIZ-type containing 2, which increases ligand-dependent transcriptional 
activity of androgen receptor and other nuclear hormone receptors (Peng et al, 2010).  
This prompted us to search for other nuclear receptor interacting proteins 
whose genes are in the proximity of differentially methylated regions. Indeed, some 
of these proteins were found to be differentially methylated (table 6.5). As a matter of 
fact, the methyl group is two-fold more enriched on the PR promoter of RPL patients 
than in the controls (average MeDIP-scores of 9.16 and 4.15, respectively) (figure 
6.9). Also the high-mobility group protein B (HMGB) 1 and 2 are differentially 
methylated (figures 6.10 and 6.11).  
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Table 6.5 Nuclear Receptors and their interacting proteins 
Gene 
Fold change 
(Control vs. 
RPL) 
P-value Gene function Reference 
NCOA7  0.32 0.03 enhances the transcriptional activities of several nuclear receptors (Shao et al, 2002) 
TRIP4 0.38 0.01 
transcription coactivator of nuclear 
receptors which functions in 
conjunction with CBP-p300 and SRC-
1  
(Jung et al, 2002) 
PGR  0.44 0.04 
member of the steroid receptor 
superfamily; mediates the 
physiological effects of progesterone 
(Scarpin et al, 2009) 
HMGB1 0.44 0.04 
DNA binding protein that associates 
with chromatin and has the ability to 
bend DNA; associates with steroid 
hormone receptors to enhance their 
DNA binding 
(Boonyaratanakornkit 
et al, 1998b) 
LCORL 2.01 0.01 ligand-dependent nuclear receptor corepressor-like protein  (Ota et al, 2004) 
NR5A2  2.79 0.01 nuclear receptor subfamily 5, group A, member 2 (Lee & Moore, 2008) 
MED7  3.24 0.04 component of multisubunit complexes which interact with nuclear receptors (Jiang et al, 1998) 
HMGB2 3.9 0.01 
DNA binding protein that associates 
with chromatin and has the ability to 
bend DNA; associates with steroid 
hormone receptors to enhance their 
DNA binding 
(Boonyaratanakornkit 
et al, 1998a) 
ARNT  4.49 0.03 aryl hydrocarbon receptor nuclear translocator (Huang et al, 2010) 
NR2C2  8.77 0.04 nuclear receptor subfamily 2, group C, member 2 
(Zhang & Dufau, 
2000) 
ZMIZ2 0 0.03 
members of a PIAS-like family of 
proteins that interact with nuclear 
hormone receptors; interacts with AR 
and enhances AR-mediated 
transcription 
(Huang et al, 2005) 
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These proteins are DNA architectural facilitators that bend the DNA thus making it 
accessible to transcriptional factors (Travers, 2003). They have also been shown to 
increase DNA binding affinity of PR and other steroid hormone receptors (Roemer et 
al, 2008). Both the HMGB proteins present altered methylation, albeit in non-CGI 
context. The HMGB1 promoter becomes hypermethylated in RPL patients (average 
MeDIP score 4.63 against 2.05 of the control samples) (figure 6.10). Whereas, DNA 
methylation on the HMGB2 gene occurs within the gene body and it is 
hypomethylated in HESCs derived from patients with recurrent miscarriages (MeDIP 
scores 6.31 in the control and 1.62 in the RPL patients) (figure 6.11). These results 
suggest that patients with recurrent miscarriages have impaired decidualization at 
least partially because the nuclear receptor complex itself is not fully functional, 
although further studies need to be carried out to confirm this. 
Along with HMGB1 and 2 other genes encoding for epigenetic effectors are 
also differentially methylated. These include a HAT (PHF17), HDACs (HDAC11 and 
MTA2), histone variants (HIST1H2AG, HIST1H2AJ, HIST1H2B, HIST1H2AG and 
CEP70) and the dioxygenase TET2, responsible for catalyzing the conversion of 
methylated to hydroxymethylated cytosines (table 6.6). Differences in the methylation 
status of these genes most likely underpin impaired expression, which in turn would 
result in aberrant chromatin architecture.  
Interestingly, the promoter of the decidual marker gene IGFBP-1 is 68% more 
methylated in HESCs of women with recurrent miscarriages than in the control cohort 
(appendix IV, figure 6.12). The average MeDIP-score of the RPL patients was 12.59 
whereas that of the control samples was 6.18. This hypermethylation could be among 
the underlying causes of impaired decidualization in patients with RPL. 
 Taken together these results indicate an altered methylome in the HESCs of 
women with recurrent pregnancy loss. This aberrant methylation status affects both 
gene loci and intergenic regions that are perhaps involved in regulation.  
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Table 6.6 Genes encoding for epigenetic effectors localized in the proximity of 
DMR regions  
Gene 
Fold 
change 
(Control 
vs. RPL) 
P-value Gene function Reference 
PHF17 3.29 0.05 
component of the HBO1 complex; 
has a histone H4-specific 
acetyltransferase activity, a reduced 
activity toward histone H3 and is 
responsible for the bulk of histone 
H4 acetylation in vivo 
(Panchenko et 
al, 2004) 
TET2 2.56 0.02 
catalyzes the conversion of 
methylcytosine to 5-
hydroxymethylcytosine 
(Koh et al, 
2011) 
HDAC11 2.38 0.01 
responsible for the deacetylation of 
lysine residues on the N-terminal 
part of the core histones 
(Gao et al, 
2002) 
MTA2 2.34 0.02 component of NuRD, a nucleosome remodeling deacetylase complex 
(Futamura et 
al, 1999) 
SIRT7 2.03 0.04 
known to regulate epigenetic gene 
silencing and suppress 
recombination of rDNA and 
suppress recombination of rDNA 
(Chanda et al, 
2010) 
HIST1H2AG 0.44 0.02 histone cluster 1 H2ag (Albig et al, 1999) 
CEP70 0.34 0.01 centrosomal protein 70kDa (Andersen et al, 2003) 
HIST1H2AJ  
HIST1H2BM 0.26 0.03 histone cluster 1 H2aj and H2bm 
(Boyne et al, 
2006) 
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6.2.5 Assessment of MeDIP-seq 
Next, in collaboration with Dr. Sascha Ott and Nigel Dyer we assessed the 
significance of these MeDIP results. The intergenic region located on chromosome 14 
(chr14:76604999-76605268), described above, was the region with the most 
significant difference in methylation (15.27 fold change; p-value < 0.001) (figure 6.3). 
We therefore selected this region to further investigate the significance of the fold 
change observed. This locus has 13 tags associated with the CpG island in the control 
samples and only one with the RPL ones. Comparison of rolling average tag density 
between a sample from each patient group suggests that the variation is indeed noise 
(figure 6.13 first track) as there are four tags associated with the control cohort and 
only one in the RPL one. A similar conclusion was drawn when analyzing the same 
region in two different samples (figure 6.13 second track). Furthermore, by looking at 
the general tag distribution of the region there appears to be no significant difference 
between the patient groups (figure 6.13 C tracks 3 to 10). In summary, due to the low 
density of tags and the large number of genomic regions being sampled it is likely that 
in at least one location there will be in the order of 13 tags associated with four of the 
samples and one associated with the other four. A similar approach was taken for 
other genomic regions that presented DMR and similar conclusions were drawn. 
Hence, it appears that there are indeed no significant differences between the two 
patient samples.  
We then compared the tag distribution, which is another way of analyzing the 
data. In brief, the window size was increased to 10,000 bp and the rolling average of a 
control sample was compared to that of an RPL sample. Again, this shows that there 
are no significant differences between the two sets of data: if a suitable window size is 
chosen, which removes the noise associated with the low fragment density, a strong 
correlation between the samples can be seen (figure 3.14).  
We then further investigated if the DMRs that we initially identified were 
generated by chance and undertook a significance test. This is a measure of how 
likely the statistical value is, given a particular null hypothesis, which in this case 
would be that there is no significant difference between the two patient groups. In this 
type of analysis the problem is often the one of knowing what the expected 
distribution is in order to work out if a value is unexpected.  
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Firstly, to find the reference distribution we created two new datasets. Each set with 
two samples from the RPL cohort and two from the controls, so any systematic 
difference should cancel out and we should just see the range of differences as a result 
of the random way the tags are distributed. As it is an arbitrary choice as to which is 
compared with which the distribution of the inverse fold change was calculated as a 
second reference distribution. Next, these two references were compared with the 
distribution obtained with original comparison of samples (RPL vs. control). The 
results show two virtually identical groups (figure 6.15). In other words, when a locus 
revealed a large fold change in methylation status it was not significant, as there are 
the number of such large fold change values that would be expected with a 
randomized dataset.  
 This lack of significant DMR between the two data sets appears to be real as 
technically the MeDIP-sequencing worked. Following sonication the fragment size 
was assessed on an Agilent 2100 BioAnalyzer. All the samples were correctly sheared 
with the majority of fragments being between 180-210bp (appendix V). The sonicated 
DNA was then subjected to MeDIP and the quality of the immunoprecipitation was 
assessed by qPCR. As may be seen in appendix V, the MeDIP was successful with the 
enrichment at methylated sites varying between 4-17% of the input, depending on the 
sample.  
 The top methylated sites on all the samples present a MeDIP-score of over 100 
and reaching 1800. Also as may be seen in the examples in figures 6.16 to 6.20, the 
peaks are consistent and the tags align across all samples. Taken together these data 
suggest that there are no significant differences in the methylome of HESCs of 
women with and without recurrent pregnancy loss.  
Chapter 6   The methylome of RPL pateints 
 
 
164 
  
Chapter 6   The methylome of RPL pateints 
 
 
165 
  
Chapter 6   The methylome of RPL pateints 
 
 
166 
  
Chapter 6   The methylome of RPL pateints 
 
 
167 
  
Chapter 6   The methylome of RPL pateints 
 
 
168 
  
Chapter 6   The methylome of RPL pateints 
 
 
169 
   
Chapter 6   The methylome of RPL pateints 
 
 
170 
6.3 Discussion 
 Many studies have shown that epigenetic changes play an important role in 
numerous diseases, especially cancer development (Ehrlich, 2002). Furthermore, it 
has been widely shown that epigenetic modifications are essential in the progression 
of the menstrual cycle (Grimaldi et al, 2011; Munro et al, 2010). Lastly, some of the 
characteristics of recurrent pregnancy loss led us to hypothesize that aberrant 
regulation of the epigenome might underlie this disorder (Teklenburg et al, 2010a). 
We started by investigating the DNA methylation status as it is believed to be more 
stable than other epigenetic marks and generally is associated with long-term cellular 
memory (Bird, 2002).  
Preliminary analysis of MeDIP-seq data did not reveal any significant 
differences in the DNA methylation status of HESCs derived from RPL and non-RPL 
patients, although technically the MeDIP-seq was successful. Most likely the over 600 
DMRs picked up with the t-test are just noise. Not only are the MeDIP-scores of these 
regions very low (maximum of 15) compared to the top methylated sited (around 
1000), but also, the tags do not align across all samples (figures 6.3 to 6.12 versus 
figures 6.16 to 6.20). This suggests that the methylation does not even occur on the 
same residues and indicates that probably the small peaks that are picked up are 
indeed background noise. Due to the nature of MeDIP-seq, low number of reads is a 
reflection of either the absence of methylated CpGs or the absence of CpG 
dinucleotides all together. Conversely, strong peaks can result in incompletely 
methylated regions provided that these regions have a sufficiently high CpG density. 
The confounding effects of CpG density can be overcome by applying adequate 
statistical corrections such as the building of a linear regression model that corrects 
for the bias caused by the DNA sequence (Down et al, 2008; Pelizzola et al, 2008). 
MethylCap-seq is a technique that uses MBD proteins to obtain methylated 
DNA fractions which are then sequenced (Brinkman et al, 2010). It results in peaks of 
similar shape, size and position as MeDIP-seq; however, the latter has a smaller 
dynamic range as it results in higher baseline levels and lower peak heights (Bock et 
al, 2010). Furthermore, anti-5mC antibodies often require more than a single 
methylated CpG for efficient binding to the DNA fragment (Meehan et al, 1992). 
These properties make MeDIP-seq a very strong technique to distinguish between 
methylated and unmethylated regions but it is not very accurate for quantifying 
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partially methylated DNA levels. A more appropriate approach for this type of 
analysis would be using Reduced Representation Bisulfite Sequencing (RRBS) (Bock 
et al, 2010) as it is more accurate in detecting a wider range of DNA methylation 
levels. However, comparing the ability of MeDIP-seq, RRBS and MethylCap-seq to 
identify DMRs showed a statistically significant general agreement of hits especially 
on non-repetitive DNA (Bock et al, 2010). However, it is worth noting that 
MethylCap-seq performs better than RRBS which in turn is better than MeDIP-seq. 
Though, even MeDIP-seq should have revealed substantial coverage of DMRs 
between RPL and control samples, if they were present. This further supports that the 
600 regions that were identified are most likely background. On the other hand, it 
could also be argued that a two-tailed t-test is not the best statistical tool to detect 
significant differences between the patient groups. A more appropriate tool is the 
Fisher’s exact test, which is able to detect DMRs genome-wide. Furthermore, if it is 
used to target specific regions (such as CGIs or promoters) it increases the sensitivity 
and is able to detect small differences in methylation. This is due to the fact that the 
multiple testing burden is, obviously, much lower in targeted regions than genome-
wide.  
Enrichment techniques (i.e. MeDIP-seq and MethylCap-seq) rely on a 
minimum number of read differences between samples to detect differential 
methylation. This drawback can be overcome by ensuring broad genome coverage. As 
a matter of fact, 20% coverage gives reliable data that does not ameliorate if the 
sequencing depth is increased to 50-100%. However, with regards to the detection of 
DMRs, when the depth is 50% there is a significant loss of accuracy in detecting 
DMRs than with higher coverages (Bock et al, 2010). This is especially true for 
MeDIP-seq as the reads are distributed across the entire genome (with a strong 
tendency towards high coverage of CpG-rich regions as CpG-poor areas are rarely 
sequenced with this method). Deeper sequencing uncovers weak DMRs found in 
regions with a low CpG density making saturation hard to reach with MeDIP-seq. 
According to a study, a depth of 30-60 million reads should ensure a high enough 
coverage to allow for reliable identification of DMRs (Bock et al, 2010). In this study, 
we used 94 million reads, which should guarantee enough coverage for the 
identification of DMRs even in CpG-poor regions. 
It is likely that DMRs in HESCs of patients with RPL occur in regions of 
intermediate methylation as expression of decidual genes is very dynamic during the 
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menstrual cycle. Therefore, these sites could be only partially methylated or only 
methylated in part of the cellular population. In vivo, only a small fraction of decidual 
cells express the decidual marker gene PRL (Richards et al, 1995). This could also be 
the case for DNA methylation where the HESCs population presents a very 
heterogeneous DNA methylation pattern on selected CGIs. This could lead to a loss 
of statistical significance and less clear-cut results.  
Although, as discussed above, RRBS is perhaps a more appropriate technique 
to identify DMRs in regions with intermediate methylation and MethylCap-seq has 
moderately higher coverage than MeDIP-seq, the drawbacks of the other two 
techniques led us to use MeDIP-seq. RRBS is designed to focus on CpG-rich regions, 
hence it is advisable to use an enrichment method, provided the CpG bias is taken into 
account. MethylCap-seq requires considerably greater quantities of DNA than 
MeDIP-seq, which can be hard to obtain especially when working with primary 
HESCs. Given that all three techniques are equally viable (Bock et al, 2010), we 
decided to use MeDIP-seq. However, MeDIP-seq requires deep sequencing and the 
use of refined statistical tools to fully overcome its drawbacks. The very deep 
coverage used makes up for both the intrinsic relatively low dynamic range of this 
technique and its weakness in quantifying intermediate methylation levels. However, 
to effectively determine whether or not the over 600 identified DMRs are merely 
background, further statistical corrections are required. As previously mentioned, 
these include: (i) adjusting for the CpG density and (ii) using the Fisher’s exact test 
instead of the two-tailed t-test to identify the DMRs between the patient groups.  
DNA methylation could act alongside other epigenetic mechanisms. For 
example, as we show in chapter 4 of this work, correct regulation of H3K27me3 is 
essential for a complete decidual response. Regulation of H3K27me3 in RPL patients 
could shed light on this disease. Thus, an integrated approach of multiple epigenetic 
mechanisms as well as RNA-seq could reveal the epigenetic causes of RPL.  
Overall, a greater understanding of the role of DNA methylation, and 
epigenetics, in physiological conditions would aid in the design of more targeted 
studies exploring not only the nature of recurrent miscarriages but also of 
reproductive disorders in general. 
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Epigenetics has a paramount role in development and differentiation and is 
associated with many diseases such as cancers and endometriosis. Epigenetic 
effectors regulate the epigenome in different ways. They can act either directly (i.e. 
DNMTs, histone modifying proteins) or indirectly such as cofactors which can recruit 
the modifiers or act as stabilizers and reinforce the interaction between enzymes and 
the chromatin. Chromatin associated proteins and the epigenetic marks themselves are 
often docking stations that facilitate binding to the chromatin or hamper it, possibly 
by causing steric hindrance.  
We show that HESCs express genes that encode over 130 different chromatin-
associated proteins. These include histone modifying enzymes and their cofactors, 
histone binding proteins; histone variants, DNA methyltransferases (DNMTs), 
DNMT-interacting proteins and CpG-binding proteins. Of these 15% are significantly 
regulated in response to the steroid hormone progesterone and the second messenger 
cAMP. The most highly represented class of epigenetic effectors are the histone 
modifying proteins and their cofactors. Together these enzymes ensure the correct 
placement of histone marks. Over 60 different modifications have been identified and 
often these occur in combination to form the histone code. HESCs express numerous 
histone-modifying enzymes but only four of them are highly regulated. A histone 
deacetylase, HDAC4, is upregulated by over two-fold and three histone 
methyltransferases EZH2, SUV390H2 and SUV420H1 are all downregulated by over 
two-fold. This implies that changes in histone modifications of HESCs upon 
decidualization are under the control of these enzymes. Another possibility is that the 
increase in HDAC4 expression and loss of the three HMTs may result in initial 
changes in the chromatin architecture which then allows the action of other histone 
modifying proteins and further alters the PTM pattern on histone tails. 
 Expression of many of these chromatin-modifying proteins appears to be 
extremely dynamic. For example, time course studies showed that mRNA expression 
of SUV39H2 and DNMT1 decreases after two days of decidualization but then start 
increasing by the fourth day and by the eighth their expression levels are comparable 
to those of undifferentiated HESCs. Transcription of other genes, such as EZH2 and 
HELLS, was decreased to very low levels by day two and they remained such 
throughout the entire time-course study. This breadth and dynamism in expression of 
epigenetic effectors implies that they are tightly regulated throughout the entire 
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menstrual cycle and that a transient downregulation of these genes might be essential 
for the correct decidual response.  
The proliferation arrest of decidual cells is coincident with changes in the 
levels of epigenetic effectors expressed by these cells. EZH2 has been shown to be 
associated with cell proliferation (especially of cancer cells) and is highly expressed 
during the proliferative phase of the menstrual cycle but lost upon decidualization. 
Another protein, which is regulated upon differentiation of HESCs, is HDAC4 that is 
known to arrest cell cycle progression through the interaction with the PCNA 
complex. Also DNMT1, which usually associates with replication, is lost during the 
secretory phase. Furthermore, gene ontology analysis following ChIP-on-chip 
revealed the repressive H3K27me3 mark in response to decidualization was enriched 
at the promoter regions of genes involved in growth/cell proliferation. These are just 
selected examples of how specific sets of epigenetic effectors are required during the 
progression of the menstrual cycle and how different epigenetic mechanisms act on 
various levels in tightly regulating key cellular processes.   
This breadth of epigenetic effectors regulated during decidualization further 
emphasizes the extent to which HESCs reprogram during the menstrual cycle 
following the surge in progesterone levels. It appears that these cells do not solely 
undergo biochemical and morphological transformation but also an epigenetic one.  
As with other activated nuclear receptors, PR binding of progesterone triggers 
a conformational change which leads to dissociation of chaperone proteins, receptor 
dimerization, and binding to specific DNA recognition sequences on the promoters of 
target genes (Maruyama & Yoshimura, 2008). However, interaction of the activated 
PR with DNA is in itself insufficient to alter gene expression as nuclear receptors do 
not possess chromatin-modifying activities necessary to enable or prevent recruitment 
of the basal transcriptional machinery (Han et al, 2009; Lonard & O'Malley, 2006; 
Onate et al, 1995; Thakur & Paramanik, 2009). Remodeling of local chromatin 
depends on recruitment of coregulators, broadly divided into coactivators and 
corepressors, to the DNA-bound receptor (Han et al, 2009; Lonard & O'Malley, 
2006). Based on their mechanisms of action, nuclear receptor coactivators can be 
categorized into three major function complexes: (i) the SWI/SNF complex, which 
remodels the local chromatin structure through adenosine triphosphate-dependent 
histone acetylation; (ii) the SRC complex, which contain acetyltransferases (e.g. CBP, 
p300, and the p300/CBP-associated factor) and methyltransferases (e.g. CARM1 and 
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PRMT1); and (iii) mediator complex, involved in the activation of RNA polymerase 
II and initiation of transcription. Although the mechanism of agonist-bound PR-
dependent gene repression is still unclear, it is widely assumed to involve interaction 
with NCoR, SMRT or possibly RIP140, corepressors capable of recruiting DNA- and 
histone-methyltransferases complexes (Kiskinis et al, 2007; Li et al, 2000). 
In this model, nuclear receptors like PR are viewed as pioneer factors 
responsible for initiating the process of chromatin remodeling near the TSSs of target 
genes. However, this paradigm is being profoundly challenged by novel techniques 
that allow genome-wide mapping of binding of nuclear receptors to DNA (John et al, 
2011; Mak et al, 2002; Wiench & Hager, 2010; Wiench et al, 2011). Contrary to 
expectations, a majority of nuclear binding events do not occur proximal to TSSs of 
target genes but at large distances from promoters (Carroll et al, 2005; Hakim et al, 
2010; Wiench & Hager, 2010). Moreover, rather than the activated receptor inducing 
a permissive chromatin environment that enables transcription, most activated 
receptors will bind at preexisting sites that are constitutively accessible. For example, 
the binding pattern of the activated glucocorticoid receptor to DNA, and subsequent 
gene regulation, was recently shown to be highly cell-specific and comprehensively 
predetermined by basal differences between cell types in chromatin structure (John et 
al, 2011). When extrapolated to the cycling endometrium, these observations strongly 
suggest that acquisition of responsiveness to differentiation signals must be preceded 
by, or at least occur in concert with, genome-wide remodeling of the chromatin. In 
this study we provide evidence that regulation of epigenetic effectors and their marks 
in HESCs contribute to the chromatin changes necessary for expression of a decidual 
phenotype in response to differentiation cues. The analysis of chromatin modifying 
enzymes and chaperones in undifferentiated and differentiated HESCs suggest that 
rapid and highly dynamic epigenetic changes underpin the acquisition of a decidual 
phenotype. This was further investigated by focusing on one of the highest regulated 
chromatin modifying proteins EZH2. EZH2 is the catalytic subunit of the PRC2 
repressive complex. Downregulation of EZH2 results in declining levels of 
H3K27me3 at the proximal promoters of key decidual marker genes, PRL and 
IGFBP-1. Loss of H3K27me3 was associated with a reciprocal enrichment in 
acetylation of the same lysine residue, indicating active remodeling from repressive to 
transcriptionally permissive chromatin. Chromatin immunoprecipitation coupled with 
DNA microarray analysis demonstrated that decidualization triggers genome-wide 
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changes in H3K27me3 distribution that only partly overlap those observed upon 
EZH2 knockdown in undifferentiated HESCs. Gene ontology revealed that loss of the 
H3K27me3 mark, (indicating increased chromatin accessibility) in decidualizing cells 
and upon EZH2 knockdown occurred at selective loci enriched for genes functionally 
implicated in responses to stimulus. The secretory cells become subjected to high 
levels of paracrine and autocrine signals that, in case of pregnancy, also originate 
from the embryo. EZH2 knockdown in undifferentiated HESCs was sufficient to 
augment the induction of decidual marker genes in response to cyclic AMP and 
progesterone signaling. Thus, loss of EZH2-dependent methyltransferase activity in 
the endometrium is integral to the process of chromatin remodeling that enables the 
transition from a proliferative to a decidual phenotype in response to differentiation 
cues. 
We also demonstrate that differentiation of HESCs into decidual cells causes a 
downregulation of DNMT1 and DNMT3b but an upregulation of DNMT3a. This 
however is not coupled with parallel changes in global methylation levels nor on 
selected CpGs of the IGFBP-1 promoter. These observations suggest that alterations 
in the methylome most likely occur on CpG island shores or intragenically (as is the 
case for PRL). MeDIP-seq confirmed that the IGFBP-1 promoter is unmethylated in 
HESCs. Histone modifications are dynamic short-term marks that change in response 
to environmental cues. In contrast, DNA methylation is a more stable epigenetic 
mark, which tends to affect wider genomic regions (such as the inactivated X 
chromosome and centromeres). It is also involved in prolonged silencing or activation 
of certain genes or gene networks. Due to this more long-term effect, DNA 
methylation is often associated with cellular memory. Furthermore, in contrast to 
histone marks, a mechanism by which DNA methylation is inherited to successive 
generations has been well characterized.  
Many studies have demonstrated that aberrant regulation of epigenetic 
effectors and their marks underlie endometrial cancers and endometriosis. For 
example endometriosis is characterized by the increased expression of mir26a – a 
microRNA that tightly regulates EZH2. This is thought to promote malignant 
transformation in endometriosis, as the strict control on cell cycle is lost (Teague et al, 
2010). Indeed, EZH2 itself is abundant in endometrial tumors, and it correlates 
positively with high proliferation rate and aggressiveness of the tumor itself 
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(Bachmann et al, 2006). Aberrant DNA methylation is also typical of numerous 
tumors including endometrial cancers. Alterations in DNA methylation of specific 
promoters (i.e. PR-B, ER-β, HoxA10 and E-cadherin) are typical of both ectopic and 
eutopic endometriosis lesions (Nasu et al, 2011). Interestingly, abnormal DNA 
methylation occurs also on ribosomal DNA of patients with endometrial cancers. 
Indeed, it has been suggested that rDNA methylation could be used as a prognostic 
indicator for this disease and for a prediction of the patient’s survival rate (Powell et 
al, 2002). However, here we show that recurrent pregnancy loss is not underpinned by 
aberrant DNA methylation of HESCs. This, of course, does not exclude the 
involvement of other epigenetic effectors as underlying causes of this disorder.  
The menstrual cycle not only results in cyclical remodeling of the 
endometrium but also in a remodeling of the chromatin landscape. Here we 
demonstrate that upon decidualization profound changes in the epigenome occur. A 
more accurate insight in the understanding of epigenetic changes during 
decidualization and the expression profile of epigenetic effectors in health and in 
disease is essential for the identification of biomarkers, possible causes and, perhaps 
in not a very distant future, possible cures of numerous reproductive disorders.   
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The above appendices may be found in the CD attached to this volume.  
Table A.1 List of appendices 
Appendix Title Format 
I  
Epigenetic effectors present in HESCs and in 
decidual cells 
pdf 
II 
Results of the decidualization ChIP-on-chip and 
the EZH2 silencing ChIP-on-chip 
MS Excel 
III 
Comparison of the decidual and EZH2 silencing 
ChIP-on-chip 
MS Excel 
IV 
Differentially methylated regions of patients with 
and without RPL 
MS Excel 
V MeDIP-seq quality control pdf 
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A.I Epigenetic effectors present in HESCs and in decidual cells 
 List of genes encoding for epigenetic effectors that are expressed in HESCs 
both undifferentiated and decidualized for three days as revealed by microarray 
analysis. The genes are subdivided according to the function of the protein they 
encode for. The column probe set is the probe set id for the Affymetrix Human U133-
Plus 2.0 Array (18h) chip. The column fold change refers to the average change in 
expression levels of three samples upon three day decidualization of HESCs with 8-
Br-cAMP and MPA. The p-value is the significance level of this differential 
expression calculated with the Student’s t-test. 
 
A.II Results of the decidualization ChIP-on-chip and the EZH2 silencing ChIP-on-
chip 
 Genome-wide redistribution of H3K27me3 in decidualizing HESCs and upon 
EZH2 knockdown in undifferentiated HESCs. Worksheet Decidualization chip is a 
list of genomic loci significantly (P < 0.05) altered in H3K27 methylation as 
determined by ChIP-chip analysis of HESCs upon decidualization with 8-Br-cAMP 
and MPA for 8 days. Worksheet EZH2 silencing chip is a list of genomic loci 
significantly (P < 0.05) altered in H3K27 methylation as determined by ChIP-chip 
analysis of HESCs upon silencing of EZH2. 
 
A.III Comparison of the decidual and EZH2 silencing ChIP-on-chip 
Loci with altered H3K27me3 upon decidualization and EZH2 knockdown. 
Worksheet H3K27me3 concordant shows the list of genomic loci in which 
H3K27me3 is altered in the same manner in HESCs when decidualized with 8-Br-
cAMP and MPA for 8 days (left) and upon EZH2 knockdown as determined by ChIP-
on-chip. The mark is either lost at these loci or gained under both conditions. 
Worksheet H3K27me3 discordant is the list of genomic loci in which H3K27me3 in 
altered differently upon decidualization and EZH2 downregulation (i.e. it is gained 
under one condition but lost in the other). 
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A.IV Differentially methylated regions of patients with and without RPL 
 This spreadsheet shows the loci that are differentially methylated in patients 
with and without RPL. Samples 1 to 4 are patients with RPL and samples 5-8 are the 
control cohort. The fold change was calculated as control versus RPLs and the 
significance was analyzed with a t-test (cut-off of 0.05). The fold change cut-off was 
set to 0.5 for hypermethylated loci in the RPL patients and 2 for those 
hypomethylated.  
The DMRs are divided into six separate worksheets according to the location of 
the methylated CpGs and, in turn, whether they are hypermethylated (worksheets 
marked with DOWN) or hypomethylated (worksheets marked with UP) in RPL 
patients.  
The worksheets marked with “CGIs_DMRs” indicate the CpG Island Methylation 
Profiles. These CpG islands are grouped into three classes (column ‘Relative location 
to gene’) on the basis of their distance to RefSeq genes (figure A.1): 
i. Promoter Islands: If an island starts 1,000 bp upstream of a RefGene 
transcription start site, and ends 300 bp downstream of a RefGene 
transcription start site. 
ii. Intragenic Islands: If an island starts 300 bp downstream of a RefGene 
transcription start site and ends 300 bp upstream of a RefGene transcription 
end site. 
iii. Intergenic Islands: If an island starts 300 bp upstream of a RefGene 
transcription end site and ends 1,000 bp upstream of neighboring RefGene 
transcription start site. 
 
 
Figure A.1 Types of CpG islands 
 
   List of Appendices 
 
 
183 
Mammalian gene promoters are known to contain divergent CpG contents with 
different methylation profiles. These are shown in the worksheets 
“Promoters_DMRs”. We subdivided the promoters into three classes (column 
‘Promoter_Classification’) based on their CpG contents: high (denoted HCP), low 
(LCP), and intermediate (ICP): 
i. HCP (High-CpG-density promoter): Promoters containing a 500 bp interval 
within -700 bp to +200 bp with a (G+C)-fraction ≥ 0.55 and a CpG observed 
to expected ratio (o/e) ≥ 0.6 were classified as HCPs. 
ii. LCP (Low-CpG-density promoter): Promoters containing no 500 bp interval 
with CpG o/e ≥ 0.4 were classified as LCPs. 
iii. ICP (Intermediate-CpG-density promoter): The remainder that do not fall into 
either class were classified as ICPs. 
Lastly, the RefSeq genes that have more than 3kb in length were chosen for gene 
body methylation analysis and reported in the worksheets marked 
“GeneBody(Genelength >3000”. The gene body region is defined as +2000bp 
downstream of the transcription start site (TSS) to the transcription termination site 
(TTS). 
The DNA methylation status of CGIs is determined by MeDIP-score. A CpG 
island is defined as unmethylated if its MeDIP-score is less than 4.25 reads·kb-1, as 
partially methylated if its MeDIP-score is between 4.25 -18.28 reads·kb-1 and 
completely methylated if its MeDIP-score is greater than 18.28 reads·kb-1. 
 
A.V MeDIP-seq quality control 
 Quantification of the starting material, analysis of the MeDIP and quality of 
the libraries were assessed. 1. Quantification of DNA in each of each sample 
following cellular extraction was carried by NanoDrop spectrophotometry. 2. To 
verify that the MeDIP was efficient RT-qPCR was carried out. The 
immunoprecipitated (and input) DNA was amplified with both primers flanking a 
known methylated region (H19) and a known unmethylated loci (GAPDH). 3. The 
quality of the sequencing library was assessed using an Agilent DNA 1000 on an 
Agilent 2100 Bioanalyzer. This is to verify the concentration of the library and most 
importantly the correct size distribution of the adapter-ligated fragment library. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY
   Bibliography 
 
 
185 
Aasland R, Gibson TJ, Stewart AF (1995) The PHD finger: implications for 
chromatin-mediated transcriptional regulation. Trends Biochem Sci 20: 56-59 
 
Abdel-Hafiz H, Takimoto GS, Tung L, Horwitz KB (2002) The inhibitory function in 
human progesterone receptor N termini binds SUMO-1 protein to regulate 
autoinhibition and transrepression. J Biol Chem 277: 33950-33956 
 
Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, 
differentiation, and transformation. Cell 117: 421-426 
 
Aghajanova L, Horcajadas JA, Weeks JL, Esteban FJ, Nezhat CN, Conti M, Giudice 
LC (2010) The protein kinase A pathway-regulated transcriptome of endometrial 
stromal fibroblasts reveals compromised differentiation and persistent proliferative 
potential in endometriosis. Endocrinology 151: 1341-1355 
 
Ait-Si-Ali S, Guasconi V, Fritsch L, Yahi H, Sekhri R, Naguibneva I, Robin P, Cabon 
F, Polesskaya A, Harel-Bellan A (2004) A Suv39h-dependent mechanism for 
silencing S-phase genes in differentiating but not in cycling cells. Embo J 23: 605-
615 
 
Al-Sabbagh M, Fusi L, Higham J, Lee Y, Lei K, Hanyaloglu AC, Lam EW, Christian 
M, Brosens JJ (2011) NADPH oxidase-derived reactive oxygen species mediate 
decidualization of human endometrial stromal cells in response to cyclic AMP 
signaling. Endocrinology 152: 730-740 
 
Albig W, Trappe R, Kardalinou E, Eick S, Doenecke D (1999) The human H2A and 
H2B histone gene complement. Biol Chem 380: 7-18 
 
Andersen JS, Wilkinson CJ, Mayor T, Mortensen P, Nigg EA, Mann M (2003) 
Proteomic characterization of the human centrosome by protein correlation profiling. 
Nature 426: 570-574 
 
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, 
Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high 
proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers 
of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273 
 
Backdahl L, Bushell A, Beck S (2009) Inflammatory signalling as mediator of 
epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell 
Biol 41: 176-184 
 
Barna M, Merghoub T, Costoya JA, Ruggero D, Branford M, Bergia A, Samori B, 
Pandolfi PP (2002) Plzf mediates transcriptional repression of HoxD gene expression 
through chromatin remodeling. Dev Cell 3: 499-510 
 
Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V, Doderlein G, 
Maltry N, Wu W, Lyko F, Niehrs C (2007) Gadd45a promotes epigenetic gene 
activation by repair-mediated DNA demethylation. Nature 445: 671-675 
 
   Bibliography 
 
 
186 
Bartsch O, Bartlick B, Ivell R (2004) Phosphodiesterase 4 inhibition synergizes with 
relaxin signaling to promote decidualization of human endometrial stromal cells. J 
Clin Endocrinol Metab 89: 324-334 
 
Beder LB, Gunduz M, Ouchida M, Gunduz E, Sakai A, Fukushima K, Nagatsuka H, 
Ito S, Honjo N, Nishizaki K, Shimizu K (2006) Identification of a candidate tumor 
suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and 
neck cancer. J Cancer Res Clin Oncol 132: 19-27 
 
Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV (2006) 
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing 
pathway in metastatic prostate cancer. Cell Cycle 5: 1886-1901 
 
Bestor TH (2000) The DNA methyltransferases of mammals. Hum Mol Genet 9: 
2395-2402 
 
Binda O, Nassif C, Branton PE (2008) SIRT1 negatively regulates HDAC1-
dependent transcriptional repression by the RBP1 family of proteins. Oncogene 27: 
3384-3392 
 
Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-
21 
 
Bock C, Tomazou EM, Brinkman AB, Muller F, Simmer F, Gu H, Jager N, Gnirke A, 
Stunnenberg HG, Meissner A (2010) Quantitative comparison of genome-wide DNA 
methylation mapping technologies. Nat Biotechnol 28: 1106-1114 
 
Bohrer LR, Chen S, Hallstrom TC, Huang H (2010) Androgens suppress EZH2 
expression via retinoblastoma (RB) and p130-dependent pathways: a potential 
mechanism of androgen-refractory progression of prostate cancer. Endocrinology 
151: 5136-5145 
 
Bonasio R, Tu S, Reinberg D (2010) Molecular signals of epigenetic states. Science 
330: 612-616 
 
Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi 
ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP (1998a) High-
mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone 
receptors to enhance their DNA binding in vitro and transcriptional activity in 
mammalian cells. Mol Cell Biol 18: 4471-4487 
 
Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi 
ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP (1998b) High-
mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone 
receptors to enhance their DNA binding in vitro and transcriptional activity in 
mammalian cells. Mol Cell Biol 18: 4471-4487 
 
Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE (2007) UHRF1 
plays a role in maintaining DNA methylation in mammalian cells. Science 317: 1760-
1764 
   Bibliography 
 
 
187 
 
Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, 
Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young 
RA, Jaenisch R (2006) Polycomb complexes repress developmental regulators in 
murine embryonic stem cells. Nature 441: 349-353 
 
Boyes J, Bird A (1992) Repression of genes by DNA methylation depends on CpG 
density and promoter strength: evidence for involvement of a methyl-CpG binding 
protein. Embo J 11: 327-333 
 
Boyne MT, 2nd, Pesavento JJ, Mizzen CA, Kelleher NL (2006) Precise 
characterization of human histones in the H2A gene family by top down mass 
spectrometry. J Proteome Res 5: 248-253 
 
Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K (2006) Genome-wide 
mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes 
Dev 20: 1123-1136 
 
Bredfeldt TG, Greathouse KL, Safe SH, Hung MC, Bedford MT, Walker CL (2010) 
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen 
receptor signaling to PI3K/AKT. Mol Endocrinol 24: 993-1006 
 
Brinkman AB, Simmer F, Ma K, Kaan A, Zhu J, Stunnenberg HG (2010) Whole-
genome DNA methylation profiling using MethylCap-seq. Methods 52: 232-236 
 
Brosens JJ, Gellersen B (2006) Death or survival--progesterone-dependent cell fate 
decisions in the human endometrial stroma. J Mol Endocrinol 36: 389-398 
 
Brosens JJ, Hayashi N, White JO (1999) Progesterone receptor regulates decidual 
prolactin expression in differentiating human endometrial stromal cells. 
Endocrinology 140: 4809-4820 
 
Brosens JJ, Parker MG, McIndoe A, Pijnenborg R, Brosens IA (2009) A role for 
menstruation in preconditioning the uterus for successful pregnancy. Am J Obstet 
Gynecol 200: 615 e611-616 
 
Brzeski J, Jerzmanowski A (2003) Deficient in DNA methylation 1 (DDM1) defines a 
novel family of chromatin-remodeling factors. J Biol Chem 278: 823-828 
 
Buchwald G, van der Stoop P, Weichenrieder O, Perrakis A, van Lohuizen M, Sixma 
TK (2006) Structure and E3-ligase activity of the Ring-Ring complex of polycomb 
proteins Bmi1 and Ring1b. Embo J 25: 2465-2474 
 
Burney RO, Talbi S, Hamilton AE, Vo KC, Nyegaard M, Nezhat CR, Lessey BA, 
Giudice LC (2007) Gene expression analysis of endometrium reveals progesterone 
resistance and candidate susceptibility genes in women with endometriosis. 
Endocrinology 148: 3814-3826 
 
Buzzio OL, Lu Z, Miller CD, Unterman TG, Kim JJ (2006) FOXO1A differentially 
regulates genes of decidualization. Endocrinology 147: 3870-3876 
   Bibliography 
 
 
188 
 
Caffarelli E, Filetici P (2011) Epigenetic regulation in cancer development. Front 
Biosci 17: 2682-2694 
 
Cao R, Tsukada Y, Zhang Y (2005) Role of Bmi-1 and Ring1A in H2A ubiquitylation 
and Hox gene silencing. Mol Cell 20: 845-854 
 
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang 
Y (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. 
Science 298: 1039-1043 
 
Cao R, Zhang Y (2004) SUZ12 is required for both the histone methyltransferase 
activity and the silencing function of the EED-EZH2 complex. Mol Cell 15: 57-67 
 
Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, 
Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M (2005) Chromosome-
wide mapping of estrogen receptor binding reveals long-range regulation requiring 
the forkhead protein FoxA1. Cell 122: 33-43 
 
Cedar H, Verdine GL (1999) Gene expression. The amazing demethylase. Nature 
397: 568-569 
 
Chamberlain SJ, Yee D, Magnuson T (2008) Polycomb repressive complex 2 is 
dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26: 
1496-1505 
 
Chanda D, Xie YB, Choi HS (2010) Transcriptional corepressor SHP recruits SIRT1 
histone deacetylase to inhibit LRH-1 transactivation. Nucleic Acids Res 38: 4607-
4619 
 
Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E (2003) 
Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-
1. J Biol Chem 278: 12335-12343 
 
Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR 
(1999) Regulation of transcription by a protein methyltransferase. Science 284: 2174-
2177 
 
Chen T, Ueda Y, Dodge JE, Wang Z, Li E (2003) Establishment and maintenance of 
genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and 
Dnmt3b. Mol Cell Biol 23: 5594-5605 
 
Cheung P, Lau P (2005) Epigenetic regulation by histone methylation and histone 
variants. Mol Endocrinol 19: 563-573 
 
Chiang CM (2009) Brd4 engagement from chromatin targeting to transcriptional 
regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep 1: 98 
 
   Bibliography 
 
 
189 
Cho YS, Kim EJ, Park UH, Sin HS, Um SJ (2006) Additional sex comb-like 1 
(ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for 
retinoic acid receptor. J Biol Chem 281: 17588-17598 
 
Christian M, Mak I, White JO, Brosens JJ (2002a) Mechanisms of decidualization. 
Reprod Biomed Online 4 Suppl 3: 24-30 
 
Christian M, Marangos P, Mak I, McVey J, Barker F, White J, Brosens JJ (2001) 
Interferon-gamma modulates prolactin and tissue factor expression in differentiating 
human endometrial stromal cells. Endocrinology 142: 3142-3151 
 
Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ (2002b) Functional 
association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-
dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-
enriched activatory protein and PR-A in human endometrial stromal cells. Mol 
Endocrinol 16: 141-154 
 
Christian M, Zhang X, Schneider-Merck T, Unterman TG, Gellersen B, White JO, 
Brosens JJ (2002c) Cyclic AMP-induced forkhead transcription factor, FKHR, 
cooperates with CCAAT/enhancer-binding protein beta in differentiating human 
endometrial stromal cells. J Biol Chem 277: 20825-20832 
 
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF (1997) Human DNA-(cytosine-5) 
methyltransferase-PCNA complex as a target for p21WAF1. Science 277: 1996-2000 
 
Citterio E, Papait R, Nicassio F, Vecchi M, Gomiero P, Mantovani R, Di Fiore PP, 
Bonapace IM (2004) Np95 is a histone-binding protein endowed with ubiquitin ligase 
activity. Mol Cell Biol 24: 2526-2535 
 
Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of 
methylated cytosines. Nucleic Acids Res 22: 2990-2997 
 
Cloke B, Huhtinen K, Fusi L, Kajihara T, Yliheikkila M, Ho KK, Teklenburg G, 
Lavery S, Jones MC, Trew G, Kim JJ, Lam EW, Cartwright JE, Poutanen M, Brosens 
JJ (2008) The androgen and progesterone receptors regulate distinct gene networks 
and cellular functions in decidualizing endometrium. Endocrinology 149: 4462-4474 
 
Cui K, Zang C, Roh TY, Schones DE, Childs RW, Peng W, Zhao K (2009) 
Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate 
of bivalent genes during differentiation. Cell Stem Cell 4: 80-93 
 
Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V (2002) Drosophila 
enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that 
marks chromosomal Polycomb sites. Cell 111: 185-196 
 
de Napoles M, Mermoud JE, Wakao R, Tang YA, Endoh M, Appanah R, Nesterova 
TB, Silva J, Otte AP, Vidal M, Koseki H, Brockdorff N (2004) Polycomb group 
proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and 
X inactivation. Dev Cell 7: 663-676 
 
   Bibliography 
 
 
190 
de Ziegler D, Fanchin R, de Moustier B, Bulletti C (1998) The hormonal control of 
endometrial receptivity: estrogen (E2) and progesterone. J Reprod Immunol 39: 149-
166 
 
Dessauer CW, Posner BA, Gilman AG (1996) Visualizing signal transduction: 
receptors, G-proteins, and adenylate cyclases. Clin Sci (Lond) 91: 527-537 
 
Dey A, Chitsaz F, Abbasi A, Misteli T, Ozato K (2003) The double bromodomain 
protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc Natl 
Acad Sci U S A 100: 8758-8763 
 
Dimitriadis E, Stoikos C, Baca M, Fairlie WD, McCoubrie JE, Salamonsen LA 
(2005a) Relaxin and prostaglandin E(2) regulate interleukin 11 during human 
endometrial stromal cell decidualization. J Clin Endocrinol Metab 90: 3458-3465 
 
Dimitriadis E, White CA, Jones RL, Salamonsen LA (2005b) Cytokines, chemokines 
and growth factors in endometrium related to implantation. Hum Reprod Update 11: 
613-630 
 
Down TA, Rakyan VK, Turner DJ, Flicek P, Li H, Kulesha E, Graf S, Johnson N, 
Herrero J, Tomazou EM, Thorne NP, Backdahl L, Herberth M, Howe KL, Jackson 
DK, Miretti MM, Marioni JC, Birney E, Hubbard TJ, Durbin R, Tavare S, Beck S 
(2008) A Bayesian deconvolution strategy for immunoprecipitation-based DNA 
methylome analysis. Nat Biotechnol 26: 779-785 
 
Dudoit S, Gentleman RC, Quackenbush J (2003) Open source software for the 
analysis of microarray data. Biotechniques Suppl: 45-51 
 
Dunn CL, Kelly RW, Critchley HO (2003) Decidualization of the human endometrial 
stromal cell: an enigmatic transformation. Reprod Biomed Online 7: 151-161 
 
Dupont C, Armant DR, Brenner CA (2009) Epigenetics: definition, mechanisms and 
clinical perspective. Semin Reprod Med 27: 351-357 
 
Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell 
DR (1999) FKHR binds the insulin response element in the insulin-like growth factor 
binding protein-1 promoter. Endocrinology 140: 3140-3146 
 
Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 
21: 5400-5413 
 
Emera D, Casola C, Lynch VJ, Wildman DE, Agnew D, Wagner GP (2011) 
Convergent Evolution of Endometrial Prolactin Expression in Primates, Mice, and 
Elephants Through the Independent Recruitment of Transposable Elements. Mol Biol 
Evol 
 
Espada J, Esteller M (2010) DNA methylation and the functional organization of the 
nuclear compartment. Semin Cell Dev Biol 21: 238-246 
 
   Bibliography 
 
 
191 
Evans J, Catalano RD, Brown P, Sherwin R, Critchley HO, Fazleabas AT, Jabbour 
HN (2009) Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial 
leukemia inhibitory factor. Faseb J 23: 2165-2175 
 
Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A, 
Fuchs E (2009) Ezh2 orchestrates gene expression for the stepwise differentiation of 
tissue-specific stem cells. Cell 136: 1122-1135 
 
Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E, Defossez PA (2006) 
A family of human zinc finger proteins that bind methylated DNA and repress 
transcription. Mol Cell Biol 26: 169-181 
 
Finn CA (1998) Menstruation: a nonadaptive consequence of uterine evolution. Q Rev 
Biol 73: 163-173 
 
Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P (1996) Transcriptional control of 
circadian hormone synthesis via the CREM feedback loop. Proc Natl Acad Sci U S A 
93: 14140-14145 
 
Furst RW, Meyer HH, Schweizer G, Ulbrich SE (2011) DNA methylation as an 
epigenetic contribution to transcriptional regulation of the bovine endometrium in 
estrous cycle and early pregnancy? Mol Cell Endocrinol 
 
Futamura M, Nishimori H, Shiratsuchi T, Saji S, Nakamura Y, Tokino T (1999) 
Molecular cloning, mapping, and characterization of a novel human gene, MTA1-L1, 
showing homology to a metastasis-associated gene, MTA1. J Hum Genet 44: 52-56 
 
Gao J, Mazella J, Tang M, Tseng L (2000a) Ligand-activated progesterone receptor 
isoform hPR-A is a stronger transactivator than hPR-B for the expression of IGFBP-1 
(insulin-like growth factor binding protein-1) in human endometrial stromal cells. Mol 
Endocrinol 14: 1954-1961 
 
Gao J, Mazella J, Tseng L (2000b) Partial characterization of the CCAAT box in the 
promoter of the hLGFBP-1 gene: interaction with negatively acting transcription 
factors in decidualized human endometrial stromal cells. Mol Cell Endocrinol 159: 
171-177 
 
Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional 
characterization of HDAC11, a novel member of the human histone deacetylase 
family. J Biol Chem 277: 25748-25755 
 
Gellersen B, Brosens IA, Brosens JJ (2007) Decidualization of the human 
endometrium: mechanisms, functions, and clinical perspectives. Semin Reprod Med 
25: 445-453 
 
Gellersen B, Brosens J (2003) Cyclic AMP and progesterone receptor cross-talk in 
human endometrium: a decidualizing affair. J Endocrinol 178: 357-372 
 
   Bibliography 
 
 
192 
Gellersen B, DiMattia GE, Friesen HG, Bohnet HG (1989) Prolactin (PRL) mRNA 
from human decidua differs from pituitary PRL mRNA but resembles the IM-9-P3 
lymphoblast PRL transcript. Mol Cell Endocrinol 64: 127-130 
 
Gellersen B, Kempf R (1990) Human prolactin gene expression: positive correlation 
between site-specific methylation and gene activity in a set of human lymphoid cell 
lines. Mol Endocrinol 4: 1874-1886 
 
Gellersen B, Kempf R, Sandhowe R, Weinbauer GF, Behr R (2002) Novel leader 
exons of the cyclic adenosine 3',5'-monophosphate response element modulator 
(CREM) gene, transcribed from promoters P3 and P4, are highly testis-specific in 
primates. Mol Hum Reprod 8: 965-976 
 
Gellersen B, Kempf R, Telgmann R (1997) Human endometrial stromal cells express 
novel isoforms of the transcriptional modulator CREM and up-regulate ICER in the 
course of decidualization. Mol Endocrinol 11: 97-113 
 
Gellersen B, Kempf R, Telgmann R, DiMattia GE (1994) Nonpituitary human 
prolactin gene transcription is independent of Pit-1 and differentially controlled in 
lymphocytes and in endometrial stroma. Mol Endocrinol 8: 356-373 
 
Georges SA, Kraus WL, Luger K, Nyborg JK, Laybourn PJ (2002) p300-mediated tax 
transactivation from recombinant chromatin: histone tail deletion mimics coactivator 
function. Mol Cell Biol 22: 127-137 
 
Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP (2000) The opposing 
transcriptional activities of the two isoforms of the human progesterone receptor are 
due to differential cofactor binding. Mol Cell Biol 20: 3102-3115 
 
Giudice LC (2004) Microarray expression profiling reveals candidate genes for 
human uterine receptivity. Am J Pharmacogenomics 4: 299-312 
 
Giudice LC, Dsupin BA, Irwin JC (1992a) Steroid and peptide regulation of insulin-
like growth factor-binding proteins secreted by human endometrial stromal cells is 
dependent on stromal differentiation. J Clin Endocrinol Metab 75: 1235-1241 
 
Giudice LC, Dsupin BA, Irwin JC, Eckert RL (1992b) Identification of insulin-like 
growth factor binding proteins in human oviduct. Fertil Steril 57: 294-301 
 
Glass CK, Rosenfeld MG (2000) The coregulator exchange in transcriptional 
functions of nuclear receptors. Genes Dev 14: 121-141 
 
Goll MG, Bestor TH (2005) Eukaryotic cytosine methyltransferases. Annu Rev 
Biochem 74: 481-514 
 
Goll MG, Kirpekar F, Maggert KA, Yoder JA, Hsieh CL, Zhang X, Golic KG, 
Jacobsen SE, Bestor TH (2006) Methylation of tRNAAsp by the DNA 
methyltransferase homolog Dnmt2. Science 311: 395-398 
 
   Bibliography 
 
 
193 
Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, 
Merajver SD, Kleer CG (2009) Downregulation of EZH2 decreases growth of 
estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 
28: 843-853 
 
Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. 
Endocr Rev 18: 502-519 
 
Grimaldi G, Christian M, Steel JH, Henriet P, Poutanen M, Brosens JJ (2011) Down-
Regulation of the Histone Methyltransferase EZH2 Contributes to the Epigenetic 
Programming of Decidualizing Human Endometrial Stromal Cells. Mol Endocrinol 
 
Grozinger CM, Hassig CA, Schreiber SL (1999) Three proteins define a class of 
human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 96: 
4868-4873 
 
Gubbay O, Critchley HO, Bowen JM, King A, Jabbour HN (2002) Prolactin induces 
ERK phosphorylation in epithelial and CD56(+) natural killer cells of the human 
endometrium. J Clin Endocrinol Metab 87: 2329-2335 
 
Hakim O, Sung MH, Hager GL (2010) 3D shortcuts to gene regulation. Curr Opin 
Cell Biol 22: 305-313 
 
Halfmann R, Lindquist S (2010) Epigenetics in the extreme: prions and the 
inheritance of environmentally acquired traits. Science 330: 629-632 
 
Han SJ, Lonard DM, O'Malley BW (2009) Multi-modulation of nuclear receptor 
coactivators through posttranslational modifications. Trends Endocrinol Metab 20: 8-
15 
 
Hansen JC (2002) Conformational dynamics of the chromatin fiber in solution: 
determinants, mechanisms, and functions. Annu Rev Biophys Biomol Struct 31: 361-
392 
 
Harbour JW, Dean DC (2000) The Rb/E2F pathway: expanding roles and emerging 
paradigms. Genes Dev 14: 2393-2409 
 
Hashimoto H, Horton JR, Zhang X, Cheng X (2009) UHRF1, a modular multi-
domain protein, regulates replication-coupled crosstalk between DNA methylation 
and histone modifications. Epigenetics 4: 8-14 
 
Hernandez-Munoz I, Taghavi P, Kuijl C, Neefjes J, van Lohuizen M (2005) 
Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and 
the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 25: 11047-11058 
 
Hochner-Celnikier D, Ron M, Eldor A, Segal S, Palti Z, Fuks Z, Vlodavsky I (1984) 
Growth characteristics of human first trimester decidual cells cultured in serum-free 
medium: production of prolactin, prostaglandins and fibronectin. Biol Reprod 31: 
827-836 
 
   Bibliography 
 
 
194 
Horakova AH, Bartova E, Galiova G, Uhlirova R, Matula P, Kozubek S (2010) 
SUV39h-independent association of HP1 beta with fibrillarin-positive nucleolar 
regions. Chromosoma 119: 227-241 
 
Hsieh CL (1994) Dependence of transcriptional repression on CpG methylation 
density. Mol Cell Biol 14: 5487-5494 
 
Huang CY, Beliakoff J, Li X, Lee J, Li X, Sharma M, Lim B, Sun Z (2005) hZimp7, a 
novel PIAS-like protein, enhances androgen receptor-mediated transcription and 
interacts with SWI/SNF-like BAF complexes. Mol Endocrinol 19: 2915-2929 
 
Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA (2000) 
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-
independent repression pathway. Genes Dev 14: 45-54 
 
Huang J, Fan T, Yan Q, Zhu H, Fox S, Issaq HJ, Best L, Gangi L, Munroe D, Muegge 
K (2004) Lsh, an epigenetic guardian of repetitive elements. Nucleic Acids Res 32: 
5019-5028 
 
Huang SJ, Zenclussen AC, Chen CP, Basar M, Yang H, Arcuri F, Li M, Kocamaz E, 
Buchwalder L, Rahman M, Kayisli U, Schatz F, Toti P, Lockwood CJ (2010) The 
implication of aberrant GM-CSF expression in decidual cells in the pathogenesis of 
preeclampsia. Am J Pathol 177: 2472-2482 
 
Hwang C, Giri VN, Wilkinson JC, Wright CW, Wilkinson AS, Cooney KA, Duckett 
CS (2008) EZH2 regulates the transcription of estrogen-responsive genes through 
association with REA, an estrogen receptor corepressor. Breast Cancer Res Treat 
107: 235-242 
 
Iguchi-Ariga SM, Schaffner W (1989) CpG methylation of the cAMP-responsive 
enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as 
transcriptional activation. Genes Dev 3: 612-619 
 
Ikeda Y, Kinoshita T (2009) DNA demethylation: a lesson from the garden. 
Chromosoma 118: 37-41 
 
Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y (2010) Role of Tet 
proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass 
specification. Nature 466: 1129-1133 
 
Jabbour HN, Critchley HO, Boddy SC (1998) Expression of functional prolactin 
receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and 
activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after 
stimulation with prolactin. J Clin Endocrinol Metab 83: 2545-2553 
 
Jeltsch A (2006a) Molecular enzymology of mammalian DNA methyltransferases. 
Curr Top Microbiol Immunol 301: 203-225 
 
   Bibliography 
 
 
195 
Jeltsch A (2006b) On the enzymatic properties of Dnmt1: specificity, processivity, 
mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 1: 
63-66 
 
Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074-1080 
 
Ji H, Ehrlich LI, Seita J, Murakami P, Doi A, Lindau P, Lee H, Aryee MJ, Irizarry 
RA, Kim K, Rossi DJ, Inlay MA, Serwold T, Karsunky H, Ho L, Daley GQ, 
Weissman IL, Feinberg AP (2010) Comprehensive methylome map of lineage 
commitment from haematopoietic progenitors. Nature 467: 338-342 
 
Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway 
RC, Kornberg RD (1998) Mammalian mediator of transcriptional regulation and its 
possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci U S 
A 95: 8538-8543 
 
John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, Hager GL, 
Stamatoyannopoulos JA (2011) Chromatin accessibility pre-determines 
glucocorticoid receptor binding patterns. Nat Genet 43: 264-268 
 
Jones MC, Fusi L, Higham JH, Abdel-Hafiz H, Horwitz KB, Lam EW, Brosens JJ 
(2006) Regulation of the SUMO pathway sensitizes differentiating human 
endometrial stromal cells to progesterone. Proc Natl Acad Sci U S A 103: 16272-
16277 
 
Jung DJ, Sung HS, Goo YW, Lee HM, Park OK, Jung SY, Lim J, Kim HJ, Lee SK, 
Kim TS, Lee JW, Lee YC (2002) Novel transcription coactivator complex containing 
activating signal cointegrator 1. Mol Cell Biol 22: 5203-5211 
 
Karanikolas BD, Figueiredo ML, Wu L (2010) Comprehensive evaluation of the role 
of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell 
lines. Prostate 70: 675-688 
 
Karlic R, Chung HR, Lasserre J, Vlahovicek K, Vingron M (2010) Histone 
modification levels are predictive for gene expression. Proc Natl Acad Sci U S A 107: 
2926-2931 
 
Kass SU, Pruss D, Wolffe AP (1997) How does DNA methylation repress 
transcription? Trends Genet 13: 444-449 
 
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) 
Two distinct estrogen-regulated promoters generate transcripts encoding the two 
functionally different human progesterone receptor forms A and B. Embo J 9: 1603-
1614 
 
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, 
Presser A, Bernstein BE, van Oudenaarden A, Regev A, Lander ES, Rinn JL (2009) 
Many human large intergenic noncoding RNAs associate with chromatin-modifying 
complexes and affect gene expression. Proc Natl Acad Sci U S A 106: 11667-11672 
 
   Bibliography 
 
 
196 
Kim H, Kang K, Kim J (2009) AEBP2 as a potential targeting protein for Polycomb 
Repression Complex PRC2. Nucleic Acids Res 37: 2940-2950 
 
Kim J, Daniel J, Espejo A, Lake A, Krishna M, Xia L, Zhang Y, Bedford MT (2006) 
Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO 
Rep 7: 397-403 
 
Kim JJ, Buzzio OL, Li S, Lu Z (2005) Role of FOXO1A in the regulation of insulin-
like growth factor-binding protein-1 in human endometrial cells: interaction with 
progesterone receptor. Biol Reprod 73: 833-839 
 
Kim JJ, Taylor HS, Akbas GE, Foucher I, Trembleau A, Jaffe RC, Fazleabas AT, 
Unterman TG (2003) Regulation of insulin-like growth factor binding protein-1 
promoter activity by FKHR and HOXA10 in primate endometrial cells. Biol Reprod 
68: 24-30 
 
Kiskinis E, Hallberg M, Christian M, Olofsson M, Dilworth SM, White R, Parker MG 
(2007) RIP140 directs histone and DNA methylation to silence Ucp1 expression in 
white adipocytes. Embo J 26: 4831-4840 
 
Kitaya K, Nakayama T, Okubo T, Kuroboshi H, Fushiki S, Honjo H (2003) 
Expression of macrophage inflammatory protein-1beta in human endometrium: its 
role in endometrial recruitment of natural killer cells. J Clin Endocrinol Metab 88: 
1809-1814 
 
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, 
Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM 
(2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic 
transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611 
 
Klemmt PA, Carver JG, Kennedy SH, Koninckx PR, Mardon HJ (2006) Stromal cells 
from endometriotic lesions and endometrium from women with endometriosis have 
reduced decidualization capacity. Fertil Steril 85: 564-572 
 
Kliman HJ (2000) Uteroplacental blood flow. The story of decidualization, 
menstruation, and trophoblast invasion. Am J Pathol 157: 1759-1768 
 
Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. 
Trends Biochem Sci 31: 89-97 
 
Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, Laiho A, Tahiliani M, 
Sommer CA, Mostoslavsky G, Lahesmaa R, Orkin SH, Rodig SJ, Daley GQ, Rao A 
(2011) Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage 
specification in mouse embryonic stem cells. Cell Stem Cell 8: 200-213 
 
Kornberg RD (1974) Chromatin structure: a repeating unit of histones and DNA. 
Science 184: 868-871 
 
Kornberg RD, Thomas JO (1974) Chromatin structure; oligomers of the histones. 
Science 184: 865-868
   Bibliography 
 
 
197 
 
Kouzarides T (2007a) Chromatin modifications and their function. Cell 128: 693-705 
 
Kouzarides T (2007b) SnapShot: Histone-modifying enzymes. Cell 128: 802 
 
Kouzarides T, Bannister A. Guide to epigenetic marks. 
http://www.abcam.com/index.html?pageconfig=resource&rid=11924&pid=5 Abcam. 
 
Kraus WL, Manning ET, Kadonaga JT (1999) Biochemical analysis of distinct 
activation functions in p300 that enhance transcription initiation with chromatin 
templates. Mol Cell Biol 19: 8123-8135 
 
Kress C, Thomassin H, Grange T (2001) Local DNA demethylation in vertebrates: 
how could it be performed and targeted? FEBS Lett 494: 135-140 
 
Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J (2007) 
Class I histone deacetylase expression in the human cyclic endometrium and 
endometrial adenocarcinomas. Hum Reprod 22: 2956-2966 
 
Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, Presser A, 
Nusbaum C, Xie X, Chi AS, Adli M, Kasif S, Ptaszek LM, Cowan CA, Lander ES, 
Koseki H, Bernstein BE (2008) Genomewide analysis of PRC1 and PRC2 occupancy 
identifies two classes of bivalent domains. PLoS Genet 4: e1000242 
 
Kudo Y, Hara T, Katsuki T, Toyofuku A, Katsura Y, Takikawa O, Fujii T, Ohama K 
(2004) Mechanisms regulating the expression of indoleamine 2,3-dioxygenase during 
decidualization of human endometrium. Hum Reprod 19: 1222-1230 
 
Laget S, Joulie M, Le Masson F, Sasai N, Christians E, Pradhan S, Roberts RJ, 
Defossez PA (2010) The human proteins MBD5 and MBD6 associate with 
heterochromatin but they do not bind methylated DNA. PLoS One 5: e11982 
 
Law JA, Jacobsen SE (2010) Establishing, maintaining and modifying DNA 
methylation patterns in plants and animals. Nat Rev Genet 11: 204-220 
 
Lee KY, Jeong JW, Wang J, Ma L, Martin JF, Tsai SY, Lydon JP, DeMayo FJ (2007) 
Bmp2 is critical for the murine uterine decidual response. Mol Cell Biol 27: 5468-
5478 
 
Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, 
Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, 
Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte 
AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA (2006) 
Control of developmental regulators by Polycomb in human embryonic stem cells. 
Cell 125: 301-313 
 
Lee WS, Liu CW, Juan SH, Liang YC, Ho PY, Lee YH (2003) Molecular mechanism 
of progesterone-induced antiproliferation in rat aortic smooth muscle cells. 
Endocrinology 144: 2785-2790 
 
   Bibliography 
 
 
198 
Lee YK, Moore DD (2008) Liver receptor homolog-1, an emerging metabolic 
modulator. Front Biosci 13: 5950-5958 
 
Leeb M, Pasini D, Novatchkova M, Jaritz M, Helin K, Wutz A (2010) Polycomb 
complexes act redundantly to repress genomic repeats and genes. Genes Dev 24: 265-
276 
 
Leonhardt H, Page AW, Weier HU, Bestor TH (1992) A targeting sequence directs 
DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71: 
865-873 
 
LeRoy G, Rickards B, Flint SJ (2008) The double bromodomain proteins Brd2 and 
Brd3 couple histone acetylation to transcription. Mol Cell 30: 51-60 
 
Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D (2010) Jarid2 and 
PRC2, partners in regulating gene expression. Genes Dev 24: 368-380 
 
Li J, Wang J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J (2000) Both corepressor 
proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. 
Embo J 19: 4342-4350 
 
Libby PR (1972) Histone acetylation and hormone action. Early effects of oestradiol-
17beta on histone acetylation in rat uterus. Biochem J 130: 663-669 
 
Liu CL, Kaplan T, Kim M, Buratowski S, Schreiber SL, Friedman N, Rando OJ 
(2005) Single-nucleosome mapping of histone modifications in S. cerevisiae. PLoS 
Biol 3: e328 
 
Logan PC, Ponnampalam AP, Rahnama F, Lobie PE, Mitchell MD (2010) The effect 
of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal 
cells. Hum Reprod 25: 2859-2869 
 
Lonard DM, O'Malley BW (2006) The expanding cosmos of nuclear receptor 
coactivators. Cell 125: 411-414 
 
Lorincz MC, Dickerson DR, Schmitt M, Groudine M (2004) Intragenic DNA 
methylation alters chromatin structure and elongation efficiency in mammalian cells. 
Nat Struct Mol Biol 11: 1068-1075 
 
Loyter A, Scangos GA, Ruddle FH (1982) Mechanisms of DNA uptake by 
mammalian cells: fate of exogenously added DNA monitored by the use of 
fluorescent dyes. Proc Natl Acad Sci U S A 79: 422-426 
 
Lynch VJ, Brayer K, Gellersen B, Wagner GP (2009) HoxA-11 and FOXO1A 
cooperate to regulate decidual prolactin expression: towards inferring the core 
transcriptional regulators of decidual genes. PLoS One 4: e6845 
 
Maenner S, Blaud M, Fouillen L, Savoye A, Marchand V, Dubois A, Sanglier-
Cianferani S, Van Dorsselaer A, Clerc P, Avner P, Visvikis A, Branlant C (2010) 2-D 
   Bibliography 
 
 
199 
structure of the A region of Xist RNA and its implication for PRC2 association. PLoS 
Biol 8: e1000276 
 
Mak IY, Brosens JJ, Christian M, Hills FA, Chamley L, Regan L, White JO (2002) 
Regulated expression of signal transducer and activator of transcription, Stat5, and its 
enhancement of PRL expression in human endometrial stromal cells in vitro. J Clin 
Endocrinol Metab 87: 2581-2588 
 
Makrigiannakis A, Zoumakis E, Kalantaridou S, Chrousos G (2004) Endometrial and 
placental CRH as regulators of human embryo implantation. J Reprod Immunol 62: 
53-59 
 
Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, Dynlacht BD, 
Reinberg D (2008) Ezh1 and Ezh2 maintain repressive chromatin through different 
mechanisms. Mol Cell 32: 503-518 
 
Margueron R, Licznar A, Lazennec G, Vignon F, Cavailles V (2003) Oestrogen 
receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative 
activity of histone deacetylase inhibitors in human breast cancer cells. J Endocrinol 
179: 41-53 
 
Margueron R, Reinberg D (2011) The Polycomb complex PRC2 and its mark in life. 
Nature 469: 343-349 
 
Martin RD (2007) The evolution of human reproduction: a primatological 
perspective. Am J Phys Anthropol Suppl 45: 59-84 
 
Maruyama T, Yoshimura Y (2008) Molecular and cellular mechanisms for 
differentiation and regeneration of the uterine endometrium. Endocr J 55: 795-810 
 
Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, 
Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen 
N, Shchors K, Heine VM, Rowitch DH, Xing X, Fiore C, Schillebeeckx M, Jones SJ, 
Haussler D, Marra MA, Hirst M, Wang T, Costello JF (2010) Conserved role of 
intragenic DNA methylation in regulating alternative promoters. Nature 466: 253-257 
 
Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-
dependent factor CREB. Nat Rev Mol Cell Biol 2: 599-609 
 
Meehan RR, Lewis JD, Bird AP (1992) Characterization of MeCP2, a vertebrate 
DNA binding protein with affinity for methylated DNA. Nucleic Acids Res 20: 5085-
5092 
 
Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide 
phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol 
Metab 13: 29-35 
 
Meilinger D, Fellinger K, Bultmann S, Rothbauer U, Bonapace IM, Klinkert WE, 
Spada F, Leonhardt H (2009) Np95 interacts with de novo DNA methyltransferases, 
   Bibliography 
 
 
200 
Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in 
embryonic stem cells. EMBO Rep 10: 1259-1264 
 
Mersfelder EL, Parthun MR (2006) The tale beyond the tail: histone core domain 
modifications and the regulation of chromatin structure. Nucleic Acids Res 34: 2653-
2662 
 
Minici F, Tiberi F, Tropea A, Orlando M, Gangale MF, Romani F, Campo S, 
Bompiani A, Lanzone A, Apa R (2008) Endometriosis and human infertility: a new 
investigation into the role of eutopic endometrium. Hum Reprod 23: 530-537 
 
Morey L, Helin K (2010) Polycomb group protein-mediated repression of 
transcription. Trends Biochem Sci 35: 323-332 
 
Mortusewicz O, Schermelleh L, Walter J, Cardoso MC, Leonhardt H (2005) 
Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci U S 
A 102: 8905-8909 
 
Mote PA, Balleine RL, McGowan EM, Clarke CL (1999) Colocalization of 
progesterone receptors A and B by dual immunofluorescent histochemistry in human 
endometrium during the menstrual cycle. J Clin Endocrinol Metab 84: 2963-2971 
 
Munro SK, Farquhar CM, Mitchell MD, Ponnampalam AP (2010) Epigenetic 
regulation of endometrium during the menstrual cycle. Mol Hum Reprod 16: 297-310 
 
Myant K, Stancheva I (2008) LSH cooperates with DNA methyltransferases to 
repress transcription. Mol Cell Biol 28: 215-226 
 
Nasu K, Kawano Y, Tsukamoto Y, Takano M, Takai N, Li H, Furukawa Y, Abe W, 
Moriyama M, Narahara H (2011) Aberrant DNA methylation status of endometriosis: 
Epigenetics as the pathogenesis, biomarker and therapeutic target. J Obstet Gynaecol 
Res 37: 683-695 
 
Nekrasov M, Klymenko T, Fraterman S, Papp B, Oktaba K, Kocher T, Cohen A, 
Stunnenberg HG, Wilm M, Muller J (2007) Pcl-PRC2 is needed to generate high 
levels of H3-K27 trimethylation at Polycomb target genes. Embo J 26: 4078-4088 
 
Niu J, Chen T, Han L, Wang P, Li N, Tong T (2011) Transcriptional activation of the 
senescence regulator Lsh by E2F1. Mech Ageing Dev 132: 180-186 
 
Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, 
membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3: 
27-41 
 
O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T (2001) The 
polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 
21: 4330-4336 
 
O'Carroll D, Scherthan H, Peters AH, Opravil S, Haynes AR, Laible G, Rea S, 
Schmid M, Lebersorger A, Jerratsch M, Sattler L, Mattei MG, Denny P, Brown SD, 
   Bibliography 
 
 
201 
Schweizer D, Jenuwein T (2000) Isolation and characterization of Suv39h2, a second 
histone H3 methyltransferase gene that displays testis-specific expression. Mol Cell 
Biol 20: 9423-9433 
 
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y (1996) The 
transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 
953-959 
 
Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and 
Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 
247-257 
 
Oliver C, Montes MJ, Galindo JA, Ruiz C, Olivares EG (1999) Human decidual 
stromal cells express alpha-smooth muscle actin and show ultrastructural similarities 
with myofibroblasts. Hum Reprod 14: 1599-1605 
 
Onate SA, Tsai SY, Tsai MJ, O'Malley BW (1995) Sequence and characterization of 
a coactivator for the steroid hormone receptor superfamily. Science 270: 1354-1357 
 
Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi 
K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara 
T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, 
Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo 
H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, 
Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, 
Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, 
Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, 
Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-
Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, 
Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, 
Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama 
H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, 
Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, 
Kawakami B, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, 
Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki 
K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, 
Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, 
Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, 
Hata H, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, 
Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita 
R, Nakai K, Yada T, Ohara O, Isogai T, Sugano S (2004) Complete sequencing and 
characterization of 21,243 full-length human cDNAs. Nat Genet 36: 40-45 
 
Panchenko MV, Zhou MI, Cohen HT (2004) von Hippel-Lindau partner Jade-1 is a 
transcriptional co-activator associated with histone acetyltransferase activity. J Biol 
Chem 279: 56032-56041 
 
Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K (2007) The polycomb group 
protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 27: 
3769-3779 
   Bibliography 
 
 
202 
 
Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K (2004) Suz12 is 
essential for mouse development and for EZH2 histone methyltransferase activity. 
Embo J 23: 4061-4071 
 
Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, Skotte J, Wutz 
A, Porse B, Jensen ON, Helin K (2010) Characterization of an antagonistic switch 
between histone H3 lysine 27 methylation and acetylation in the transcriptional 
regulation of Polycomb group target genes. Nucleic Acids Res 38: 4958-4969 
 
Pelizzola M, Koga Y, Urban AE, Krauthammer M, Weissman S, Halaban R, 
Molinaro AM (2008) MEDME: an experimental and analytical methodology for the 
estimation of DNA methylation levels based on microarray derived MeDIP-
enrichment. Genome Res 18: 1652-1659 
 
Pena PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Gozani O, Zhao R, 
Kutateladze TG (2006) Molecular mechanism of histone H3K4me3 recognition by 
plant homeodomain of ING2. Nature 442: 100-103 
 
Peng Y, Lee J, Zhu C, Sun Z (2010) A novel role for protein inhibitor of activated 
STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like 
protein, in androgen receptor-mediated transcription. J Biol Chem 285: 11465-11475 
 
Peters AH, Kubicek S, Mechtler K, O'Sullivan RJ, Derijck AA, Perez-Burgos L, 
Kohlmaier A, Opravil S, Tachibana M, Shinkai Y, Martens JH, Jenuwein T (2003) 
Partitioning and plasticity of repressive histone methylation states in mammalian 
chromatin. Mol Cell 12: 1577-1589 
 
Peterson CL, Laniel MA (2004) Histones and histone modifications. Curr Biol 14: 
R546-551 
 
Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz 
CC, Otte AP, Panning B, Zhang Y (2003) Role of histone H3 lysine 27 methylation in 
X inactivation. Science 300: 131-135 
 
Pohnke Y, Kempf R, Gellersen B (1999) CCAAT/enhancer-binding proteins are 
mediators in the protein kinase A-dependent activation of the decidual prolactin 
promoter. J Biol Chem 274: 24808-24818 
 
Pollina EA, Brunet A (2011) Epigenetic regulation of aging stem cells. Oncogene 30: 
3105-3126 
 
Popovici RM, Kao LC, Giudice LC (2000) Discovery of new inducible genes in in 
vitro decidualized human endometrial stromal cells using microarray technology. 
Endocrinology 141: 3510-3513 
 
Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ (2002) 
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent 
prognostic marker. Cancer 94: 2941-2952 
 
   Bibliography 
 
 
203 
Prezioso C, Orlando V (2011) Polycomb proteins in mammalian cell differentiation 
and plasticity. FEBS Lett 585: 2067-2077 
 
Profet M (1993) Menstruation as a defense against pathogens transported by sperm. Q 
Rev Biol 68: 335-386 
 
Prokhortchouk A, Hendrich B, Jorgensen H, Ruzov A, Wilm M, Georgiev G, Bird A, 
Prokhortchouk E (2001) The p120 catenin partner Kaiso is a DNA methylation-
dependent transcriptional repressor. Genes Dev 15: 1613-1618 
 
Prokhortchouk E, Defossez PA (2008) The cell biology of DNA methylation in 
mammals. Biochim Biophys Acta 1783: 2167-2173 
 
Quenby S, Vince G, Farquharson R, Aplin J (2002) Recurrent miscarriage: a defect in 
nature's quality control? Hum Reprod 17: 1959-1963 
 
Ramji DP, Foka P (2002) CCAAT/enhancer-binding proteins: structure, function and 
regulation. Biochem J 365: 561-575 
 
Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fisher SJ 
(2004) Trophoblast differentiation during embryo implantation and formation of the 
maternal-fetal interface. J Clin Invest 114: 744-754 
 
Richards RG, Brar AK, Frank GR, Hartman SM, Jikihara H (1995) Fibroblast cells 
from term human decidua closely resemble endometrial stromal cells: induction of 
prolactin and insulin-like growth factor binding protein-1 expression. Biol Reprod 52: 
609-615 
 
Riddihough G, Zahn LM (2010) Epigenetics. What is epigenetics? Introduction. 
Science 330: 611 
 
Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, 
Helms JA, Farnham PJ, Segal E, Chang HY (2007) Functional demarcation of active 
and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129: 
1311-1323 
 
Robzyk K, Recht J, Osley MA (2000) Rad6-dependent ubiquitination of histone H2B 
in yeast. Science 287: 501-504 
 
Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M, Peinado MA (2008) 
Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer 
cells. Proc Natl Acad Sci U S A 105: 19809-19814 
 
Roemer SC, Adelman J, Churchill ME, Edwards DP (2008) Mechanism of high-
mobility group protein B enhancement of progesterone receptor sequence-specific 
DNA binding. Nucleic Acids Res 36: 3655-3666 
 
Rowan BG, Garrison N, Weigel NL, O'Malley BW (2000) 8-Bromo-cyclic AMP 
induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent 
   Bibliography 
 
 
204 
activation of the chicken progesterone receptor and are critical for functional 
cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 20: 8720-8730 
 
Sakai N, Maruyama T, Sakurai R, Masuda H, Yamamoto Y, Shimizu A, Kishi I, 
Asada H, Yamagoe S, Yoshimura Y (2003) Involvement of histone acetylation in 
ovarian steroid-induced decidualization of human endometrial stromal cells. J Biol 
Chem 278: 16675-16682 
 
Salker M, Teklenburg G, Molokhia M, Lavery S, Trew G, Aojanepong T, Mardon HJ, 
Lokugamage AU, Rai R, Landles C, Roelen BA, Quenby S, Kuijk EW, Kavelaars A, 
Heijnen CJ, Regan L, Macklon NS, Brosens JJ (2010) Natural selection of human 
embryos: impaired decidualization of endometrium disables embryo-maternal 
interactions and causes recurrent pregnancy loss. PLoS One 5: e10287 
 
Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms 
of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 
39-85 
 
Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, Giudice LC, 
Lessey BA (2011) Progesterone resistance in PCOS endometrium: a microarray 
analysis in clomiphene citrate-treated and artificial menstrual cycles. J Clin 
Endocrinol Metab 96: 1737-1746 
 
Scarpin KM, Graham JD, Mote PA, Clarke CL (2009) Progesterone action in human 
tissues: regulation by progesterone receptor (PR) isoform expression, nuclear 
positioning and coregulator expression. Nucl Recept Signal 7: e009 
 
Schatz F, Krikun G, Caze R, Rahman M, Lockwood CJ (2003) Progestin-regulated 
expression of tissue factor in decidual cells: implications in endometrial hemostasis, 
menstruation and angiogenesis. Steroids 68: 849-860 
 
Schuettengruber B, Cavalli G (2009) Recruitment of polycomb group complexes and 
their role in the dynamic regulation of cell fate choice. Development 136: 3531-3542 
 
Schwartz YB, Pirrotta V (2007) Polycomb silencing mechanisms and the 
management of genomic programmes. Nat Rev Genet 8: 9-22 
 
Seenundun S, Rampalli S, Liu QC, Aziz A, Palii C, Hong S, Blais A, Brand M, Ge K, 
Dilworth FJ (2010) UTX mediates demethylation of H3K27me3 at muscle-specific 
genes during myogenesis. Embo J 29: 1401-1411 
 
Serra MJ, Ledford BE, Baggett B (1979) Synthesis and modification of the histones 
during the decidual cell reaction in the mouse uterus. Biol Reprod 20: 214-220 
 
Shaknovich R, Yeyati PL, Ivins S, Melnick A, Lempert C, Waxman S, Zelent A, 
Licht JD (1998) The promyelocytic leukemia zinc finger protein affects myeloid cell 
growth, differentiation, and apoptosis. Mol Cell Biol 18: 5533-5545 
 
Shao W, Halachmi S, Brown M (2002) ERAP140, a conserved tissue-specific nuclear 
receptor coactivator. Mol Cell Biol 22: 3358-3372 
   Bibliography 
 
 
205 
 
Sharov AA, Nishiyama A, Piao Y, Correa-Cerro LS, Amano T, Thomas M, Mehta S, 
Ko MS (2011) Responsiveness of genes to manipulation of transcription factors in ES 
cells is associated with histone modifications and tissue specificity. BMC Genomics 
12: 102 
 
Skalhegg BS, Tasken K (2000) Specificity in the cAMP/PKA signaling pathway. 
Differential expression,regulation, and subcellular localization of subunits of PKA. 
Front Biosci 5: D678-693 
 
Smith SS (2000) Gilbert's conjecture: the search for DNA (cytosine-5) demethylases 
and the emergence of new functions for eukaryotic DNA (cytosine-5) 
methyltransferases. J Mol Biol 302: 1-7 
 
Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 
403: 41-45 
 
Strassmann BI (1996) The evolution of endometrial cycles and menstruation. Q Rev 
Biol 71: 181-220 
 
Swigut T, Wysocka J (2007) H3K27 demethylases, at long last. Cell 131: 29-32 
 
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, 
Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-
hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 
930-935 
 
Takano M, Lu Z, Goto T, Fusi L, Higham J, Francis J, Withey A, Hardt J, Cloke B, 
Stavropoulou AV, Ishihara O, Lam EW, Unterman TG, Brosens JJ, Kim JJ (2007) 
Transcriptional cross talk between the forkhead transcription factor forkhead box 
O1A and the progesterone receptor coordinates cell cycle regulation and 
differentiation in human endometrial stromal cells. Mol Endocrinol 21: 2334-2349 
 
Teague EM, Print CG, Hull ML (2010) The role of microRNAs in endometriosis and 
associated reproductive conditions. Hum Reprod Update 16: 142-165 
 
Teklenburg G, Salker M, Heijnen C, Macklon NS, Brosens JJ (2010a) The molecular 
basis of recurrent pregnancy loss: impaired natural embryo selection. Mol Hum 
Reprod 16: 886-895 
 
Teklenburg G, Salker M, Molokhia M, Lavery S, Trew G, Aojanepong T, Mardon HJ, 
Lokugamage AU, Rai R, Landles C, Roelen BA, Quenby S, Kuijk EW, Kavelaars A, 
Heijnen CJ, Regan L, Brosens JJ, Macklon NS (2010b) Natural selection of human 
embryos: decidualizing endometrial stromal cells serve as sensors of embryo quality 
upon implantation. PLoS One 5: e10258 
 
Telgmann R, Gellersen B (1998) Marker genes of decidualization: activation of the 
decidual prolactin gene. Hum Reprod Update 4: 472-479 
 
   Bibliography 
 
 
206 
Telgmann R, Maronde E, Tasken K, Gellersen B (1997) Activated protein kinase A is 
required for differentiation-dependent transcription of the decidual prolactin gene in 
human endometrial stromal cells. Endocrinology 138: 929-937 
 
Thakur MK, Paramanik V (2009) Role of steroid hormone coregulators in health and 
disease. Horm Res 71: 194-200 
 
Tie F, Banerjee R, Stratton CA, Prasad-Sinha J, Stepanik V, Zlobin A, Diaz MO, 
Scacheri PC, Harte PJ (2009) CBP-mediated acetylation of histone H3 lysine 27 
antagonizes Drosophila Polycomb silencing. Development 136: 3131-3141 
 
Travers AA (2003) Priming the nucleosome: a role for HMGB proteins? EMBO Rep 
4: 131-136 
 
Truong AT, Duez C, Belayew A, Renard A, Pictet R, Bell GI, Martial JA (1984) 
Isolation and characterization of the human prolactin gene. Embo J 3: 429-437 
 
Tryndyak VP, Kovalchuk O, Pogribny IP (2006) Loss of DNA methylation and 
histone H4 lysine 20 trimethylation in human breast cancer cells is associated with 
aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone 
methyltransferase and methyl-binding proteins. Cancer Biol Ther 5: 65-70 
 
Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, 
Chang HY (2010) Long noncoding RNA as modular scaffold of histone modification 
complexes. Science 329: 689-693 
 
Valinluck V, Sowers LC (2007) Endogenous cytosine damage products alter the site 
selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 67: 
946-950 
 
Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M (2004) Stem cells and cancer; 
the polycomb connection. Cell 118: 409-418 
 
van Kaam KJ, Delvoux B, Romano A, D'Hooghe T, Dunselman GA, Groothuis PG 
(2011) Deoxyribonucleic acid methyltransferases and methyl-CpG-binding domain 
proteins in human endometrium and endometriosis. Fertil Steril 95: 1421-1427 
 
Vincenz C, Kerppola TK (2008) Different polycomb group CBX family proteins 
associate with distinct regions of chromatin using nonhomologous protein sequences. 
Proc Natl Acad Sci U S A 105: 16572-16577 
 
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde 
A, Bernard D, Vanderwinden JM, Bollen M, Esteller M, Di Croce L, de Launoit Y, 
Fuks F (2006) The Polycomb group protein EZH2 directly controls DNA 
methylation. Nature 439: 871-874 
 
Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP (1998) The nuclear 
corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic 
AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell 
Biol 18: 1369-1378 
   Bibliography 
 
 
207 
 
Walker E, Chang WY, Hunkapiller J, Cagney G, Garcha K, Torchia J, Krogan NJ, 
Reiter JF, Stanford WL (2010) Polycomb-like 2 associates with PRC2 and regulates 
transcriptional networks during mouse embryonic stem cell self-renewal and 
differentiation. Cell Stem Cell 6: 153-166 
 
Walker WH, Habener JF (1996) Role of transcription factors CREB and CREM in 
cAMP-regulated transcription during spermatogenesis. Trends Endocrinol Metab 7: 
133-138 
 
Wang H, Critchley HO, Kelly RW, Shen D, Baird DT (1998) Progesterone receptor 
subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod 
4: 407-412 
 
Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, Zhang Y 
(2004) Role of histone H2A ubiquitination in Polycomb silencing. Nature 431: 873-
878 
 
Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP (2002) 
Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain 
coactivator. Mol Cell Biol 22: 5451-5466 
 
Watanabe H, Nonoguchi K, Sakurai T, Masuda T, Itoh K, Fujita J (2005) A novel 
protein Depp, which is induced by progesterone in human endometrial stromal cells 
activates Elk-1 transcription factor. Mol Hum Reprod 11: 471-476 
 
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese 
JL, Mills GB, Bast RC, Jr., Hortobagyi GN, Hung MC (2008) Loss of trimethylation 
at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and 
pancreatic cancers. Mol Carcinog 47: 701-706 
 
Wettenhall JM, Smyth GK (2004) limmaGUI: a graphical user interface for linear 
modeling of microarray data. Bioinformatics 20: 3705-3706 
 
Wettschureck N, Offermanns S (2005) Mammalian G proteins and their cell type 
specific functions. Physiol Rev 85: 1159-1204 
 
Wiench M, Hager GL (2010) Expanding horizons for nuclear receptors. EMBO Rep 
11: 569-571 
 
Wiench M, Miranda TB, Hager GL (2011) Control of Nuclear Receptor Function by 
Local Chromatin Structure. Febs J 
 
Wieser F, Schneeberger C, Hudelist G, Singer C, Kurz C, Nagele F, Gruber C, Huber 
JC, Tschugguel W (2002) Endometrial nuclear receptor co-factors SRC-1 and N-CoR 
are increased in human endometrium during menstruation. Mol Hum Reprod 8: 644-
650 
 
   Bibliography 
 
 
208 
Woo HR, Dittmer TA, Richards EJ (2008) Three SRA-domain methylcytosine-
binding proteins cooperate to maintain global CpG methylation and epigenetic 
silencing in Arabidopsis. PLoS Genet 4: e1000156 
 
Wu JC, Santi DV (1985) On the mechanism and inhibition of DNA cytosine 
methyltransferases. Prog Clin Biol Res 198: 119-129 
 
Wu SC, Zhang Y (2010) Active DNA demethylation: many roads lead to Rome. Nat 
Rev Mol Cell Biol 11: 607-620 
 
Wu Y, Strawn E, Basir Z, Halverson G, Guo SW (2006) Promoter hypermethylation 
of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 1: 106-111 
 
Wu Y, Strawn E, Basir Z, Halverson G, Guo SW (2007) Aberrant expression of 
deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in 
women with endometriosis. Fertil Steril 87: 24-32 
 
Wynn RM (1974) Ultrastructural development of the human decidua. Am J Obstet 
Gynecol 118: 652-670 
 
Xue Q, Lin Z, Cheng YH, Huang CC, Marsh E, Yin P, Milad MP, Confino E, 
Reierstad S, Innes J, Bulun SE (2007) Promoter methylation regulates estrogen 
receptor 2 in human endometrium and endometriosis. Biol Reprod 77: 681-687 
 
Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, Taniguchi K, Taketani T, 
Matsuoka A, Tamura H, Sugino N (2009) DNA methyltransferase expression in the 
human endometrium: down-regulation by progesterone and estrogen. Hum Reprod 
24: 1126-1132 
 
Yan Q, Huang J, Fan T, Zhu H, Muegge K (2003) Lsh, a modulator of CpG 
methylation, is crucial for normal histone methylation. Embo J 22: 5154-5162 
 
Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP (2004) A simple 
method for estimating global DNA methylation using bisulfite PCR of repetitive 
DNA elements. Nucleic Acids Res 32: e38 
 
Yang H, Pesavento JJ, Starnes TW, Cryderman DE, Wallrath LL, Kelleher NL, 
Mizzen CA (2008) Preferential dimethylation of histone H4 lysine 20 by Suv4-20. J 
Biol Chem 283: 12085-12092 
 
Yokochi T, Robertson KD (2002) Preferential methylation of unmethylated DNA by 
Mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 277: 11735-
11745 
 
Zhang Y, Dufau ML (2000) Nuclear orphan receptors regulate transcription of the 
gene for the human luteinizing hormone receptor. J Biol Chem 275: 2763-2770 
 
Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT (2008) Polycomb proteins targeted by a 
short repeat RNA to the mouse X chromosome. Science 322: 750-756 
 
   Bibliography 
 
 
209 
Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A, Orlov YL, Sung WK, Shahab 
A, Kuznetsov VA, Bourque G, Oh S, Ruan Y, Ng HH, Wei CL (2007) Whole-
genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic 
compartments in human embryonic stem cells. Cell Stem Cell 1: 286-298 
 
Zheng P, Patel B, McMenamin M, Paprocki AM, Schramm RD, Nagl NG, Jr., 
Wilsker D, Wang X, Moran E, Latham KE (2004) Expression of genes encoding 
chromatin regulatory factors in developing rhesus monkey oocytes and 
preimplantation stage embryos: possible roles in genome activation. Biol Reprod 70: 
1419-1427 
 
 
   
 
 
210 
PUBLICATIONS 
 
 
 
 
 
 
Grimaldi G, Christian M, Steel JH, Henriet P, Poutanen M, Brosens JJ (2011) Down-
Regulation of the Histone Methyltransferase EZH2 Contributes to the Epigenetic 
Programming of Decidualizing Human Endometrial Stromal Cells. Mol Endocrinol. 
25, me.2011-1139 
